US20160130265A1 - Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity - Google Patents
Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity Download PDFInfo
- Publication number
- US20160130265A1 US20160130265A1 US14/981,999 US201514981999A US2016130265A1 US 20160130265 A1 US20160130265 A1 US 20160130265A1 US 201514981999 A US201514981999 A US 201514981999A US 2016130265 A1 US2016130265 A1 US 2016130265A1
- Authority
- US
- United States
- Prior art keywords
- preparation
- methyl
- acid
- phenyl
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 title abstract description 32
- 108010028275 Leukocyte Elastase Proteins 0.000 title abstract description 12
- 102000016799 Leukocyte elastase Human genes 0.000 title abstract description 12
- 230000000694 effects Effects 0.000 title abstract description 9
- MPOYBFYHRQBZPM-UHFFFAOYSA-N 3h-pyridin-4-one Chemical class O=C1CC=NC=C1 MPOYBFYHRQBZPM-UHFFFAOYSA-N 0.000 title abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 92
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 43
- 150000003839 salts Chemical class 0.000 claims description 42
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 33
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 23
- 125000003118 aryl group Chemical group 0.000 claims description 23
- -1 1-methylpyrazolyl Chemical group 0.000 claims description 21
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 17
- 229910052794 bromium Inorganic materials 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 125000004076 pyridyl group Chemical group 0.000 claims description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
- 229910052731 fluorine Inorganic materials 0.000 claims description 9
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 77
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 30
- 201000010099 disease Diseases 0.000 abstract description 19
- 238000011282 treatment Methods 0.000 abstract description 17
- 230000002265 prevention Effects 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- 230000000172 allergic effect Effects 0.000 abstract description 4
- 208000010668 atopic eczema Diseases 0.000 abstract description 4
- 230000001363 autoimmune Effects 0.000 abstract description 4
- 208000027866 inflammatory disease Diseases 0.000 abstract description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract description 2
- 208000019693 Lung disease Diseases 0.000 abstract description 2
- 208000025609 Urogenital disease Diseases 0.000 abstract description 2
- 230000002496 gastric effect Effects 0.000 abstract description 2
- 230000000771 oncological effect Effects 0.000 abstract description 2
- 230000002685 pulmonary effect Effects 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 195
- 238000002360 preparation method Methods 0.000 description 193
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 168
- 239000000203 mixture Substances 0.000 description 105
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 100
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 95
- 238000004128 high performance liquid chromatography Methods 0.000 description 92
- 239000000543 intermediate Substances 0.000 description 68
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 65
- 230000002829 reductive effect Effects 0.000 description 56
- 239000000243 solution Substances 0.000 description 56
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 48
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 48
- 239000008279 sol Substances 0.000 description 43
- 238000006243 chemical reaction Methods 0.000 description 38
- 239000007858 starting material Substances 0.000 description 34
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 32
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 31
- 239000005557 antagonist Substances 0.000 description 31
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 26
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 26
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 239000012044 organic layer Substances 0.000 description 24
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 24
- 238000004296 chiral HPLC Methods 0.000 description 23
- 239000002904 solvent Substances 0.000 description 23
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 20
- 239000003643 water by type Substances 0.000 description 19
- 0 *.*C.*C.[2*]N1C([3*])=C([4*])C(=O)C(C(=O)NC([6*])([7*])C)=C1[5*] Chemical compound *.*C.*C.[2*]N1C([3*])=C([4*])C(=O)C(C(=O)NC([6*])([7*])C)=C1[5*] 0.000 description 18
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 18
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 17
- 239000007832 Na2SO4 Substances 0.000 description 17
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 17
- 239000003960 organic solvent Substances 0.000 description 17
- 229910052938 sodium sulfate Inorganic materials 0.000 description 17
- 229920006395 saturated elastomer Polymers 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000002585 base Substances 0.000 description 15
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 14
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 14
- 239000000651 prodrug Substances 0.000 description 14
- 229940002612 prodrug Drugs 0.000 description 14
- 238000004007 reversed phase HPLC Methods 0.000 description 13
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000377 silicon dioxide Substances 0.000 description 12
- 229960000583 acetic acid Drugs 0.000 description 11
- 230000002349 favourable effect Effects 0.000 description 11
- 238000003818 flash chromatography Methods 0.000 description 11
- 150000003254 radicals Chemical class 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 11
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 10
- 239000012317 TBTU Substances 0.000 description 10
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 10
- 229910000027 potassium carbonate Inorganic materials 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 150000002825 nitriles Chemical class 0.000 description 9
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical class ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 9
- 239000003039 volatile agent Substances 0.000 description 9
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 8
- LPLPPKHEXSDCRZ-UHFFFAOYSA-N [[4-[(1,3-dioxoisoindol-2-yl)methyl]phenyl]-methyl-oxo-$l^{6}-sulfanylidene]cyanamide Chemical compound C1=CC(S(=O)(=NC#N)C)=CC=C1CN1C(=O)C2=CC=CC=C2C1=O LPLPPKHEXSDCRZ-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 230000002503 metabolic effect Effects 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 6
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 6
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- HMEYPCZVQBYGAF-UHFFFAOYSA-N [[4-[(1,3-dioxoisoindol-2-yl)methyl]phenyl]-methyl-$l^{4}-sulfanylidene]cyanamide Chemical compound C1=CC(S(=NC#N)C)=CC=C1CN1C(=O)C2=CC=CC=C2C1=O HMEYPCZVQBYGAF-UHFFFAOYSA-N 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 125000001246 bromo group Chemical group Br* 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- OYAZXWLAZWTIBD-UHFFFAOYSA-N n-[[4-(n-cyano-s-methylsulfonimidoyl)phenyl]methyl]-6-methyl-1-(2-methylpyrazol-3-yl)-4-oxo-5-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound O=C1C(C(=O)NCC=2C=CC(=CC=2)S(C)(=O)=NC#N)=CN(C=2N(N=CC=2)C)C(C)=C1C1=CC=CC(C(F)(F)F)=C1 OYAZXWLAZWTIBD-UHFFFAOYSA-N 0.000 description 6
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 6
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 6
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- MMVZREZJIOXUQU-UHFFFAOYSA-N 2-[[4-(methylsulfonimidoyl)phenyl]methyl]isoindole-1,3-dione Chemical compound C1=CC(S(=N)(=O)C)=CC=C1CN1C(=O)C2=CC=CC=C2C1=O MMVZREZJIOXUQU-UHFFFAOYSA-N 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 5
- MRXCYZMATZMFSG-UHFFFAOYSA-N 5-bromo-n-[[4-(n-cyano-s-methylsulfonimidoyl)phenyl]methyl]-6-methyl-1-(2-methylpyrazol-3-yl)-4-oxopyridine-3-carboxamide Chemical compound CC1=C(Br)C(=O)C(C(=O)NCC=2C=CC(=CC=2)S(C)(=O)=NC#N)=CN1C1=CC=NN1C MRXCYZMATZMFSG-UHFFFAOYSA-N 0.000 description 5
- HUTSLNFNUATIJS-UHFFFAOYSA-N 5-bromo-n-[[4-(n-cyano-s-methylsulfonimidoyl)phenyl]methyl]-6-methyl-4-oxo-1-propan-2-ylpyridine-3-carboxamide Chemical compound O=C1C(Br)=C(C)N(C(C)C)C=C1C(=O)NCC1=CC=C(S(C)(=O)=NC#N)C=C1 HUTSLNFNUATIJS-UHFFFAOYSA-N 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- MYJVGNXKXAYCTH-UHFFFAOYSA-N [3-(difluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC(C(F)F)=C1 MYJVGNXKXAYCTH-UHFFFAOYSA-N 0.000 description 5
- DDRVRIVUNIJLLZ-UHFFFAOYSA-N [[4-(aminomethyl)phenyl]-methyl-oxo-$l^{6}-sulfanylidene]cyanamide Chemical compound N#CN=S(=O)(C)C1=CC=C(CN)C=C1 DDRVRIVUNIJLLZ-UHFFFAOYSA-N 0.000 description 5
- JURQHCIWAOCWKQ-UHFFFAOYSA-N [[4-(aminomethyl)phenyl]-oxo-propan-2-yl-$l^{6}-sulfanylidene]cyanamide Chemical compound N#CN=S(=O)(C(C)C)C1=CC=C(CN)C=C1 JURQHCIWAOCWKQ-UHFFFAOYSA-N 0.000 description 5
- LDKKOUDVLZKZDY-UHFFFAOYSA-N [[6-(aminomethyl)pyridin-3-yl]-methyl-oxo-$l^{6}-sulfanylidene]cyanamide Chemical compound N#CN=S(=O)(C)C1=CC=C(CN)N=C1 LDKKOUDVLZKZDY-UHFFFAOYSA-N 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 239000003246 corticosteroid Substances 0.000 description 5
- 229960001334 corticosteroids Drugs 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000007866 imination reaction Methods 0.000 description 5
- CWYKJPKYCZQIHZ-UHFFFAOYSA-N n-[[4-(n,s-dimethylsulfonimidoyl)phenyl]methyl]-6-methyl-4-oxo-1-propan-2-yl-5-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1=CC(S(C)(=O)=NC)=CC=C1CNC(=O)C(C1=O)=CN(C(C)C)C(C)=C1C1=CC=CC(C(F)(F)F)=C1 CWYKJPKYCZQIHZ-UHFFFAOYSA-N 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 235000019345 sodium thiosulphate Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 4
- HSSDUDITJPHOMG-UHFFFAOYSA-N 1-[(4-cyanophenyl)methyl]-6-methyl-4-oxo-5-[3-(trifluoromethyl)phenyl]pyridine-3-carboxylic acid Chemical compound O=C1C(C(O)=O)=CN(CC=2C=CC(=CC=2)C#N)C(C)=C1C1=CC=CC(C(F)(F)F)=C1 HSSDUDITJPHOMG-UHFFFAOYSA-N 0.000 description 4
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 4
- MGYRYHWNSVKNGJ-UHFFFAOYSA-N 2-[(4-methylsulfanylphenyl)methyl]isoindole-1,3-dione Chemical compound C1=CC(SC)=CC=C1CN1C(=O)C2=CC=CC=C2C1=O MGYRYHWNSVKNGJ-UHFFFAOYSA-N 0.000 description 4
- CCFOWRBNCGUNJC-UHFFFAOYSA-N 5-bromo-n-[[4-(n-cyano-s-methylsulfonimidoyl)phenyl]methyl]-1-cyclobutyl-6-methyl-4-oxopyridine-3-carboxamide Chemical compound CC1=C(Br)C(=O)C(C(=O)NCC=2C=CC(=CC=2)S(C)(=O)=NC#N)=CN1C1CCC1 CCFOWRBNCGUNJC-UHFFFAOYSA-N 0.000 description 4
- QMUSFZMNXSQLKA-UHFFFAOYSA-N 5-bromo-n-[[4-(n-cyano-s-methylsulfonimidoyl)phenyl]methyl]-1-ethyl-6-methyl-4-oxopyridine-3-carboxamide Chemical compound O=C1C(Br)=C(C)N(CC)C=C1C(=O)NCC1=CC=C(S(C)(=O)=NC#N)C=C1 QMUSFZMNXSQLKA-UHFFFAOYSA-N 0.000 description 4
- WPOULMWKCYZLCF-UHFFFAOYSA-N 6-methyl-4-oxo-1-propan-2-yl-5-[3-(trifluoromethyl)phenyl]pyridine-3-carboxylic acid Chemical compound CC(C)N1C=C(C(O)=O)C(=O)C(C=2C=C(C=CC=2)C(F)(F)F)=C1C WPOULMWKCYZLCF-UHFFFAOYSA-N 0.000 description 4
- FFEVTWGCXJRHOG-UHFFFAOYSA-N 6-methyl-4-oxo-1-propan-2-ylpyridine-3-carboxylic acid Chemical compound CC(C)N1C=C(C(O)=O)C(=O)C=C1C FFEVTWGCXJRHOG-UHFFFAOYSA-N 0.000 description 4
- 102000003902 Cathepsin C Human genes 0.000 description 4
- 108090000267 Cathepsin C Proteins 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- FENPIUFTWVKXST-UHFFFAOYSA-N [[4-(aminomethyl)-2-fluorophenyl]-methyl-oxo-$l^{6}-sulfanylidene]cyanamide Chemical compound N#CN=S(=O)(C)C1=CC=C(CN)C=C1F FENPIUFTWVKXST-UHFFFAOYSA-N 0.000 description 4
- KJGMAYRMDSQTDO-UHFFFAOYSA-N [[4-(aminomethyl)-3-fluorophenyl]-methyl-oxo-$l^{6}-sulfanylidene]cyanamide Chemical compound N#CN=S(=O)(C)C1=CC=C(CN)C(F)=C1 KJGMAYRMDSQTDO-UHFFFAOYSA-N 0.000 description 4
- VFNRWJXUJXSJSN-UHFFFAOYSA-N [[4-(aminomethyl)phenyl]-ethyl-oxo-$l^{6}-sulfanylidene]cyanamide Chemical compound N#CN=S(=O)(CC)C1=CC=C(CN)C=C1 VFNRWJXUJXSJSN-UHFFFAOYSA-N 0.000 description 4
- ZBIKORITPGTTGI-UHFFFAOYSA-N [acetyloxy(phenyl)-$l^{3}-iodanyl] acetate Chemical compound CC(=O)OI(OC(C)=O)C1=CC=CC=C1 ZBIKORITPGTTGI-UHFFFAOYSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- TXTKPDAPVJABHS-UHFFFAOYSA-N methyl 5-bromo-6-methyl-1-(2-methylpyrazol-3-yl)-4-oxopyridine-3-carboxylate Chemical compound CC1=C(Br)C(=O)C(C(=O)OC)=CN1C1=CC=NN1C TXTKPDAPVJABHS-UHFFFAOYSA-N 0.000 description 4
- GFSVCTVDJAVYEO-UHFFFAOYSA-N n-[1-[4-(n-cyano-s-methylsulfonimidoyl)phenyl]ethyl]-6-methyl-4-oxo-1-propan-2-yl-5-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound O=C1C(C=2C=C(C=CC=2)C(F)(F)F)=C(C)N(C(C)C)C=C1C(=O)NC(C)C1=CC=C(S(C)(=O)=NC#N)C=C1 GFSVCTVDJAVYEO-UHFFFAOYSA-N 0.000 description 4
- SDPUZAQJFQEMQK-UHFFFAOYSA-N n-[[4-(n-cyano-s-cyclopropylsulfonimidoyl)phenyl]methyl]-6-methyl-4-oxo-1-propan-2-yl-5-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound O=C1C(C=2C=C(C=CC=2)C(F)(F)F)=C(C)N(C(C)C)C=C1C(=O)NCC(C=C1)=CC=C1S(=O)(=NC#N)C1CC1 SDPUZAQJFQEMQK-UHFFFAOYSA-N 0.000 description 4
- IEAHGQDTTUUJDU-UHFFFAOYSA-N n-[[4-(n-cyano-s-methylsulfonimidoyl)-3-methylphenyl]methyl]-6-methyl-4-oxo-1-propan-2-yl-5-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound O=C1C(C=2C=C(C=CC=2)C(F)(F)F)=C(C)N(C(C)C)C=C1C(=O)NCC1=CC=C(S(C)(=O)=NC#N)C(C)=C1 IEAHGQDTTUUJDU-UHFFFAOYSA-N 0.000 description 4
- UHBBLFVKDXQBBI-UHFFFAOYSA-N n-[[4-[n-(cyanomethyl)-s-methylsulfonimidoyl]phenyl]methyl]-6-methyl-4-oxo-1-propan-2-yl-5-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound O=C1C(C=2C=C(C=CC=2)C(F)(F)F)=C(C)N(C(C)C)C=C1C(=O)NCC1=CC=C(S(C)(=O)=NCC#N)C=C1 UHBBLFVKDXQBBI-UHFFFAOYSA-N 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 239000012286 potassium permanganate Substances 0.000 description 4
- OIEMGKDPZBUUHK-UHFFFAOYSA-N (2-fluoro-4-methylsulfanylphenyl)methanamine Chemical compound CSC1=CC=C(CN)C(F)=C1 OIEMGKDPZBUUHK-UHFFFAOYSA-N 0.000 description 3
- SMGSGMPCSAPFDN-UHFFFAOYSA-N (3-methyl-4-methylsulfanylphenyl)methanamine Chemical compound CSC1=CC=C(CN)C=C1C SMGSGMPCSAPFDN-UHFFFAOYSA-N 0.000 description 3
- ZTXNLRPIRSOCPR-UHFFFAOYSA-N (4-cyclopropylsulfanylphenyl)methanamine Chemical compound C1=CC(CN)=CC=C1SC1CC1 ZTXNLRPIRSOCPR-UHFFFAOYSA-N 0.000 description 3
- HNEGVVYFSABXEY-UHFFFAOYSA-N 1-cyclobutyl-6-methyl-4-oxopyridine-3-carboxylic acid Chemical compound CC1=CC(=O)C(C(O)=O)=CN1C1CCC1 HNEGVVYFSABXEY-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- OHGNETQNATWUND-UHFFFAOYSA-N 2-[(3-fluoro-4-methylsulfanylphenyl)methyl]isoindole-1,3-dione Chemical compound C1=C(F)C(SC)=CC=C1CN1C(=O)C2=CC=CC=C2C1=O OHGNETQNATWUND-UHFFFAOYSA-N 0.000 description 3
- KHQKZFSRHQLPLI-UHFFFAOYSA-N 2-[(5-methylsulfanylpyridin-2-yl)methyl]isoindole-1,3-dione Chemical compound N1=CC(SC)=CC=C1CN1C(=O)C2=CC=CC=C2C1=O KHQKZFSRHQLPLI-UHFFFAOYSA-N 0.000 description 3
- OWEWAVQRXUBMDG-UHFFFAOYSA-N 2-[[4-(n,s-dimethylsulfonimidoyl)phenyl]methyl]isoindole-1,3-dione Chemical compound C1=CC(S(C)(=O)=NC)=CC=C1CN1C(=O)C2=CC=CC=C2C1=O OWEWAVQRXUBMDG-UHFFFAOYSA-N 0.000 description 3
- NZPFOXKCDMKVOL-UHFFFAOYSA-N 2-[[[4-(aminomethyl)phenyl]-methyl-oxo-$l^{6}-sulfanylidene]amino]acetonitrile Chemical compound N#CCN=S(=O)(C)C1=CC=C(CN)C=C1 NZPFOXKCDMKVOL-UHFFFAOYSA-N 0.000 description 3
- ADEUEVAJMDWAMU-UHFFFAOYSA-N 2-[[[4-[(1,3-dioxoisoindol-2-yl)methyl]phenyl]-methyl-oxo-$l^{6}-sulfanylidene]amino]acetonitrile Chemical compound C1=CC(S(=O)(=NCC#N)C)=CC=C1CN1C(=O)C2=CC=CC=C2C1=O ADEUEVAJMDWAMU-UHFFFAOYSA-N 0.000 description 3
- BGEOBICMHWOYBC-UHFFFAOYSA-N 3-methyl-4-methylsulfanylbenzonitrile Chemical compound CSC1=CC=C(C#N)C=C1C BGEOBICMHWOYBC-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- XKDWIALWZGZEQL-UHFFFAOYSA-N 4-cyclopropylsulfanylbenzamide Chemical compound C1=CC(C(=O)N)=CC=C1SC1CC1 XKDWIALWZGZEQL-UHFFFAOYSA-N 0.000 description 3
- YFDZJHOCGBLXMQ-UHFFFAOYSA-N 5-bromo-1-[(4-cyanophenyl)methyl]-6-methyl-4-oxopyridine-3-carboxylic acid Chemical compound CC1=C(Br)C(=O)C(C(O)=O)=CN1CC1=CC=C(C#N)C=C1 YFDZJHOCGBLXMQ-UHFFFAOYSA-N 0.000 description 3
- PWRCPZGDBDGWGC-UHFFFAOYSA-N 5-bromo-1-cyclobutyl-6-methyl-4-oxopyridine-3-carboxylic acid Chemical compound CC1=C(Br)C(=O)C(C(O)=O)=CN1C1CCC1 PWRCPZGDBDGWGC-UHFFFAOYSA-N 0.000 description 3
- KYAYXXHPUMTZDW-UHFFFAOYSA-N 5-bromo-6-methyl-4-oxo-1-propan-2-ylpyridine-3-carboxylic acid Chemical compound CC(C)N1C=C(C(O)=O)C(=O)C(Br)=C1C KYAYXXHPUMTZDW-UHFFFAOYSA-N 0.000 description 3
- APFCUNHVYZNRHC-UHFFFAOYSA-N 6-methyl-n-[(3-methyl-4-methylsulfanylphenyl)methyl]-4-oxo-1-propan-2-yl-5-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1=C(C)C(SC)=CC=C1CNC(=O)C(C1=O)=CN(C(C)C)C(C)=C1C1=CC=CC(C(F)(F)F)=C1 APFCUNHVYZNRHC-UHFFFAOYSA-N 0.000 description 3
- MICHJZXALHNGDU-UHFFFAOYSA-N 6-methyl-n-[1-(4-methylsulfanylphenyl)ethyl]-4-oxo-1-propan-2-yl-5-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1=CC(SC)=CC=C1C(C)NC(=O)C(C1=O)=CN(C(C)C)C(C)=C1C1=CC=CC(C(F)(F)F)=C1 MICHJZXALHNGDU-UHFFFAOYSA-N 0.000 description 3
- 230000035502 ADME Effects 0.000 description 3
- IVSZLXZYQVIEFR-UHFFFAOYSA-N CC1=CC=CC(C)=C1 Chemical compound CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 description 3
- WYIULOUGUQFKMH-UHFFFAOYSA-N CCS(=O)(=NC#N)C1=CC=C(CNC(=O)C2=CN(C3CC3)C(C)=C(C3=CC(C(F)(F)F)=CC=C3)C2=O)C=C1 Chemical compound CCS(=O)(=NC#N)C1=CC=C(CNC(=O)C2=CN(C3CC3)C(C)=C(C3=CC(C(F)(F)F)=CC=C3)C2=O)C=C1 WYIULOUGUQFKMH-UHFFFAOYSA-N 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 238000006069 Suzuki reaction reaction Methods 0.000 description 3
- WOAORAPRPVIATR-UHFFFAOYSA-N [3-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC(C(F)(F)F)=C1 WOAORAPRPVIATR-UHFFFAOYSA-N 0.000 description 3
- QJMRAPZNZRCPHZ-UHFFFAOYSA-N [4-(n,s-dimethylsulfonimidoyl)phenyl]methanamine Chemical compound CN=S(C)(=O)C1=CC=C(CN)C=C1 QJMRAPZNZRCPHZ-UHFFFAOYSA-N 0.000 description 3
- FFENKBHHTNQWGG-UHFFFAOYSA-N [[4-[(1,3-dioxoisoindol-2-yl)methyl]-2-fluorophenyl]-methyl-$l^{4}-sulfanylidene]cyanamide Chemical compound C1=C(F)C(S(=NC#N)C)=CC=C1CN1C(=O)C2=CC=CC=C2C1=O FFENKBHHTNQWGG-UHFFFAOYSA-N 0.000 description 3
- XCXVCDAAHYCKMH-UHFFFAOYSA-N [[4-[(1,3-dioxoisoindol-2-yl)methyl]-2-fluorophenyl]-methyl-oxo-$l^{6}-sulfanylidene]cyanamide Chemical compound C1=C(F)C(S(=O)(=NC#N)C)=CC=C1CN1C(=O)C2=CC=CC=C2C1=O XCXVCDAAHYCKMH-UHFFFAOYSA-N 0.000 description 3
- ULZINHRLQBPPAZ-UHFFFAOYSA-N [[4-[(1,3-dioxoisoindol-2-yl)methyl]phenyl]-ethyl-$l^{4}-sulfanylidene]cyanamide Chemical compound C1=CC(S(=NC#N)CC)=CC=C1CN1C(=O)C2=CC=CC=C2C1=O ULZINHRLQBPPAZ-UHFFFAOYSA-N 0.000 description 3
- DEWCQONQLZQEQM-UHFFFAOYSA-N [[4-[(1,3-dioxoisoindol-2-yl)methyl]phenyl]-ethyl-oxo-$l^{6}-sulfanylidene]cyanamide Chemical compound C1=CC(S(=O)(=NC#N)CC)=CC=C1CN1C(=O)C2=CC=CC=C2C1=O DEWCQONQLZQEQM-UHFFFAOYSA-N 0.000 description 3
- RKONZQCGEDSMTI-UHFFFAOYSA-N [[4-[(1,3-dioxoisoindol-2-yl)methyl]phenyl]-oxo-propan-2-yl-$l^{6}-sulfanylidene]cyanamide Chemical compound C1=CC(S(=O)(=NC#N)C(C)C)=CC=C1CN1C(=O)C2=CC=CC=C2C1=O RKONZQCGEDSMTI-UHFFFAOYSA-N 0.000 description 3
- QGAIXQCOZIEBIQ-UHFFFAOYSA-N [[4-[(1,3-dioxoisoindol-2-yl)methyl]phenyl]-propan-2-yl-$l^{4}-sulfanylidene]cyanamide Chemical compound C1=CC(S(=NC#N)C(C)C)=CC=C1CN1C(=O)C2=CC=CC=C2C1=O QGAIXQCOZIEBIQ-UHFFFAOYSA-N 0.000 description 3
- 125000002015 acyclic group Chemical group 0.000 description 3
- 239000000808 adrenergic beta-agonist Substances 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 230000003454 betamimetic effect Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 125000002837 carbocyclic group Chemical group 0.000 description 3
- 239000000812 cholinergic antagonist Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- GBFOVGYSKHACRD-UHFFFAOYSA-N dichloro-imino-oxo-lambda6-sulfane Chemical class ClS(Cl)(=N)=O GBFOVGYSKHACRD-UHFFFAOYSA-N 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 102000052502 human ELANE Human genes 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- SUIYCHARDILZQF-UHFFFAOYSA-N n-[(4-cyclopropylsulfanylphenyl)methyl]-6-methyl-4-oxo-1-propan-2-yl-5-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound O=C1C(C=2C=C(C=CC=2)C(F)(F)F)=C(C)N(C(C)C)C=C1C(=O)NCC(C=C1)=CC=C1SC1CC1 SUIYCHARDILZQF-UHFFFAOYSA-N 0.000 description 3
- OCHXEUZKJOBTBL-UHFFFAOYSA-N n-[[4-(n-cyano-s-cyclopropylsulfinimidoyl)phenyl]methyl]-6-methyl-4-oxo-1-propan-2-yl-5-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound O=C1C(C=2C=C(C=CC=2)C(F)(F)F)=C(C)N(C(C)C)C=C1C(=O)NCC(C=C1)=CC=C1S(=NC#N)C1CC1 OCHXEUZKJOBTBL-UHFFFAOYSA-N 0.000 description 3
- RUSOURHRHIHMJO-UHFFFAOYSA-N n-[[4-(n-cyano-s-methylsulfinimidoyl)-3-methylphenyl]methyl]-6-methyl-4-oxo-1-propan-2-yl-5-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound O=C1C(C=2C=C(C=CC=2)C(F)(F)F)=C(C)N(C(C)C)C=C1C(=O)NCC1=CC=C(S(C)=NC#N)C(C)=C1 RUSOURHRHIHMJO-UHFFFAOYSA-N 0.000 description 3
- VCLCRACBNRTEEF-UHFFFAOYSA-N n-[[4-(n-cyano-s-methylsulfonimidoyl)phenyl]methyl]-1-cyclobutyl-5-[3-(difluoromethyl)phenyl]-6-methyl-4-oxopyridine-3-carboxamide Chemical compound O=C1C(C(=O)NCC=2C=CC(=CC=2)S(C)(=O)=NC#N)=CN(C2CCC2)C(C)=C1C1=CC=CC(C(F)F)=C1 VCLCRACBNRTEEF-UHFFFAOYSA-N 0.000 description 3
- GNEYOYVCYVWAHK-UHFFFAOYSA-N n-[[4-(n-cyano-s-methylsulfonimidoyl)phenyl]methyl]-1-ethyl-6-methyl-4-oxo-5-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound O=C1C(C=2C=C(C=CC=2)C(F)(F)F)=C(C)N(CC)C=C1C(=O)NCC1=CC=C(S(C)(=O)=NC#N)C=C1 GNEYOYVCYVWAHK-UHFFFAOYSA-N 0.000 description 3
- ZALWVUVZOXXWDZ-UHFFFAOYSA-N n-[[4-(n-cyano-s-methylsulfonimidoyl)phenyl]methyl]-5-[3-(difluoromethyl)phenyl]-1-ethyl-6-methyl-4-oxopyridine-3-carboxamide Chemical compound O=C1C(C=2C=C(C=CC=2)C(F)F)=C(C)N(CC)C=C1C(=O)NCC1=CC=C(S(C)(=O)=NC#N)C=C1 ZALWVUVZOXXWDZ-UHFFFAOYSA-N 0.000 description 3
- RJUWXTJXBNIBHT-UHFFFAOYSA-N n-[[4-(n-cyano-s-methylsulfonimidoyl)phenyl]methyl]-5-[3-(difluoromethyl)phenyl]-6-methyl-1-(2-methylpyrazol-3-yl)-4-oxopyridine-3-carboxamide Chemical compound O=C1C(C(=O)NCC=2C=CC(=CC=2)S(C)(=O)=NC#N)=CN(C=2N(N=CC=2)C)C(C)=C1C1=CC=CC(C(F)F)=C1 RJUWXTJXBNIBHT-UHFFFAOYSA-N 0.000 description 3
- AZXSDCIAYWNUDE-UHFFFAOYSA-N n-[[4-(n-cyano-s-methylsulfonimidoyl)phenyl]methyl]-5-[3-(difluoromethyl)phenyl]-6-methyl-4-oxo-1-propan-2-ylpyridine-3-carboxamide Chemical compound O=C1C(C=2C=C(C=CC=2)C(F)F)=C(C)N(C(C)C)C=C1C(=O)NCC1=CC=C(S(C)(=O)=NC#N)C=C1 AZXSDCIAYWNUDE-UHFFFAOYSA-N 0.000 description 3
- UIONDWDXFGWGIK-UHFFFAOYSA-N n-[[4-(n-cyano-s-methylsulfonimidoyl)phenyl]methyl]-6-methyl-1-(2-methylpyrazol-3-yl)-4-oxopyridine-3-carboxamide Chemical compound CC1=CC(=O)C(C(=O)NCC=2C=CC(=CC=2)S(C)(=O)=NC#N)=CN1C1=CC=NN1C UIONDWDXFGWGIK-UHFFFAOYSA-N 0.000 description 3
- STVDCPQWTZATOS-UHFFFAOYSA-N n-[[4-(n-cyano-s-methylsulfonimidoyl)phenyl]methyl]-6-methyl-4-oxo-1-propan-2-yl-5-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound O=C1C(C=2C=C(C=CC=2)C(F)(F)F)=C(C)N(C(C)C)C=C1C(=O)NCC1=CC=C(S(C)(=O)=NC#N)C=C1 STVDCPQWTZATOS-UHFFFAOYSA-N 0.000 description 3
- YEWJFODLZRYADA-UHFFFAOYSA-N n-[[4-[(1,3-dioxoisoindol-2-yl)methyl]phenyl]-methyl-oxo-$l^{6}-sulfanylidene]-2,2,2-trifluoroacetamide Chemical compound C1=CC(S(=O)(=NC(=O)C(F)(F)F)C)=CC=C1CN1C(=O)C2=CC=CC=C2C1=O YEWJFODLZRYADA-UHFFFAOYSA-N 0.000 description 3
- XDJHGHPIRUWDOT-UHFFFAOYSA-N n-[[4-[(1,3-dioxoisoindol-2-yl)methyl]phenyl]-methyl-oxo-$l^{6}-sulfanylidene]methanesulfonamide Chemical compound C1=CC(S(C)(=O)=NS(=O)(=O)C)=CC=C1CN1C(=O)C2=CC=CC=C2C1=O XDJHGHPIRUWDOT-UHFFFAOYSA-N 0.000 description 3
- WJLCQUDEYSYVRA-UHFFFAOYSA-N n-[[4-[s-(dimethylamino)-n-methylsulfonimidoyl]phenyl]methyl]-6-methyl-4-oxo-1-propan-2-yl-5-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1=CC(S(=O)(N(C)C)=NC)=CC=C1CNC(=O)C(C1=O)=CN(C(C)C)C(C)=C1C1=CC=CC(C(F)(F)F)=C1 WJLCQUDEYSYVRA-UHFFFAOYSA-N 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 206010039083 rhinitis Diseases 0.000 description 3
- 201000000306 sarcoidosis Diseases 0.000 description 3
- 150000003335 secondary amines Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 125000001010 sulfinic acid amide group Chemical group 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- IXZDIALLLMRYOU-UHFFFAOYSA-N tert-butyl hypochlorite Chemical compound CC(C)(C)OCl IXZDIALLLMRYOU-UHFFFAOYSA-N 0.000 description 3
- OGGJFTPADGBTFT-UHFFFAOYSA-N tert-butyl n-[(2-fluoro-4-methylsulfanylphenyl)methyl]carbamate Chemical compound CSC1=CC=C(CNC(=O)OC(C)(C)C)C(F)=C1 OGGJFTPADGBTFT-UHFFFAOYSA-N 0.000 description 3
- SRKLSNCDRFPJKF-UHFFFAOYSA-N tert-butyl n-[[4-(n-cyano-s-methylsulfinimidoyl)-2-fluorophenyl]methyl]carbamate Chemical compound N#CN=S(C)C1=CC=C(CNC(=O)OC(C)(C)C)C(F)=C1 SRKLSNCDRFPJKF-UHFFFAOYSA-N 0.000 description 3
- SRQHZMABWRYGQS-UHFFFAOYSA-N tert-butyl n-[[4-(n-cyano-s-methylsulfonimidoyl)-2-fluorophenyl]methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=C(S(C)(=O)=NC#N)C=C1F SRQHZMABWRYGQS-UHFFFAOYSA-N 0.000 description 3
- 150000003512 tertiary amines Chemical class 0.000 description 3
- 150000003568 thioethers Chemical class 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- UBUPKYLDQOUBFF-UHFFFAOYSA-N (4-ethylsulfanylphenyl)methanamine Chemical compound CCSC1=CC=C(CN)C=C1 UBUPKYLDQOUBFF-UHFFFAOYSA-N 0.000 description 2
- SBMPBXFNKYJNIC-UHFFFAOYSA-N (4-methylsulfanylphenyl)methanamine Chemical compound CSC1=CC=C(CN)C=C1 SBMPBXFNKYJNIC-UHFFFAOYSA-N 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- LQACYSUZMJXUJY-UHFFFAOYSA-N 1-[(4-cyanophenyl)methyl]-6-methyl-4-oxopyridine-3-carboxylic acid Chemical compound CC1=CC(=O)C(C(O)=O)=CN1CC1=CC=C(C#N)C=C1 LQACYSUZMJXUJY-UHFFFAOYSA-N 0.000 description 2
- UOCKZXIOTNFZSN-UHFFFAOYSA-N 1-ethyl-6-methyl-4-oxopyridine-3-carboxylic acid Chemical compound CCN1C=C(C(O)=O)C(=O)C=C1C UOCKZXIOTNFZSN-UHFFFAOYSA-N 0.000 description 2
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 2
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- CBXJAPKOLAKEEF-UHFFFAOYSA-N 3-(dimethylaminomethylidene)-6-methylpyran-2,4-dione Chemical compound CN(C)C=C1C(=O)OC(C)=CC1=O CBXJAPKOLAKEEF-UHFFFAOYSA-N 0.000 description 2
- NATGKFYJHRNRHO-UHFFFAOYSA-N 3-fluoro-4-methylsulfanylbenzonitrile Chemical compound CSC1=CC=C(C#N)C=C1F NATGKFYJHRNRHO-UHFFFAOYSA-N 0.000 description 2
- VEJSQIFOENKKBH-UHFFFAOYSA-N 4-[(1,3-dioxoisoindol-2-yl)methyl]-n-methylbenzenesulfinamide Chemical compound C1=CC(S(=O)NC)=CC=C1CN1C(=O)C2=CC=CC=C2C1=O VEJSQIFOENKKBH-UHFFFAOYSA-N 0.000 description 2
- QCXJEYYXVJIFCE-UHFFFAOYSA-N 4-acetamidobenzoic acid Chemical compound CC(=O)NC1=CC=C(C(O)=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-N 0.000 description 2
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 2
- YREZNZOSVLUAFH-UHFFFAOYSA-N 5-[3-(difluoromethyl)phenyl]-n-[[4-[s-(dimethylamino)-n-methylsulfonimidoyl]phenyl]methyl]-6-methyl-4-oxo-1-propan-2-ylpyridine-3-carboxamide Chemical compound C1=CC(S(=O)(N(C)C)=NC)=CC=C1CNC(=O)C(C1=O)=CN(C(C)C)C(C)=C1C1=CC=CC(C(F)F)=C1 YREZNZOSVLUAFH-UHFFFAOYSA-N 0.000 description 2
- PXSVVCCUYPEETF-UHFFFAOYSA-N 5-bromo-1-ethyl-6-methyl-4-oxopyridine-3-carboxylic acid Chemical compound CCN1C=C(C(O)=O)C(=O)C(Br)=C1C PXSVVCCUYPEETF-UHFFFAOYSA-N 0.000 description 2
- KZHLGJKZUUYHIS-UHFFFAOYSA-N 6-methyl-1-(2-methylpyrazol-3-yl)-4-oxopyridine-3-carboxylic acid Chemical compound CC1=CC(=O)C(C(O)=O)=CN1C1=CC=NN1C KZHLGJKZUUYHIS-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 2
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WYRYWYAAHYRFBH-UHFFFAOYSA-N CC(C)C.CC1=CC=NN1C.CC1CCC1.CCC.CCC(C)C.CCC1=CC=C(C#N)C=C1 Chemical compound CC(C)C.CC1=CC=NN1C.CC1CCC1.CCC.CCC(C)C.CCC1=CC=C(C#N)C=C1 WYRYWYAAHYRFBH-UHFFFAOYSA-N 0.000 description 2
- CBXJAPKOLAKEEF-ALCCZGGFSA-N CC(OC(/C1=C\N(C)C)=O)=CC1=O Chemical compound CC(OC(/C1=C\N(C)C)=O)=CC1=O CBXJAPKOLAKEEF-ALCCZGGFSA-N 0.000 description 2
- RDHVQUJPGUEJNV-UHFFFAOYSA-N CC1=C(Br)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1CCOCC1 Chemical compound CC1=C(Br)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1CCOCC1 RDHVQUJPGUEJNV-UHFFFAOYSA-N 0.000 description 2
- FKAAJPMCDFLCIR-UHFFFAOYSA-N CC1=C(C2=CC(C(F)(F)F)=CC=C2)C(=O)C(C(=O)NCC2=CC=C(S(=O)(=NC#N)C(C)C)C=C2)=CN1C1=CC=NN1C Chemical compound CC1=C(C2=CC(C(F)(F)F)=CC=C2)C(=O)C(C(=O)NCC2=CC=C(S(=O)(=NC#N)C(C)C)C=C2)=CN1C1=CC=NN1C FKAAJPMCDFLCIR-UHFFFAOYSA-N 0.000 description 2
- JKWRPJPXBVEAPE-UHFFFAOYSA-N CC1=C(C2=CC(C(F)F)=CC=C2)C(=O)C(C(=O)NCC2=C(F)C=C(S(C)(=O)=NC#N)C=C2)=CN1C(C)C Chemical compound CC1=C(C2=CC(C(F)F)=CC=C2)C(=O)C(C(=O)NCC2=C(F)C=C(S(C)(=O)=NC#N)C=C2)=CN1C(C)C JKWRPJPXBVEAPE-UHFFFAOYSA-N 0.000 description 2
- IOBNXLHGERJNKS-UHFFFAOYSA-N CC1=C(C2=CC=C(F)C(C(F)(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C(C)C Chemical compound CC1=C(C2=CC=C(F)C(C(F)(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C(C)C IOBNXLHGERJNKS-UHFFFAOYSA-N 0.000 description 2
- AWFZTOAZFFMAJP-UHFFFAOYSA-N CC1=C(C2=CC=C(F)C(C(F)(F)F)=C2)C(=O)C(C(=O)O)=CN1C(C)C Chemical compound CC1=C(C2=CC=C(F)C(C(F)(F)F)=C2)C(=O)C(C(=O)O)=CN1C(C)C AWFZTOAZFFMAJP-UHFFFAOYSA-N 0.000 description 2
- SEILLDBZYNFDPU-UHFFFAOYSA-N CC1=C(C2=CC=C(F)C(C(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C(C)C Chemical compound CC1=C(C2=CC=C(F)C(C(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C(C)C SEILLDBZYNFDPU-UHFFFAOYSA-N 0.000 description 2
- FVTUJBMADZROPN-UHFFFAOYSA-N CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1=CC=CC=N1 Chemical compound CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1=CC=CC=N1 FVTUJBMADZROPN-UHFFFAOYSA-N 0.000 description 2
- CODUVNXMSSBRMC-UHFFFAOYSA-N CC1=C(C2=CC=NC(C(F)(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1=CC=CN=C1 Chemical compound CC1=C(C2=CC=NC(C(F)(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1=CC=CN=C1 CODUVNXMSSBRMC-UHFFFAOYSA-N 0.000 description 2
- MEWLFCZBXUUIOV-UHFFFAOYSA-N CC1=C(C2=CC=NC(C(F)(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1=CC=NC=C1 Chemical compound CC1=C(C2=CC=NC(C(F)(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1=CC=NC=C1 MEWLFCZBXUUIOV-UHFFFAOYSA-N 0.000 description 2
- AAIJEURQKZASKQ-UHFFFAOYSA-N CC1=CC(C)=C(F)C=C1 Chemical compound CC1=CC(C)=C(F)C=C1 AAIJEURQKZASKQ-UHFFFAOYSA-N 0.000 description 2
- GUGJEVJERDAWPA-UHFFFAOYSA-N CC1=CC(C)=C(F)C=C1.CC1=CC(C)=C(F)C=C1.CC1=CC(C)=NC=C1.CC1=CC=CC(C)=C1.CC1=CC=CC(C)=C1 Chemical compound CC1=CC(C)=C(F)C=C1.CC1=CC(C)=C(F)C=C1.CC1=CC(C)=NC=C1.CC1=CC=CC(C)=C1.CC1=CC=CC(C)=C1 GUGJEVJERDAWPA-UHFFFAOYSA-N 0.000 description 2
- JEXRVDGDYHAUHR-UHFFFAOYSA-N CC1=CC(C)=NC=C1.CC1=CC=CC(C)=C1.CC1=CC=CC(C)=C1 Chemical compound CC1=CC(C)=NC=C1.CC1=CC=CC(C)=C1.CC1=CC=CC(C)=C1 JEXRVDGDYHAUHR-UHFFFAOYSA-N 0.000 description 2
- MYHUFIBIAFXGEH-UHFFFAOYSA-N CC1=CC(N2C=C(C(=O)NCC3=CC=C(S(C)(=O)=NC#N)C=C3)C(=O)C(Br)=C2C)=NO1 Chemical compound CC1=CC(N2C=C(C(=O)NCC3=CC=C(S(C)(=O)=NC#N)C=C3)C(=O)C(Br)=C2C)=NO1 MYHUFIBIAFXGEH-UHFFFAOYSA-N 0.000 description 2
- UUOQMBVPAYQEEJ-UHFFFAOYSA-N CC1=CC(N2C=C(C(=O)NCC3=CC=C(S(C)(=O)=NC#N)C=C3)C(=O)C(C3=CC=CC(C(F)(F)F)=C3)=C2C)=CN=C1 Chemical compound CC1=CC(N2C=C(C(=O)NCC3=CC=C(S(C)(=O)=NC#N)C=C3)C(=O)C(C3=CC=CC(C(F)(F)F)=C3)=C2C)=CN=C1 UUOQMBVPAYQEEJ-UHFFFAOYSA-N 0.000 description 2
- VPJXHWCPYFNBRA-UHFFFAOYSA-N CC1=CN=CC(N2C=C(C(=O)O)C(=O)C(Br)=C2C)=C1 Chemical compound CC1=CN=CC(N2C=C(C(=O)O)C(=O)C(Br)=C2C)=C1 VPJXHWCPYFNBRA-UHFFFAOYSA-N 0.000 description 2
- QUFKKGIVYVWNAY-UHFFFAOYSA-N CCN1C=C(C(=O)NCC2=CC=C(S(=O)(=NC#N)C(C)C)C=C2)C(=O)C(C2=CC(C(F)(F)F)=CC=C2)=C1C Chemical compound CCN1C=C(C(=O)NCC2=CC=C(S(=O)(=NC#N)C(C)C)C=C2)C(=O)C(C2=CC(C(F)(F)F)=CC=C2)=C1C QUFKKGIVYVWNAY-UHFFFAOYSA-N 0.000 description 2
- OVKJVLYFEIYLMF-UHFFFAOYSA-N CCN1C=C(C(=O)NCC2=CC=C(S(=O)(=NC#N)C(C)C)C=C2)C(=O)C(C2=CC(C(F)F)=CC=C2)=C1C Chemical compound CCN1C=C(C(=O)NCC2=CC=C(S(=O)(=NC#N)C(C)C)C=C2)C(=O)C(C2=CC(C(F)F)=CC=C2)=C1C OVKJVLYFEIYLMF-UHFFFAOYSA-N 0.000 description 2
- BSQBAKAINSQNBD-UHFFFAOYSA-N CCN1C=C(C(=O)NCC2=CC=C(S(=O)(CC)=NC#N)C=C2)C(=O)C(C2=CC(C(F)(F)F)=CC=C2)=C1C Chemical compound CCN1C=C(C(=O)NCC2=CC=C(S(=O)(CC)=NC#N)C=C2)C(=O)C(C2=CC(C(F)(F)F)=CC=C2)=C1C BSQBAKAINSQNBD-UHFFFAOYSA-N 0.000 description 2
- XVRYMSYJRGKUOF-UHFFFAOYSA-N CCN1C=C(C(=O)NCC2=CC=C(S(=O)(CC)=NC#N)C=C2)C(=O)C(C2=CC(C(F)F)=CC=C2)=C1C Chemical compound CCN1C=C(C(=O)NCC2=CC=C(S(=O)(CC)=NC#N)C=C2)C(=O)C(C2=CC(C(F)F)=CC=C2)=C1C XVRYMSYJRGKUOF-UHFFFAOYSA-N 0.000 description 2
- YKBXENGOXPIFNN-UHFFFAOYSA-N CCS(=O)(=NC#N)C1=CC=C(CNC(=O)C2=CN(C(C)C)C(C)=C(C3=CC(C(F)(F)F)=CC=C3)C2=O)C=C1 Chemical compound CCS(=O)(=NC#N)C1=CC=C(CNC(=O)C2=CN(C(C)C)C(C)=C(C3=CC(C(F)(F)F)=CC=C3)C2=O)C=C1 YKBXENGOXPIFNN-UHFFFAOYSA-N 0.000 description 2
- ZGUDSLFOUKUORG-UHFFFAOYSA-N CCS(=O)(=NC#N)C1=CC=C(CNC(=O)C2=CN(C(C)C)C(C)=C(C3=CC(C(F)F)=CC=C3)C2=O)C=C1 Chemical compound CCS(=O)(=NC#N)C1=CC=C(CNC(=O)C2=CN(C(C)C)C(C)=C(C3=CC(C(F)F)=CC=C3)C2=O)C=C1 ZGUDSLFOUKUORG-UHFFFAOYSA-N 0.000 description 2
- NCTIPCHNYRXTOW-UHFFFAOYSA-N CCS(=O)(=NC#N)C1=CC=C(CNC(=O)C2=CN(C3=CC=NN3C)C(C)=C(C3=CC(C(F)(F)F)=CC=C3)C2=O)C=C1 Chemical compound CCS(=O)(=NC#N)C1=CC=C(CNC(=O)C2=CN(C3=CC=NN3C)C(C)=C(C3=CC(C(F)(F)F)=CC=C3)C2=O)C=C1 NCTIPCHNYRXTOW-UHFFFAOYSA-N 0.000 description 2
- GKHNSWMWXRKSJT-UHFFFAOYSA-N CS(=O)(=O)N=S(C)(=O)C1=CC=C(CN)C=C1 Chemical compound CS(=O)(=O)N=S(C)(=O)C1=CC=C(CN)C=C1 GKHNSWMWXRKSJT-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 108090000426 Caspase-1 Proteins 0.000 description 2
- 208000002691 Choroiditis Diseases 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 208000003971 Posterior uveitis Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 108050000258 Prostaglandin D receptors Proteins 0.000 description 2
- 102100024218 Prostaglandin D2 receptor 2 Human genes 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102000002255 Secretory Proteinase Inhibitory Proteins Human genes 0.000 description 2
- 108010000303 Secretory Proteinase Inhibitory Proteins Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- PHLLTVDZCKUNJN-UHFFFAOYSA-N [2-(trifluoromethyl)pyridin-4-yl]boronic acid Chemical compound OB(O)C1=CC=NC(C(F)(F)F)=C1 PHLLTVDZCKUNJN-UHFFFAOYSA-N 0.000 description 2
- MUXVFANCCWKWCB-UHFFFAOYSA-N [4-[s-(dimethylamino)-n-methylsulfonimidoyl]phenyl]methanamine Chemical group CN=S(=O)(N(C)C)C1=CC=C(CN)C=C1 MUXVFANCCWKWCB-UHFFFAOYSA-N 0.000 description 2
- GLDBOEVYOWHVGN-UHFFFAOYSA-N [[4-(aminomethyl)-3-methylphenyl]-methyl-oxo-$l^{6}-sulfanylidene]cyanamide Chemical compound CC1=CC(S(C)(=O)=NC#N)=CC=C1CN GLDBOEVYOWHVGN-UHFFFAOYSA-N 0.000 description 2
- PGWXOPFZRXXINP-UHFFFAOYSA-N [[6-(1,3-dioxoisoindol-2-yl)pyridin-3-yl]-methyl-$l^{4}-sulfanylidene]cyanamide Chemical compound N1=CC(S(=NC#N)C)=CC=C1N1C(=O)C2=CC=CC=C2C1=O PGWXOPFZRXXINP-UHFFFAOYSA-N 0.000 description 2
- SQYYOJUROAHHMO-UHFFFAOYSA-N [[6-(1,3-dioxoisoindol-2-yl)pyridin-3-yl]-methyl-oxo-$l^{6}-sulfanylidene]cyanamide Chemical compound N1=CC(S(=O)(=NC#N)C)=CC=C1N1C(=O)C2=CC=CC=C2C1=O SQYYOJUROAHHMO-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 206010069351 acute lung injury Diseases 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- CHKQALUEEULCPZ-UHFFFAOYSA-N amino 2,4,6-trimethylbenzenesulfonate Chemical compound CC1=CC(C)=C(S(=O)(=O)ON)C(C)=C1 CHKQALUEEULCPZ-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 150000004982 aromatic amines Chemical class 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 229960004132 diethyl ether Drugs 0.000 description 2
- LHXNDZQKLAXNKX-UHFFFAOYSA-N difluoro-imino-oxo-$l^{6}-sulfane Chemical class FS(F)(=N)=O LHXNDZQKLAXNKX-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 229940121647 egfr inhibitor Drugs 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 2
- 230000008570 general process Effects 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 238000005658 halogenation reaction Methods 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000026045 iodination Effects 0.000 description 2
- 238000006192 iodination reaction Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000003591 leukocyte elastase inhibitor Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- CMZSYUCUXPNBAQ-UHFFFAOYSA-N methyl 6-methyl-1-(2-methylpyrazol-3-yl)-4-oxopyridine-3-carboxylate Chemical compound CC1=CC(=O)C(C(=O)OC)=CN1C1=CC=NN1C CMZSYUCUXPNBAQ-UHFFFAOYSA-N 0.000 description 2
- UEGPMTIDRIIUSJ-UHFFFAOYSA-N n-[[4-(n-cyano-s-methylsulfonimidoyl)phenyl]methyl]-1-[(4-cyanophenyl)methyl]-6-methyl-4-oxo-5-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound O=C1C(C(=O)NCC=2C=CC(=CC=2)S(C)(=O)=NC#N)=CN(CC=2C=CC(=CC=2)C#N)C(C)=C1C1=CC=CC(C(F)(F)F)=C1 UEGPMTIDRIIUSJ-UHFFFAOYSA-N 0.000 description 2
- MRZNKMQAGZEUIF-UHFFFAOYSA-N n-[[4-(n-cyano-s-methylsulfonimidoyl)phenyl]methyl]-6-methyl-4-oxo-1-propan-2-yl-5-[2-(trifluoromethyl)pyridin-4-yl]pyridine-3-carboxamide Chemical compound O=C1C(C=2C=C(N=CC=2)C(F)(F)F)=C(C)N(C(C)C)C=C1C(=O)NCC1=CC=C(S(C)(=O)=NC#N)C=C1 MRZNKMQAGZEUIF-UHFFFAOYSA-N 0.000 description 2
- OHTBUXQSOPJKFO-UHFFFAOYSA-N n-[[5-(n-cyano-s-methylsulfonimidoyl)pyridin-2-yl]methyl]-6-methyl-4-oxo-1-propan-2-yl-5-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound O=C1C(C=2C=C(C=CC=2)C(F)(F)F)=C(C)N(C(C)C)C=C1C(=O)NCC1=CC=C(S(C)(=O)=NC#N)C=N1 OHTBUXQSOPJKFO-UHFFFAOYSA-N 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- WYGFXMYWUZUYGY-UHFFFAOYSA-N o-[4-[(1,3-dioxoisoindol-2-yl)methyl]phenyl] ethanethioate Chemical compound C1=CC(OC(=S)C)=CC=C1CN1C(=O)C2=CC=CC=C2C1=O WYGFXMYWUZUYGY-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- NSYSSMYQPLSPOD-UHFFFAOYSA-N triacetate lactone Chemical compound CC1=CC(O)=CC(=O)O1 NSYSSMYQPLSPOD-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- IKXCHOUDIPZROZ-LXGUWJNJSA-N (2r,3r,4r,5s)-6-(ethylamino)hexane-1,2,3,4,5-pentol Chemical compound CCNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO IKXCHOUDIPZROZ-LXGUWJNJSA-N 0.000 description 1
- GUQCKXBHBXOXBH-UHFFFAOYSA-N (4-propan-2-ylsulfanylphenyl)methanamine Chemical compound CC(C)SC1=CC=C(CN)C=C1 GUQCKXBHBXOXBH-UHFFFAOYSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N 1,1'-Carbonyldiimidazole Substances C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- YOYGMCGRAMSGSR-UHFFFAOYSA-N 1-(4-methylsulfanylphenyl)ethanamine Chemical compound CSC1=CC=C(C(C)N)C=C1 YOYGMCGRAMSGSR-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- INOGLHRUEYDAHX-UHFFFAOYSA-N 1-chlorobenzotriazole Chemical compound C1=CC=C2N(Cl)N=NC2=C1 INOGLHRUEYDAHX-UHFFFAOYSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- HUTNOYOBQPAKIA-UHFFFAOYSA-N 1h-pyrazin-2-one Chemical compound OC1=CN=CC=N1 HUTNOYOBQPAKIA-UHFFFAOYSA-N 0.000 description 1
- GMACPPQKLRQSSU-UHFFFAOYSA-N 2-(2-hydroxyethylamino)ethanol Chemical compound OCCNCCO.OCCNCCO GMACPPQKLRQSSU-UHFFFAOYSA-N 0.000 description 1
- KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
- BBFCZCZRPXGONA-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanol Chemical compound OCCN(CCO)CCO.OCCN(CCO)CCO BBFCZCZRPXGONA-UHFFFAOYSA-N 0.000 description 1
- WKAVKKUXZAWHDM-UHFFFAOYSA-N 2-acetamidopentanedioic acid;2-(dimethylamino)ethanol Chemical compound CN(C)CCO.CC(=O)NC(C(O)=O)CCC(O)=O WKAVKKUXZAWHDM-UHFFFAOYSA-N 0.000 description 1
- REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- LKZYNWBZLPDDII-UHFFFAOYSA-N 2-fluoro-4-methylsulfanylbenzonitrile Chemical compound CSC1=CC=C(C#N)C(F)=C1 LKZYNWBZLPDDII-UHFFFAOYSA-N 0.000 description 1
- NRXOILPYFSPPSX-UHFFFAOYSA-N 2-methyl-4-methylsulfanylbenzonitrile Chemical compound CSC1=CC=C(C#N)C(C)=C1 NRXOILPYFSPPSX-UHFFFAOYSA-N 0.000 description 1
- JESRNIJXVIFVOV-UHFFFAOYSA-N 2-methylpyrazol-3-amine Chemical compound CN1N=CC=C1N JESRNIJXVIFVOV-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- LFIWXXXFJFOECP-UHFFFAOYSA-N 4-(aminomethyl)benzonitrile Chemical compound NCC1=CC=C(C#N)C=C1 LFIWXXXFJFOECP-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- FQFXHZATRHYKCE-UHFFFAOYSA-N 4-cyclopropylsulfanylbenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1SC1CC1 FQFXHZATRHYKCE-UHFFFAOYSA-N 0.000 description 1
- ZMEAHKIIWJDJFT-UHFFFAOYSA-N 4-fluoro-3-methylbenzonitrile Chemical compound CC1=CC(C#N)=CC=C1F ZMEAHKIIWJDJFT-UHFFFAOYSA-N 0.000 description 1
- 239000003406 5-lipoxygenase-activating protein inhibitor Substances 0.000 description 1
- SWCWUMYYZJHKIN-UHFFFAOYSA-N 5-methylsulfanylpyridine-2-carbonitrile Chemical compound CSC1=CC=C(C#N)N=C1 SWCWUMYYZJHKIN-UHFFFAOYSA-N 0.000 description 1
- AOJLDZLRTUWFFY-UHFFFAOYSA-N 6-methyl-4-oxo-1h-pyridine-3-carboxylic acid Chemical compound CC1=CC(=O)C(C(O)=O)=CN1 AOJLDZLRTUWFFY-UHFFFAOYSA-N 0.000 description 1
- PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 102100028163 ATP-binding cassette sub-family C member 4 Human genes 0.000 description 1
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 102000009346 Adenosine receptors Human genes 0.000 description 1
- 108050000203 Adenosine receptors Proteins 0.000 description 1
- 102100022455 Adrenocorticotropic hormone receptor Human genes 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000035939 Alveolitis allergic Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N Azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- XQOSHWPKADMSKX-UHFFFAOYSA-N C(#N)N=[SH2]=O Chemical class C(#N)N=[SH2]=O XQOSHWPKADMSKX-UHFFFAOYSA-N 0.000 description 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 description 1
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 1
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 description 1
- 102100025618 C-X-C chemokine receptor type 6 Human genes 0.000 description 1
- MDEUXXUIQLTCGJ-UHFFFAOYSA-I C.CI.CI.CS(C)(=N)=O.CS(C)(=O)=NC#N.CS(C)=N.CS(C)=NC#N.CS(C)=NC(=O)C(F)(F)F.CSC.ICI.I[V](I)I.I[V]I Chemical compound C.CI.CI.CS(C)(=N)=O.CS(C)(=O)=NC#N.CS(C)=N.CS(C)=NC#N.CS(C)=NC(=O)C(F)(F)F.CSC.ICI.I[V](I)I.I[V]I MDEUXXUIQLTCGJ-UHFFFAOYSA-I 0.000 description 1
- DOLNDJUISIVBOY-UHFFFAOYSA-N C/S(=N\C#N)C1=CN=C(CN2C(=O)C3=C(C=CC=C3)C2=O)C=C1 Chemical compound C/S(=N\C#N)C1=CN=C(CN2C(=O)C3=C(C=CC=C3)C2=O)C=C1 DOLNDJUISIVBOY-UHFFFAOYSA-N 0.000 description 1
- RBPWDSRDPHAKJR-UHFFFAOYSA-N C1=CC=NC=C1.C1=CC=NC=C1.C1=CCC=C1.C1=CCN=C1.C1=CN=CC1.C1=CN=CC=N1.C1=CN=NC1.C1=CN=NC=C1.C1=COC=C1.C1=COC=N1.C1=CON=C1.C1=CON=N1.C1=CSC=C1.C1=CSC=N1.C1=CSN=C1.C1=CSN=N1.C1=NC=NC=N1.C1=NC=NN=C1.C1=NC=NO1.C1=NC=NS1.C1=NN=CC1.C1=NN=CO1.C1=NN=CS1.C1=NN=NC1.C1=NON=C1.C1=NSN=C1.O=S1C=CC=C1.[O-][N+]1=CC=CC=C1 Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.C1=CCC=C1.C1=CCN=C1.C1=CN=CC1.C1=CN=CC=N1.C1=CN=NC1.C1=CN=NC=C1.C1=COC=C1.C1=COC=N1.C1=CON=C1.C1=CON=N1.C1=CSC=C1.C1=CSC=N1.C1=CSN=C1.C1=CSN=N1.C1=NC=NC=N1.C1=NC=NN=C1.C1=NC=NO1.C1=NC=NS1.C1=NN=CC1.C1=NN=CO1.C1=NN=CS1.C1=NN=NC1.C1=NON=C1.C1=NSN=C1.O=S1C=CC=C1.[O-][N+]1=CC=CC=C1 RBPWDSRDPHAKJR-UHFFFAOYSA-N 0.000 description 1
- ZRHAUULIZRQGEA-UHFFFAOYSA-N CC(=O)SC1=CC=C(CN2C(=O)C3=C(C=CC=C3)C2=O)C=C1 Chemical compound CC(=O)SC1=CC=C(CN2C(=O)C3=C(C=CC=C3)C2=O)C=C1 ZRHAUULIZRQGEA-UHFFFAOYSA-N 0.000 description 1
- DSPZNBCXPQKETC-UHFFFAOYSA-N CC1(C)OB(C2=CC=C(F)C(C(F)F)=C2)OC1(C)C Chemical compound CC1(C)OB(C2=CC=C(F)C(C(F)F)=C2)OC1(C)C DSPZNBCXPQKETC-UHFFFAOYSA-N 0.000 description 1
- WNNNXDYONPLALG-UHFFFAOYSA-N CC1=C(Br)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1=CN(C)N=C1 Chemical compound CC1=C(Br)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1=CN(C)N=C1 WNNNXDYONPLALG-UHFFFAOYSA-N 0.000 description 1
- PNDQOGACIJUTES-UHFFFAOYSA-N CC1=C(Br)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1=NC=CS1 Chemical compound CC1=C(Br)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1=NC=CS1 PNDQOGACIJUTES-UHFFFAOYSA-N 0.000 description 1
- QIFDFZZVTJRYGM-UHFFFAOYSA-N CC1=C(Br)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1CCCOC1 Chemical compound CC1=C(Br)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1CCCOC1 QIFDFZZVTJRYGM-UHFFFAOYSA-N 0.000 description 1
- GTIGBWOARNJEAG-UHFFFAOYSA-N CC1=C(Br)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1CCOC1 Chemical compound CC1=C(Br)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1CCOC1 GTIGBWOARNJEAG-UHFFFAOYSA-N 0.000 description 1
- KGLVDQUDCMZUFG-UHFFFAOYSA-N CC1=C(Br)C(=O)C(C(=O)O)=CN1C1=CC=CC=C1 Chemical compound CC1=C(Br)C(=O)C(C(=O)O)=CN1C1=CC=CC=C1 KGLVDQUDCMZUFG-UHFFFAOYSA-N 0.000 description 1
- NOVIVNLLEHTMHS-UHFFFAOYSA-N CC1=C(Br)C(=O)C(C(=O)O)=CN1C1=CC=CC=N1 Chemical compound CC1=C(Br)C(=O)C(C(=O)O)=CN1C1=CC=CC=N1 NOVIVNLLEHTMHS-UHFFFAOYSA-N 0.000 description 1
- IXBBTWZREKNOJJ-UHFFFAOYSA-N CC1=C(Br)C(=O)C(C(=O)O)=CN1C1=CC=CN=C1 Chemical compound CC1=C(Br)C(=O)C(C(=O)O)=CN1C1=CC=CN=C1 IXBBTWZREKNOJJ-UHFFFAOYSA-N 0.000 description 1
- USZWWJPMDIWKGM-UHFFFAOYSA-N CC1=C(Br)C(=O)C(C(=O)O)=CN1C1=CC=NC=C1 Chemical compound CC1=C(Br)C(=O)C(C(=O)O)=CN1C1=CC=NC=C1 USZWWJPMDIWKGM-UHFFFAOYSA-N 0.000 description 1
- GJXZLJQCUDDIBO-UHFFFAOYSA-N CC1=C(Br)C(=O)C(C(=O)O)=CN1C1=CN(C)N=C1 Chemical compound CC1=C(Br)C(=O)C(C(=O)O)=CN1C1=CN(C)N=C1 GJXZLJQCUDDIBO-UHFFFAOYSA-N 0.000 description 1
- LHBDJFXKLTZZRO-UHFFFAOYSA-N CC1=C(Br)C(=O)C(C(=O)O)=CN1C1=CN=CN=C1 Chemical compound CC1=C(Br)C(=O)C(C(=O)O)=CN1C1=CN=CN=C1 LHBDJFXKLTZZRO-UHFFFAOYSA-N 0.000 description 1
- XQVYTTFJTRDJSJ-UHFFFAOYSA-N CC1=C(Br)C(=O)C(C(=O)O)=CN1C1=NC=CS1 Chemical compound CC1=C(Br)C(=O)C(C(=O)O)=CN1C1=NC=CS1 XQVYTTFJTRDJSJ-UHFFFAOYSA-N 0.000 description 1
- MZTMMQOZSYPHIH-UHFFFAOYSA-N CC1=C(Br)C(=O)C(C(=O)O)=CN1C1CC1 Chemical compound CC1=C(Br)C(=O)C(C(=O)O)=CN1C1CC1 MZTMMQOZSYPHIH-UHFFFAOYSA-N 0.000 description 1
- PWWFVZJZYXUVQU-UHFFFAOYSA-N CC1=C(Br)C(=O)C(C(=O)O)=CN1C1CCCOC1 Chemical compound CC1=C(Br)C(=O)C(C(=O)O)=CN1C1CCCOC1 PWWFVZJZYXUVQU-UHFFFAOYSA-N 0.000 description 1
- QECJHJXFLWQJAS-UHFFFAOYSA-N CC1=C(Br)C(=O)C(C(=O)O)=CN1C1CCOC1 Chemical compound CC1=C(Br)C(=O)C(C(=O)O)=CN1C1CCOC1 QECJHJXFLWQJAS-UHFFFAOYSA-N 0.000 description 1
- RSHCGCZDBKRXBC-UHFFFAOYSA-N CC1=C(Br)C(=O)C(C(=O)O)=CN1C1CCOCC1 Chemical compound CC1=C(Br)C(=O)C(C(=O)O)=CN1C1CCOCC1 RSHCGCZDBKRXBC-UHFFFAOYSA-N 0.000 description 1
- GYJCVXXUZJQZEJ-UHFFFAOYSA-N CC1=C(C2=CC(C(F)(F)F)=CC=C2)C(=O)C(C(=O)NCC2=C(F)C=C(S(C)(=O)=NC#N)C=C2)=CN1C(C)C Chemical compound CC1=C(C2=CC(C(F)(F)F)=CC=C2)C(=O)C(C(=O)NCC2=C(F)C=C(S(C)(=O)=NC#N)C=C2)=CN1C(C)C GYJCVXXUZJQZEJ-UHFFFAOYSA-N 0.000 description 1
- YHDRHJBIRHOBRS-UHFFFAOYSA-N CC1=C(C2=CC(C(F)(F)F)=CC=C2)C(=O)C(C(=O)NCC2=CC(F)=C(S(C)(=O)=NC#N)C=C2)=CN1C(C)C Chemical compound CC1=C(C2=CC(C(F)(F)F)=CC=C2)C(=O)C(C(=O)NCC2=CC(F)=C(S(C)(=O)=NC#N)C=C2)=CN1C(C)C YHDRHJBIRHOBRS-UHFFFAOYSA-N 0.000 description 1
- LNBJRTJBKWJDEJ-UHFFFAOYSA-N CC1=C(C2=CC(C(F)(F)F)=CC=C2)C(=O)C(C(=O)NCC2=CC=C(S(=O)(=NC#N)C(C)C)C=C2)=CN1C1CC1 Chemical compound CC1=C(C2=CC(C(F)(F)F)=CC=C2)C(=O)C(C(=O)NCC2=CC=C(S(=O)(=NC#N)C(C)C)C=C2)=CN1C1CC1 LNBJRTJBKWJDEJ-UHFFFAOYSA-N 0.000 description 1
- CLLXPVQUNZDZLA-UHFFFAOYSA-N CC1=C(C2=CC(C(F)(F)F)=CC=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1CC1 Chemical compound CC1=C(C2=CC(C(F)(F)F)=CC=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1CC1 CLLXPVQUNZDZLA-UHFFFAOYSA-N 0.000 description 1
- RHNOVIOEMJLFSN-UHFFFAOYSA-N CC1=C(C2=CC(C(F)(F)F)=CC=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NS(C)(=O)=O)C=C2)=CN1C(C)C Chemical compound CC1=C(C2=CC(C(F)(F)F)=CC=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NS(C)(=O)=O)C=C2)=CN1C(C)C RHNOVIOEMJLFSN-UHFFFAOYSA-N 0.000 description 1
- DRAPTYRXJHYRNW-UHFFFAOYSA-N CC1=C(C2=CC(C(F)F)=CC=C2)C(=O)C(C(=O)NCC2=CC=C(S(=O)(=NC#N)C(C)C)C=C2)=CN1C1=CC=NN1C Chemical compound CC1=C(C2=CC(C(F)F)=CC=C2)C(=O)C(C(=O)NCC2=CC=C(S(=O)(=NC#N)C(C)C)C=C2)=CN1C1=CC=NN1C DRAPTYRXJHYRNW-UHFFFAOYSA-N 0.000 description 1
- GWCJWFQAHDVBJQ-UHFFFAOYSA-N CC1=C(C2=CC(C(F)F)=CC=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C(F)=C2)=CN1C(C)C Chemical compound CC1=C(C2=CC(C(F)F)=CC=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C(F)=C2)=CN1C(C)C GWCJWFQAHDVBJQ-UHFFFAOYSA-N 0.000 description 1
- IAYOLQRAEBEISR-UHFFFAOYSA-N CC1=C(C2=CC(C(F)F)=CC=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NS(C)(=O)=O)C=C2)=CN1C(C)C Chemical compound CC1=C(C2=CC(C(F)F)=CC=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NS(C)(=O)=O)C=C2)=CN1C(C)C IAYOLQRAEBEISR-UHFFFAOYSA-N 0.000 description 1
- NEHBARWHGAHXJH-UHFFFAOYSA-N CC1=C(C2=CC=C(F)C(C(F)F)=C2)C(=O)C(C(=O)O)=CN1C(C)C Chemical compound CC1=C(C2=CC=C(F)C(C(F)F)=C2)C(=O)C(C(=O)O)=CN1C(C)C NEHBARWHGAHXJH-UHFFFAOYSA-N 0.000 description 1
- LKJSBLFRMZHVSS-UHFFFAOYSA-N CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1=CC=CC=C1 Chemical compound CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1=CC=CC=C1 LKJSBLFRMZHVSS-UHFFFAOYSA-N 0.000 description 1
- QWKQEYMDMZZLKG-UHFFFAOYSA-N CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1=CC=NC=C1 Chemical compound CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1=CC=NC=C1 QWKQEYMDMZZLKG-UHFFFAOYSA-N 0.000 description 1
- ZGEULVPOKVIEBP-UHFFFAOYSA-N CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1=CN(C)N=C1 Chemical compound CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1=CN(C)N=C1 ZGEULVPOKVIEBP-UHFFFAOYSA-N 0.000 description 1
- BCVHWGSDAMRMAD-UHFFFAOYSA-N CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1=CN=CN=C1 Chemical compound CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1=CN=CN=C1 BCVHWGSDAMRMAD-UHFFFAOYSA-N 0.000 description 1
- ULRXYYIWBULQDH-UHFFFAOYSA-N CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1=NC=CS1 Chemical compound CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1=NC=CS1 ULRXYYIWBULQDH-UHFFFAOYSA-N 0.000 description 1
- RGVMQLWCXJIJPM-UHFFFAOYSA-N CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1CCCOC1 Chemical compound CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1CCCOC1 RGVMQLWCXJIJPM-UHFFFAOYSA-N 0.000 description 1
- AOIFTRNKICFEAI-UHFFFAOYSA-N CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1CCOC1 Chemical compound CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1CCOC1 AOIFTRNKICFEAI-UHFFFAOYSA-N 0.000 description 1
- JTWKXKKUCPGUDI-UHFFFAOYSA-N CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1CCOCC1 Chemical compound CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1CCOCC1 JTWKXKKUCPGUDI-UHFFFAOYSA-N 0.000 description 1
- QNHIWQVRUJUWIA-UHFFFAOYSA-N CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)NCC2=[N+]([O-])C=C(S(C)(=O)=NC#N)C=C2)=CN1C(C)C Chemical compound CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)NCC2=[N+]([O-])C=C(S(C)(=O)=NC#N)C=C2)=CN1C(C)C QNHIWQVRUJUWIA-UHFFFAOYSA-N 0.000 description 1
- QJBUVXSLXDSQQA-UHFFFAOYSA-N CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)O)=CN1C1=CC=CC=C1 Chemical compound CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)O)=CN1C1=CC=CC=C1 QJBUVXSLXDSQQA-UHFFFAOYSA-N 0.000 description 1
- FBTCATNVLXQKSX-UHFFFAOYSA-N CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)O)=CN1C1=CC=CC=N1 Chemical compound CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)O)=CN1C1=CC=CC=N1 FBTCATNVLXQKSX-UHFFFAOYSA-N 0.000 description 1
- YNHVWZFSXHFRTR-UHFFFAOYSA-N CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)O)=CN1C1=CC=CN=C1 Chemical compound CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)O)=CN1C1=CC=CN=C1 YNHVWZFSXHFRTR-UHFFFAOYSA-N 0.000 description 1
- XOSJSAHYTRJSHE-UHFFFAOYSA-N CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)O)=CN1C1=CC=NC=C1 Chemical compound CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)O)=CN1C1=CC=NC=C1 XOSJSAHYTRJSHE-UHFFFAOYSA-N 0.000 description 1
- VWQKXYKUBICKAN-UHFFFAOYSA-N CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)O)=CN1C1=CC=NN1C Chemical compound CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)O)=CN1C1=CC=NN1C VWQKXYKUBICKAN-UHFFFAOYSA-N 0.000 description 1
- PKDKWXKBIOKSTO-UHFFFAOYSA-N CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)O)=CN1C1=CN=CN=C1 Chemical compound CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)O)=CN1C1=CN=CN=C1 PKDKWXKBIOKSTO-UHFFFAOYSA-N 0.000 description 1
- JIEJUGMQMFUPAK-UHFFFAOYSA-N CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)O)=CN1C1CC1 Chemical compound CC1=C(C2=CC=CC(C(F)(F)F)=C2)C(=O)C(C(=O)O)=CN1C1CC1 JIEJUGMQMFUPAK-UHFFFAOYSA-N 0.000 description 1
- IHFMBDIFKZQTNB-UHFFFAOYSA-N CC1=C(C2=CC=CC(C(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1=CC=CC=C1 Chemical compound CC1=C(C2=CC=CC(C(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1=CC=CC=C1 IHFMBDIFKZQTNB-UHFFFAOYSA-N 0.000 description 1
- WZTNZPSMJRDPNI-UHFFFAOYSA-N CC1=C(C2=CC=CC(C(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1=CC=CN=C1 Chemical compound CC1=C(C2=CC=CC(C(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1=CC=CN=C1 WZTNZPSMJRDPNI-UHFFFAOYSA-N 0.000 description 1
- HJWFRMCLDZFFAN-UHFFFAOYSA-N CC1=C(C2=CC=CC(C(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1=CC=NC=C1 Chemical compound CC1=C(C2=CC=CC(C(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1=CC=NC=C1 HJWFRMCLDZFFAN-UHFFFAOYSA-N 0.000 description 1
- JUYIVKWUMCDJJX-UHFFFAOYSA-N CC1=C(C2=CC=CC(C(F)F)=C2)C(=O)C(C(=O)O)=CN1C(C)C Chemical compound CC1=C(C2=CC=CC(C(F)F)=C2)C(=O)C(C(=O)O)=CN1C(C)C JUYIVKWUMCDJJX-UHFFFAOYSA-N 0.000 description 1
- ALYJTJCPBXTZLX-UHFFFAOYSA-N CC1=C(C2=CC=CC(C(F)F)=C2)C(=O)C(C(=O)O)=CN1C1=CC=CC=C1 Chemical compound CC1=C(C2=CC=CC(C(F)F)=C2)C(=O)C(C(=O)O)=CN1C1=CC=CC=C1 ALYJTJCPBXTZLX-UHFFFAOYSA-N 0.000 description 1
- IODLIANPCNAACG-UHFFFAOYSA-N CC1=C(C2=CC=CC(C(F)F)=C2)C(=O)C(C(=O)O)=CN1C1=CC=CN=C1 Chemical compound CC1=C(C2=CC=CC(C(F)F)=C2)C(=O)C(C(=O)O)=CN1C1=CC=CN=C1 IODLIANPCNAACG-UHFFFAOYSA-N 0.000 description 1
- BPSKTWLWSIPAPI-UHFFFAOYSA-N CC1=C(C2=CC=CC(C(F)F)=C2)C(=O)C(C(=O)O)=CN1C1=CC=NC=C1 Chemical compound CC1=C(C2=CC=CC(C(F)F)=C2)C(=O)C(C(=O)O)=CN1C1=CC=NC=C1 BPSKTWLWSIPAPI-UHFFFAOYSA-N 0.000 description 1
- LJTRHXXITRUCGT-UHFFFAOYSA-N CC1=C(C2=CC=CC(C(F)F)=C2)C(=O)C(C(=O)O)=CN1C1=CC=NN1C Chemical compound CC1=C(C2=CC=CC(C(F)F)=C2)C(=O)C(C(=O)O)=CN1C1=CC=NN1C LJTRHXXITRUCGT-UHFFFAOYSA-N 0.000 description 1
- NHHONHCWBUNAKU-UHFFFAOYSA-N CC1=C(C2=CC=NC(C(F)(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1=CC=CC=C1 Chemical compound CC1=C(C2=CC=NC(C(F)(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1=CC=CC=C1 NHHONHCWBUNAKU-UHFFFAOYSA-N 0.000 description 1
- XNXAQFQJQPFPTM-UHFFFAOYSA-N CC1=C(C2=CC=NC(C(F)(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1=CC=CC=N1 Chemical compound CC1=C(C2=CC=NC(C(F)(F)F)=C2)C(=O)C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)=CN1C1=CC=CC=N1 XNXAQFQJQPFPTM-UHFFFAOYSA-N 0.000 description 1
- MQZOVGNZCHWUOP-UHFFFAOYSA-N CC1=C(C2=CC=NC(C(F)(F)F)=C2)C(=O)C(C(=O)O)=CN1C1=CC=CC=C1 Chemical compound CC1=C(C2=CC=NC(C(F)(F)F)=C2)C(=O)C(C(=O)O)=CN1C1=CC=CC=C1 MQZOVGNZCHWUOP-UHFFFAOYSA-N 0.000 description 1
- RPKTWMSRZWSBMZ-UHFFFAOYSA-N CC1=C(C2=CC=NC(C(F)(F)F)=C2)C(=O)C(C(=O)O)=CN1C1=CC=CC=N1 Chemical compound CC1=C(C2=CC=NC(C(F)(F)F)=C2)C(=O)C(C(=O)O)=CN1C1=CC=CC=N1 RPKTWMSRZWSBMZ-UHFFFAOYSA-N 0.000 description 1
- GTDRVDGCARXOHY-UHFFFAOYSA-N CC1=C(C2=CC=NC(C(F)(F)F)=C2)C(=O)C(C(=O)O)=CN1C1=CC=CN=C1 Chemical compound CC1=C(C2=CC=NC(C(F)(F)F)=C2)C(=O)C(C(=O)O)=CN1C1=CC=CN=C1 GTDRVDGCARXOHY-UHFFFAOYSA-N 0.000 description 1
- HXKAGTPJWVALHI-UHFFFAOYSA-N CC1=C(C2=CC=NC(C(F)(F)F)=C2)C(=O)C(C(=O)O)=CN1C1=CC=NC=C1 Chemical compound CC1=C(C2=CC=NC(C(F)(F)F)=C2)C(=O)C(C(=O)O)=CN1C1=CC=NC=C1 HXKAGTPJWVALHI-UHFFFAOYSA-N 0.000 description 1
- CDZHGEABVVICPW-UHFFFAOYSA-N CC1=C(CNC(=O)C2=CN(C(C)C)C(C)=C(C3=CC(C(F)(F)F)=CC=C3)C2=O)C=CC(S(C)(=O)=NC#N)=C1 Chemical compound CC1=C(CNC(=O)C2=CN(C(C)C)C(C)=C(C3=CC(C(F)(F)F)=CC=C3)C2=O)C=CC(S(C)(=O)=NC#N)=C1 CDZHGEABVVICPW-UHFFFAOYSA-N 0.000 description 1
- WXEJZGUCKMSEAY-UHFFFAOYSA-N CC1=C(CNC(=O)C2=CN(C(C)C)C(C)=C(C3=CC(C(F)F)=CC=C3)C2=O)C=CC(S(C)(=O)=NC#N)=C1 Chemical compound CC1=C(CNC(=O)C2=CN(C(C)C)C(C)=C(C3=CC(C(F)F)=CC=C3)C2=O)C=CC(S(C)(=O)=NC#N)=C1 WXEJZGUCKMSEAY-UHFFFAOYSA-N 0.000 description 1
- HLVFKXWHCGHKMT-UHFFFAOYSA-N CC1=C(N2C=C(C(=O)NCC3=CC=C(S(C)(=O)=NC#N)C=C3)C(=O)C(Br)=C2C)C=NC=C1 Chemical compound CC1=C(N2C=C(C(=O)NCC3=CC=C(S(C)(=O)=NC#N)C=C3)C(=O)C(Br)=C2C)C=NC=C1 HLVFKXWHCGHKMT-UHFFFAOYSA-N 0.000 description 1
- QSCVCXRIJARQES-UHFFFAOYSA-N CC1=C(N2C=C(C(=O)O)C(=O)C(Br)=C2C)C=NC=C1 Chemical compound CC1=C(N2C=C(C(=O)O)C(=O)C(Br)=C2C)C=NC=C1 QSCVCXRIJARQES-UHFFFAOYSA-N 0.000 description 1
- XNGKRSFSAXZFFD-UHFFFAOYSA-N CC1=CC(=O)C(C(=O)O)=CN1C1=C(C)C(C)=NO1 Chemical compound CC1=CC(=O)C(C(=O)O)=CN1C1=C(C)C(C)=NO1 XNGKRSFSAXZFFD-UHFFFAOYSA-N 0.000 description 1
- URLHGVMCCKEDCF-UHFFFAOYSA-N CC1=CC(=O)C(C(=O)O)=CN1C1=C(C)C=CN=C1 Chemical compound CC1=CC(=O)C(C(=O)O)=CN1C1=C(C)C=CN=C1 URLHGVMCCKEDCF-UHFFFAOYSA-N 0.000 description 1
- ILOGMEOBDLMZOJ-UHFFFAOYSA-N CC1=CC(=O)C(C(=O)O)=CN1C1=C(C)ON=C1C Chemical compound CC1=CC(=O)C(C(=O)O)=CN1C1=C(C)ON=C1C ILOGMEOBDLMZOJ-UHFFFAOYSA-N 0.000 description 1
- DKVITSFAMRZJIT-UHFFFAOYSA-N CC1=CC(=O)C(C(=O)O)=CN1C1=CC(C)=NN1C Chemical compound CC1=CC(=O)C(C(=O)O)=CN1C1=CC(C)=NN1C DKVITSFAMRZJIT-UHFFFAOYSA-N 0.000 description 1
- TXSPLYSSBCWOAQ-UHFFFAOYSA-N CC1=CC(=O)C(C(=O)O)=CN1C1=CC(C)=NO1 Chemical compound CC1=CC(=O)C(C(=O)O)=CN1C1=CC(C)=NO1 TXSPLYSSBCWOAQ-UHFFFAOYSA-N 0.000 description 1
- STAQAOHDTHFNEL-UHFFFAOYSA-N CC1=CC(=O)C(C(=O)O)=CN1C1=CC=CC=C1 Chemical compound CC1=CC(=O)C(C(=O)O)=CN1C1=CC=CC=C1 STAQAOHDTHFNEL-UHFFFAOYSA-N 0.000 description 1
- HJLCRXGLLHKOFT-UHFFFAOYSA-N CC1=CC(=O)C(C(=O)O)=CN1C1=CC=CC=N1 Chemical compound CC1=CC(=O)C(C(=O)O)=CN1C1=CC=CC=N1 HJLCRXGLLHKOFT-UHFFFAOYSA-N 0.000 description 1
- OVBPBWIUMSDYPA-UHFFFAOYSA-N CC1=CC(=O)C(C(=O)O)=CN1C1=CC=CN=C1 Chemical compound CC1=CC(=O)C(C(=O)O)=CN1C1=CC=CN=C1 OVBPBWIUMSDYPA-UHFFFAOYSA-N 0.000 description 1
- FKAUQFZWTXGGAL-UHFFFAOYSA-N CC1=CC(=O)C(C(=O)O)=CN1C1=CC=NC=C1 Chemical compound CC1=CC(=O)C(C(=O)O)=CN1C1=CC=NC=C1 FKAUQFZWTXGGAL-UHFFFAOYSA-N 0.000 description 1
- NLHOPGWRCCADOW-UHFFFAOYSA-N CC1=CC(=O)C(C(=O)O)=CN1C1=CN(C)N=C1 Chemical compound CC1=CC(=O)C(C(=O)O)=CN1C1=CN(C)N=C1 NLHOPGWRCCADOW-UHFFFAOYSA-N 0.000 description 1
- AVZGKHRWTUWILL-UHFFFAOYSA-N CC1=CC(=O)C(C(=O)O)=CN1C1=CN=CN=C1 Chemical compound CC1=CC(=O)C(C(=O)O)=CN1C1=CN=CN=C1 AVZGKHRWTUWILL-UHFFFAOYSA-N 0.000 description 1
- OLMSASODOZSXEY-UHFFFAOYSA-N CC1=CC(=O)C(C(=O)O)=CN1C1=NC=CS1 Chemical compound CC1=CC(=O)C(C(=O)O)=CN1C1=NC=CS1 OLMSASODOZSXEY-UHFFFAOYSA-N 0.000 description 1
- RVSBPEJBKHUQRY-UHFFFAOYSA-N CC1=CC(=O)C(C(=O)O)=CN1C1CC1 Chemical compound CC1=CC(=O)C(C(=O)O)=CN1C1CC1 RVSBPEJBKHUQRY-UHFFFAOYSA-N 0.000 description 1
- JVTGQHLSXMDVCI-UHFFFAOYSA-N CC1=CC(=O)C(C(=O)O)=CN1C1CCCOC1 Chemical compound CC1=CC(=O)C(C(=O)O)=CN1C1CCCOC1 JVTGQHLSXMDVCI-UHFFFAOYSA-N 0.000 description 1
- MGYMJOLXIBBPCV-UHFFFAOYSA-N CC1=CC(=O)C(C(=O)O)=CN1C1CCOC1 Chemical compound CC1=CC(=O)C(C(=O)O)=CN1C1CCOC1 MGYMJOLXIBBPCV-UHFFFAOYSA-N 0.000 description 1
- SJQOLDCWKMNTMT-UHFFFAOYSA-N CC1=CC(=O)C(C(=O)O)=CN1C1CCOCC1 Chemical compound CC1=CC(=O)C(C(=O)O)=CN1C1CCOCC1 SJQOLDCWKMNTMT-UHFFFAOYSA-N 0.000 description 1
- JYYNAJVZFGKDEQ-UHFFFAOYSA-N CC1=CC(C)=NC=C1 Chemical compound CC1=CC(C)=NC=C1 JYYNAJVZFGKDEQ-UHFFFAOYSA-N 0.000 description 1
- ZCCMPSPWXYCJRQ-UHFFFAOYSA-N CC1=CC(N2C=C(C(=O)NCC3=CC=C(S(C)(=O)=NC#N)C=C3)C(=O)C(C3=CC=CC(C(F)(F)F)=C3)=C2C)=NO1 Chemical compound CC1=CC(N2C=C(C(=O)NCC3=CC=C(S(C)(=O)=NC#N)C=C3)C(=O)C(C3=CC=CC(C(F)(F)F)=C3)=C2C)=NO1 ZCCMPSPWXYCJRQ-UHFFFAOYSA-N 0.000 description 1
- SHZUWZBCCNYGBF-UHFFFAOYSA-N CC1=CC(N2C=C(C(=O)O)C(=O)C(Br)=C2C)=NO1 Chemical compound CC1=CC(N2C=C(C(=O)O)C(=O)C(Br)=C2C)=NO1 SHZUWZBCCNYGBF-UHFFFAOYSA-N 0.000 description 1
- HVSKVBBCBAABOI-UHFFFAOYSA-N CC1=CC(N2C=C(C(=O)O)C(=O)C=C2C)=NO1 Chemical compound CC1=CC(N2C=C(C(=O)O)C(=O)C=C2C)=NO1 HVSKVBBCBAABOI-UHFFFAOYSA-N 0.000 description 1
- YPZHEHJWJYLXSO-UHFFFAOYSA-N CC1=CC=C(N2C=C(C(=O)NCC3=CC=C(S(C)(=O)=NC#N)C=C3)C(=O)C(Br)=C2C)C=N1 Chemical compound CC1=CC=C(N2C=C(C(=O)NCC3=CC=C(S(C)(=O)=NC#N)C=C3)C(=O)C(Br)=C2C)C=N1 YPZHEHJWJYLXSO-UHFFFAOYSA-N 0.000 description 1
- PPXFQGGMBNLXTL-UHFFFAOYSA-N CC1=CC=C(N2C=C(C(=O)O)C(=O)C(Br)=C2C)C=N1 Chemical compound CC1=CC=C(N2C=C(C(=O)O)C(=O)C(Br)=C2C)C=N1 PPXFQGGMBNLXTL-UHFFFAOYSA-N 0.000 description 1
- FLWROPGAVUSXLX-UHFFFAOYSA-N CC1=CC=C(N2C=C(C(=O)O)C(=O)C=C2C)C=N1 Chemical compound CC1=CC=C(N2C=C(C(=O)O)C(=O)C=C2C)C=N1 FLWROPGAVUSXLX-UHFFFAOYSA-N 0.000 description 1
- QHYKWIDLVKJBLK-UHFFFAOYSA-N CC1=CC=CC(C(C)(F)F)=C1.CC1=CC=CC(C(C)F)=C1.CC1=CC=NC(C(C)(F)F)=C1 Chemical compound CC1=CC=CC(C(C)(F)F)=C1.CC1=CC=CC(C(C)F)=C1.CC1=CC=NC(C(C)(F)F)=C1 QHYKWIDLVKJBLK-UHFFFAOYSA-N 0.000 description 1
- CMPDAJMBLIDHHS-UHFFFAOYSA-N CC1=CC=NC=C1N1C=C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)C(=O)C(C2=CC=CC(C(F)(F)F)=C2)=C1C Chemical compound CC1=CC=NC=C1N1C=C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)C(=O)C(C2=CC=CC(C(F)(F)F)=C2)=C1C CMPDAJMBLIDHHS-UHFFFAOYSA-N 0.000 description 1
- AHBHZSOOZCWXPO-UHFFFAOYSA-N CC1=CN=CC(N2C=C(C(=O)NCC3=CC=C(S(C)(=O)=NC#N)C=C3)C(=O)C(Br)=C2C)=C1 Chemical compound CC1=CN=CC(N2C=C(C(=O)NCC3=CC=C(S(C)(=O)=NC#N)C=C3)C(=O)C(Br)=C2C)=C1 AHBHZSOOZCWXPO-UHFFFAOYSA-N 0.000 description 1
- PTMFHLXZBJOCIE-UHFFFAOYSA-N CC1=CN=CC(N2C=C(C(=O)O)C(=O)C=C2C)=C1 Chemical compound CC1=CN=CC(N2C=C(C(=O)O)C(=O)C=C2C)=C1 PTMFHLXZBJOCIE-UHFFFAOYSA-N 0.000 description 1
- BGWZLZCLWBZOFY-UHFFFAOYSA-N CC1=NC=C(N2C=C(C(=O)NCC3=CC=C(S(C)(=O)=NC#N)C=C3)C(=O)C(C3=CC=CC(C(F)(F)F)=C3)=C2C)C=C1 Chemical compound CC1=NC=C(N2C=C(C(=O)NCC3=CC=C(S(C)(=O)=NC#N)C=C3)C(=O)C(C3=CC=CC(C(F)(F)F)=C3)=C2C)C=C1 BGWZLZCLWBZOFY-UHFFFAOYSA-N 0.000 description 1
- KNPXXRJISKMDEP-UHFFFAOYSA-N CC1=NN(C)C(N2C=C(C(=O)NCC3=CC=C(S(C)(=O)=NC#N)C=C3)C(=O)C(Br)=C2C)=C1 Chemical compound CC1=NN(C)C(N2C=C(C(=O)NCC3=CC=C(S(C)(=O)=NC#N)C=C3)C(=O)C(Br)=C2C)=C1 KNPXXRJISKMDEP-UHFFFAOYSA-N 0.000 description 1
- NHFGYBRODRBETJ-UHFFFAOYSA-N CC1=NN(C)C(N2C=C(C(=O)NCC3=CC=C(S(C)(=O)=NC#N)C=C3)C(=O)C(C3=CC=CC(C(F)(F)F)=C3)=C2C)=C1 Chemical compound CC1=NN(C)C(N2C=C(C(=O)NCC3=CC=C(S(C)(=O)=NC#N)C=C3)C(=O)C(C3=CC=CC(C(F)(F)F)=C3)=C2C)=C1 NHFGYBRODRBETJ-UHFFFAOYSA-N 0.000 description 1
- AQORZUAFEWAQDN-UHFFFAOYSA-N CC1=NN(C)C(N2C=C(C(=O)O)C(=O)C(Br)=C2C)=C1 Chemical compound CC1=NN(C)C(N2C=C(C(=O)O)C(=O)C(Br)=C2C)=C1 AQORZUAFEWAQDN-UHFFFAOYSA-N 0.000 description 1
- QPAFJKANEICUNO-UHFFFAOYSA-N CC1=NOC(C)=C1N1C=C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)C(=O)C(C2=CC=CC(C(F)(F)F)=C2)=C1C Chemical compound CC1=NOC(C)=C1N1C=C(C(=O)NCC2=CC=C(S(C)(=O)=NC#N)C=C2)C(=O)C(C2=CC=CC(C(F)(F)F)=C2)=C1C QPAFJKANEICUNO-UHFFFAOYSA-N 0.000 description 1
- AORDFWKUCUAQOP-UHFFFAOYSA-N CC1=NOC(C)=C1N1C=C(C(=O)O)C(=O)C(Br)=C1C Chemical compound CC1=NOC(C)=C1N1C=C(C(=O)O)C(=O)C(Br)=C1C AORDFWKUCUAQOP-UHFFFAOYSA-N 0.000 description 1
- VUKVTDANEWAIKQ-UHFFFAOYSA-N CC1=NOC(C)=C1N1C=C(C(=O)O)C(=O)C(C2=CC=CC(C(F)(F)F)=C2)=C1C Chemical compound CC1=NOC(C)=C1N1C=C(C(=O)O)C(=O)C(C2=CC=CC(C(F)(F)F)=C2)=C1C VUKVTDANEWAIKQ-UHFFFAOYSA-N 0.000 description 1
- OMIJLLUUHJMMOX-UHFFFAOYSA-N CC1=NOC(N2C=C(C(=O)NCC3=CC=C(S(C)(=O)=NC#N)C=C3)C(=O)C(Br)=C2C)=C1 Chemical compound CC1=NOC(N2C=C(C(=O)NCC3=CC=C(S(C)(=O)=NC#N)C=C3)C(=O)C(Br)=C2C)=C1 OMIJLLUUHJMMOX-UHFFFAOYSA-N 0.000 description 1
- MZPQSGJTXVUBPZ-UHFFFAOYSA-N CC1=NOC(N2C=C(C(=O)NCC3=CC=C(S(C)(=O)=NC#N)C=C3)C(=O)C(Br)=C2C)=C1C Chemical compound CC1=NOC(N2C=C(C(=O)NCC3=CC=C(S(C)(=O)=NC#N)C=C3)C(=O)C(Br)=C2C)=C1C MZPQSGJTXVUBPZ-UHFFFAOYSA-N 0.000 description 1
- BGFAJWAKWRYKHW-UHFFFAOYSA-N CC1=NOC(N2C=C(C(=O)NCC3=CC=C(S(C)(=O)=NC#N)C=C3)C(=O)C(C3=CC=CC(C(F)(F)F)=C3)=C2C)=C1 Chemical compound CC1=NOC(N2C=C(C(=O)NCC3=CC=C(S(C)(=O)=NC#N)C=C3)C(=O)C(C3=CC=CC(C(F)(F)F)=C3)=C2C)=C1 BGFAJWAKWRYKHW-UHFFFAOYSA-N 0.000 description 1
- NQIRDCJHKYDNNU-UHFFFAOYSA-N CC1=NOC(N2C=C(C(=O)NCC3=CC=C(S(C)(=O)=NC#N)C=C3)C(=O)C(C3=CC=CC(C(F)(F)F)=C3)=C2C)=C1C Chemical compound CC1=NOC(N2C=C(C(=O)NCC3=CC=C(S(C)(=O)=NC#N)C=C3)C(=O)C(C3=CC=CC(C(F)(F)F)=C3)=C2C)=C1C NQIRDCJHKYDNNU-UHFFFAOYSA-N 0.000 description 1
- VZSHTUHEOPUNPO-UHFFFAOYSA-N CC1=NOC(N2C=C(C(=O)O)C(=O)C(Br)=C2C)=C1 Chemical compound CC1=NOC(N2C=C(C(=O)O)C(=O)C(Br)=C2C)=C1 VZSHTUHEOPUNPO-UHFFFAOYSA-N 0.000 description 1
- ZVMHMEAMRKPOLQ-UHFFFAOYSA-N CC1=NOC(N2C=C(C(=O)O)C(=O)C(Br)=C2C)=C1C Chemical compound CC1=NOC(N2C=C(C(=O)O)C(=O)C(Br)=C2C)=C1C ZVMHMEAMRKPOLQ-UHFFFAOYSA-N 0.000 description 1
- XCLGETSFVUYSAP-UHFFFAOYSA-N CCC(C)(C)C.CCC(C)C.CCC1CC1 Chemical compound CCC(C)(C)C.CCC(C)C.CCC1CC1 XCLGETSFVUYSAP-UHFFFAOYSA-N 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N CCCCC(=O)O Chemical compound CCCCC(=O)O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- VAVUSSBPDVHFBB-UHFFFAOYSA-N CCN1C=C(C(=O)O)C(=O)C(C2=CC=CC(C(F)(F)F)=C2)=C1C Chemical compound CCN1C=C(C(=O)O)C(=O)C(C2=CC=CC(C(F)(F)F)=C2)=C1C VAVUSSBPDVHFBB-UHFFFAOYSA-N 0.000 description 1
- LEDWMQNRKGRQDC-UHFFFAOYSA-N CCN1C=C(C(=O)O)C(=O)C(C2=CC=CC(C(F)F)=C2)=C1C Chemical compound CCN1C=C(C(=O)O)C(=O)C(C2=CC=CC(C(F)F)=C2)=C1C LEDWMQNRKGRQDC-UHFFFAOYSA-N 0.000 description 1
- UHDHXMQNBRHFQO-UHFFFAOYSA-N CCS(=O)(=NC#N)C1=CC=C(CNC(=O)C2=CN(C3=CC=NN3C)C(C)=C(C3=CC(C(F)F)=CC=C3)C2=O)C=C1 Chemical compound CCS(=O)(=NC#N)C1=CC=C(CNC(=O)C2=CN(C3=CC=NN3C)C(C)=C(C3=CC(C(F)F)=CC=C3)C2=O)C=C1 UHDHXMQNBRHFQO-UHFFFAOYSA-N 0.000 description 1
- KEUJSXWKIVFVLD-UHFFFAOYSA-N CCS(=O)C1=CC=C(CN2C(=O)C3=C(C=CC=C3)C2=O)C=C1 Chemical compound CCS(=O)C1=CC=C(CN2C(=O)C3=C(C=CC=C3)C2=O)C=C1 KEUJSXWKIVFVLD-UHFFFAOYSA-N 0.000 description 1
- 229940127597 CGRP antagonist Drugs 0.000 description 1
- XHOQLCJYAJBRSV-IBGZPJMESA-N CN1C(C2=C(N(C(N[C@H]2C2=CC=C(C#N)C=C2)=O)C2=CC(=CC=C2)C(F)(F)F)CC1)=O Chemical compound CN1C(C2=C(N(C(N[C@H]2C2=CC=C(C#N)C=C2)=O)C2=CC(=CC=C2)C(F)(F)F)CC1)=O XHOQLCJYAJBRSV-IBGZPJMESA-N 0.000 description 1
- JBDVQIHAHXAFKR-UHFFFAOYSA-N CN=S(=O)(C1=CC=C(CN2C(=O)C3=C(C=CC=C3)C2=O)C=C1)N(C)C Chemical compound CN=S(=O)(C1=CC=C(CN2C(=O)C3=C(C=CC=C3)C2=O)C=C1)N(C)C JBDVQIHAHXAFKR-UHFFFAOYSA-N 0.000 description 1
- UGTJCAAXMDIONW-UHFFFAOYSA-N CS(=O)(=NC#N)C1=CN=C(CN2C(=O)C3=C(C=CC=C3)C2=O)C=C1 Chemical compound CS(=O)(=NC#N)C1=CN=C(CN2C(=O)C3=C(C=CC=C3)C2=O)C=C1 UGTJCAAXMDIONW-UHFFFAOYSA-N 0.000 description 1
- NKJDVSMDQHCOPF-UHFFFAOYSA-N CSC1=CN=C(CN)C=C1 Chemical compound CSC1=CN=C(CN)C=C1 NKJDVSMDQHCOPF-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 102100035904 Caspase-1 Human genes 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000006081 Cryptococcal meningitis Diseases 0.000 description 1
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
- 102100029921 Dipeptidyl peptidase 1 Human genes 0.000 description 1
- 101710087078 Dipeptidyl peptidase 1 Proteins 0.000 description 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
- 208000019872 Drug Eruptions Diseases 0.000 description 1
- 231100000491 EC50 Toxicity 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 206010065563 Eosinophilic bronchitis Diseases 0.000 description 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 208000027445 Farmer Lung Diseases 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 208000032678 Fixed drug eruption Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 102000027484 GABAA receptors Human genes 0.000 description 1
- 108091008681 GABAA receptors Proteins 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 102000003834 Histamine H1 Receptors Human genes 0.000 description 1
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 1
- 229940124056 Histamine H1 receptor antagonist Drugs 0.000 description 1
- 102000004384 Histamine H3 receptors Human genes 0.000 description 1
- 108090000981 Histamine H3 receptors Proteins 0.000 description 1
- 229940119240 Histamine H4 receptor antagonist Drugs 0.000 description 1
- 229940122236 Histamine receptor antagonist Drugs 0.000 description 1
- 102100022893 Histone acetyltransferase KAT5 Human genes 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 101000986629 Homo sapiens ATP-binding cassette sub-family C member 4 Proteins 0.000 description 1
- 101000678419 Homo sapiens Adrenocorticotropic hormone receptor Proteins 0.000 description 1
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 description 1
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 description 1
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 description 1
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 description 1
- 101000856683 Homo sapiens C-X-C chemokine receptor type 6 Proteins 0.000 description 1
- 101100236208 Homo sapiens LTB4R gene Proteins 0.000 description 1
- 101001017969 Homo sapiens Leukotriene B4 receptor 2 Proteins 0.000 description 1
- 101000978431 Homo sapiens Melanocortin receptor 3 Proteins 0.000 description 1
- 101000978418 Homo sapiens Melanocortin receptor 4 Proteins 0.000 description 1
- 101001134060 Homo sapiens Melanocyte-stimulating hormone receptor Proteins 0.000 description 1
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
- 101000628949 Homo sapiens Mitogen-activated protein kinase 10 Proteins 0.000 description 1
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 1
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 1
- 101000818546 Homo sapiens N-formyl peptide receptor 2 Proteins 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100021854 Inhibitor of nuclear factor kappa-B kinase subunit beta Human genes 0.000 description 1
- 101710205525 Inhibitor of nuclear factor kappa-B kinase subunit beta Proteins 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- 208000009388 Job Syndrome Diseases 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 102100022118 Leukotriene A-4 hydrolase Human genes 0.000 description 1
- 102100033374 Leukotriene B4 receptor 1 Human genes 0.000 description 1
- 102100033375 Leukotriene B4 receptor 2 Human genes 0.000 description 1
- 102000003680 Leukotriene B4 receptors Human genes 0.000 description 1
- 108090000093 Leukotriene B4 receptors Proteins 0.000 description 1
- 206010024434 Lichen sclerosus Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108020002496 Lysophospholipase Proteins 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000030612 Melanocortin 5 receptor Human genes 0.000 description 1
- 108010088565 Melanocortin 5 receptor Proteins 0.000 description 1
- 108090000950 Melanocortin Receptors Proteins 0.000 description 1
- 102000004378 Melanocortin Receptors Human genes 0.000 description 1
- 102100023726 Melanocortin receptor 3 Human genes 0.000 description 1
- 102100023724 Melanocortin receptor 4 Human genes 0.000 description 1
- 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 description 1
- 206010027209 Meningitis cryptococcal Diseases 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 102100026931 Mitogen-activated protein kinase 10 Human genes 0.000 description 1
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 1
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- WITXFYCLPDFRNM-UHFFFAOYSA-N N-Benzylphthalimide Chemical compound O=C1C2=CC=CC=C2C(=O)N1CC1=CC=CC=C1 WITXFYCLPDFRNM-UHFFFAOYSA-N 0.000 description 1
- 102100021126 N-formyl peptide receptor 2 Human genes 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- GUJYFCBXDUPORN-UHFFFAOYSA-N OB(O)C1=CC=C(F)C(C(F)(F)F)=C1 Chemical compound OB(O)C1=CC=C(F)C(C(F)(F)F)=C1 GUJYFCBXDUPORN-UHFFFAOYSA-N 0.000 description 1
- 239000012425 OXONE® Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241001420836 Ophthalmitis Species 0.000 description 1
- 102100037602 P2X purinoceptor 7 Human genes 0.000 description 1
- 101710189965 P2X purinoceptor 7 Proteins 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 208000004362 Penile Induration Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- SCKXCAADGDQQCS-UHFFFAOYSA-N Performic acid Chemical compound OOC=O SCKXCAADGDQQCS-UHFFFAOYSA-N 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 208000020758 Peyronie disease Diseases 0.000 description 1
- 229940123263 Phosphodiesterase 3 inhibitor Drugs 0.000 description 1
- 229940123304 Phosphodiesterase 7 inhibitor Drugs 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102000000033 Purinergic Receptors Human genes 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 206010039094 Rhinitis perennial Diseases 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- 102100027720 SH2 domain-containing protein 1A Human genes 0.000 description 1
- 208000007893 Salpingitis Diseases 0.000 description 1
- 101100437750 Schizosaccharomyces pombe (strain 972 / ATCC 24843) blt1 gene Proteins 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 108010045517 Serum Amyloid P-Component Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 229940127530 Sphingosine 1-Phosphate Receptor Modulators Drugs 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 208000010265 Sweet syndrome Diseases 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000003938 Thromboxane Receptors Human genes 0.000 description 1
- 108090000300 Thromboxane Receptors Proteins 0.000 description 1
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 1
- 206010057970 Toxic skin eruption Diseases 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical class [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241000870995 Variola Species 0.000 description 1
- 206010047112 Vasculitides Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000035222 X-linked skeletal dysplasia-intellectual disability syndrome Diseases 0.000 description 1
- 102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 description 1
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ZSEUEKCXNXRIKT-UHFFFAOYSA-N [N].O=C1C=CC=CN1 Chemical compound [N].O=C1C=CC=CN1 ZSEUEKCXNXRIKT-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- 230000010085 airway hyperresponsiveness Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001347 alkyl bromides Chemical class 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229940095643 calcium hydroxide Drugs 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000017760 chronic graft versus host disease Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 201000009151 chronic rhinitis Diseases 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 229940109248 cromoglycate Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 238000007333 cyanation reaction Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- 125000005046 dihydronaphthyl group Chemical group 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- FFHWGQQFANVOHV-UHFFFAOYSA-N dimethyldioxirane Chemical compound CC1(C)OO1 FFHWGQQFANVOHV-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 239000002713 epithelial sodium channel blocking agent Substances 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 208000022195 farmer lung disease Diseases 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 208000012587 fixed pigmented erythema Diseases 0.000 description 1
- 150000004673 fluoride salts Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- 239000003396 histamine H4 receptor antagonist Substances 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000004093 hydrolase inhibitor Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 206010051040 hyper-IgE syndrome Diseases 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 229940033355 lauric acid Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 108010072713 leukotriene A4 hydrolase Proteins 0.000 description 1
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 1
- 150000002635 lipoxin A4 derivatives Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 239000002697 lyase inhibitor Substances 0.000 description 1
- 230000001589 lymphoproliferative effect Effects 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- CMEUDEVBFFPSEI-NFHWZJRKSA-N methyl 4-[[(2s)-1-[[(2s)-1-[(2s)-2-[[(2s)-3-methyl-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoate Chemical compound COC(=O)CCC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)NC1=CC=C(C(C)=CC(=O)O2)C2=C1 CMEUDEVBFFPSEI-NFHWZJRKSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 244000309715 mini pig Species 0.000 description 1
- 208000008588 molluscum contagiosum Diseases 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- NALMPLUMOWIVJC-UHFFFAOYSA-N n,n,4-trimethylbenzeneamine oxide Chemical compound CC1=CC=C([N+](C)(C)[O-])C=C1 NALMPLUMOWIVJC-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- GYVPCGWBZBCXKJ-UHFFFAOYSA-N n-methyl-5-methylsulfanylpyridin-2-amine Chemical compound CNC1=CC=C(SC)C=N1 GYVPCGWBZBCXKJ-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 208000005963 oophoritis Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 208000010403 panophthalmitis Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 208000012111 paraneoplastic syndrome Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 208000022719 perennial allergic rhinitis Diseases 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 description 1
- 239000002606 phosphodiesterase VII inhibitor Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 239000013312 porous aromatic framework Substances 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- OKBMCNHOEMXPTM-UHFFFAOYSA-M potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000003590 rho kinase inhibitor Substances 0.000 description 1
- SYBXSZMNKDOUCA-UHFFFAOYSA-J rhodium(2+);tetraacetate Chemical compound [Rh+2].[Rh+2].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O SYBXSZMNKDOUCA-UHFFFAOYSA-J 0.000 description 1
- SVOOVMQUISJERI-UHFFFAOYSA-K rhodium(3+);triacetate Chemical class [Rh+3].CC([O-])=O.CC([O-])=O.CC([O-])=O SVOOVMQUISJERI-UHFFFAOYSA-K 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229910001927 ruthenium tetroxide Inorganic materials 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 208000017022 seasonal allergic rhinitis Diseases 0.000 description 1
- 229940116353 sebacic acid Drugs 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 208000025869 skeletal dysplasia-intellectual disability syndrome Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000011697 sodium iodate Substances 0.000 description 1
- 235000015281 sodium iodate Nutrition 0.000 description 1
- 229940032753 sodium iodate Drugs 0.000 description 1
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 108010014501 sphingosine 1-phosphate lyase (aldolase) Proteins 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 125000005555 sulfoximide group Chemical group 0.000 description 1
- 229940032330 sulfuric acid Drugs 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- ACXPNVRTMHEHMQ-UHFFFAOYSA-N tert-butyl 3-(4-cyanophenyl)oxaziridine-2-carboxylate Chemical compound CC(C)(C)OC(=O)N1OC1C1=CC=C(C#N)C=C1 ACXPNVRTMHEHMQ-UHFFFAOYSA-N 0.000 description 1
- HWCKGOZZJDHMNC-UHFFFAOYSA-M tetraethylammonium bromide Chemical compound [Br-].CC[N+](CC)(CC)CC HWCKGOZZJDHMNC-UHFFFAOYSA-M 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000000101 thioether group Chemical group 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000003156 vasculitic effect Effects 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 208000001319 vasomotor rhinitis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 208000010484 vulvovaginitis Diseases 0.000 description 1
- 238000013389 whole blood assay Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
- 229940007718 zinc hydroxide Drugs 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- This invention relates to substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.
- Neutrophil elastase is a 29 kDa serine protease. It is expressed in bone marrow precursor cells, stored in the granula of peripheral blood granulocytes at high concentrations and it is released upon cellular activation. To the substrates of NE belong major elements of the extracellular matrix: elastin, fibronectin, laminin, collagen and proteoglycans. Neutrophil elastase activity leads to ECM degradation, increases migration and chemotaxis of monocytes and vascular smooth muscle cells and directly affects components of the coagulation and fibrinolytic pathways (PAI-1 and TFPI). Increased activity of neutrophil elastase is associated with chronic inflammatory and fibrotic diseases of several organs. Inhibitors of neutrophil elastase will therefore have an important role for the treatment of different diseases like COPD, fibrosis, cancer and others.
- the compounds according to the present invention are effective as inhibitors of neutrophil elastase and exhibit favourable inhibitory potency, as determined by the half maximal inhibitory concentration (IC 50 ), in an enzymatic inhibition assay.
- Some compounds according to the present invention exhibit favourable inhibitory potency, as determined by the half maximal effective concentration (EC 50 ), in a plasma or whole-blood assay, for instance as described in T. Stevens et al., J. Pharm. Exp. Ther. 339, 313-320 (2011).
- Some compounds according to the present invention exhibit favourable in vivo potency, as determined, for example, by the half maximal effective dose (ED 50 ), in models of human neutrophil elastase-induced lung injury in mice, rat or hamster, for instance as described in Tremblay et al. ( Chest 2002, 121, 582-588) or T. Stevens et al. ( J. Pharm. Exp. Ther. 2011, 339, 313-320).
- ED 50 half maximal effective dose
- Some compounds according to the present invention exhibit favourable metabolic stability in an in vitro microsomal assay for metabolic stability as described in E. Kerns & L. Di, Drug-like properties: concepts, structure design and methods: from ADME to toxicity optimization, Elsevier, 1 st ed, 2008, chapter 29 and references therein.
- Some compounds according to the present invention exhibit favourable metabolic stability in an in vitro hepatocytes assay for metabolic stability as described in E. Kerns & L. Di, Drug-like properties: concepts, structure design and methods: from ADME to toxicity optimization, Elsevier, 1 st ed, 2008, chapter 29 and references therein.
- Some compounds according to the present invention exhibit favourable permeability in an in vitro Caco-2 cell layer method for permeability as described in E. Kerns & L. Di, Drug-like properties: concepts, structure design and methods: from ADME to toxicity optimization, Elsevier, 1 st ed, 2008, chapter 26 and references therein.
- improved permeability is expected to translate into a higher fraction of the drug absorbed in the intestinal tract, thus, resulting in higher dose-normalized systemic exposure (AUC).
- Comparatively higher dose-normalized systemic exposure can be advantageous in several ways: (1) If a certain systemic exposure (AUC) needs to be achieved for efficacy, the drug can be dosed in a lower amount. Lower dosages have the advantages of lower drug load (parent drug and metabolites thereof) for the patient causing potentially less side effects, and lower production costs for the drug product. (2) Comparatively higher dose-normalized systemic exposure (AUC) can lead to increased efficacy or prolonged duration of action of the drug when the same dose is applied.
- Some compounds according to the present invention exhibit favourable metabolic stability and favourable permeability. Accordingly, some compounds of the present invention are expected to exhibit favourable pharmacokinetic (PK) properties, in particular favourable systemic exposure (area under the curve, AUC).
- PK pharmacokinetic
- PK properties can be determined in pre-clinical animal species, for example mouse, rat, dog, guinea pig, mini pig, cynomolgus monkey, rhesus monkey.
- the PK properties of a compound can be described, for example, by the following parameters: Mean residence time (MRT), elimination half-live (t 1/2 ), volume-of-distribution (V D ), area under the curve (AUC), clearance (CL), bioavailability after oral administration (F oral ).
- R 4 is one of the above mentioned ring carrying the above mentioned optional substituted in meta-position to the element connection R 4 with the compound of formula 1.
- Example # Structure 1 2 4 5 6 8 10 11 12 18 19 21 29 30 31 41 42 47 # example numbers are according to the numbering in the Preparation/experimental section
- the residue R 1a is chiral, preferred is the Eutomer.
- C 1-6 -alkyl means an alkyl group or radical having 1 to 6 carbon atoms.
- radical attachment point(s) to the molecule from the free valences of the group itself.
- the last named subgroup is the radical attachment point, for example, the substituent “aryl-C 1-3 -alkyl-” means an aryl group which is bound to a C 1-3 -alkyl-group, the latter of which is bound to the core or to the group to which the substituent is attached.
- 3-carboxypropyl-group represents the following substituent:
- a X with a subscript number or “#”, a dashed or a dotted line may be used in sub-formulas to indicate the bond which is connected to the core molecule as defined.
- substituted means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valence is not exceeded, and that the substitution results in a stable compound.
- prevention should be understood synonymous and in the sense that the risk to develop a condition mentioned hereinbefore is reduced, especially in a patient having elevated risk for said conditions or a corresponding anamnesis, e.g. elevated risk of developing metabolic disorder such as diabetes or obesity or another disorder mentioned herein.
- prevention of a disease means the management and care of an individual at risk of developing the disease prior to the clinical onset of the disease.
- the purpose of prevention is to combat the development of the disease, condition or disorder, and includes the administration of the active compounds to prevent or delay the onset of the symptoms or complications and to prevent or delay the development of related diseases, conditions or disorders. Success of said preventive treatment is reflected statistically by reduced incidence of said condition within a patient population at risk for this condition in comparison to an equivalent patient population without preventive treatment.
- treatment means therapeutic treatment of patients having already developed one or more of said conditions in manifest, acute or chronic form, including symptomatic treatment in order to relieve symptoms of the specific indication or causal treatment in order to reverse or partially reverse the condition or to delay the progression of the indication as far as this may be possible, depending on the condition and the severity thereof.
- treatment of a disease means the management and care of a patient having developed the disease, condition or disorder.
- the purpose of treatment is to combat the disease, condition or disorder.
- Treatment includes the administration of the active compounds to eliminate or control the disease, condition or disorder as well as to alleviate the symptoms or complications associated with the disease, condition or disorder.
- a given chemical formula or name shall encompass tautomers and all stereo, optical and geometrical isomers (e.g. enantiomers, diastereomers, E/Z isomers etc. . . . ) and racemates thereof as well as mixtures in different proportions of the separate enantiomers, mixtures of diastereomers, or mixtures of any of the foregoing forms where such isomers and enantiomers exist, as well as salts, including pharmaceutically acceptable salts thereof and solvates thereof such as for instance hydrates including solvates of the free compounds or solvates of a salt of the compound.
- halogen generally denotes fluorine, chlorine, bromine and iodine.
- prodrug refers to (i) an inactive form of a drug that exerts its effects after metabolic processes within the body converting it to a usable or active form, or (ii) a substance that gives rise to a pharmacologically active metabolite, although not itself active (i.e. an inactive precursor).
- prodrug or “prodrug derivative” mean a covalently-bonded derivative, carrier or precursor of the parent compound or active drug substance which undergoes at least some biotransformation prior to exhibiting its pharmacological effect(s).
- prodrugs either have metabolically cleavable or otherwise convertible groups and are rapidly transformed in vivo to yield the parent compound, for example, by hydrolysis in blood or by activation via oxidation as in case of thioether groups.
- Most common prodrugs include esters and amide analogs of the parent compounds.
- prodrug is formulated with the objectives of improved chemical stability, improved patient acceptance and compliance, improved bioavailability, prolonged duration of action, improved organ selectivity, improved formulation (e.g., increased hydrosolubility), and/or decreased side effects (e.g., toxicity).
- prodrugs themselves have weak or no biological activity and are stable under ordinary conditions.
- Prodrugs can be readily prepared from the parent compounds using methods known in the art, such as those described in A Textbook of Drug Design and Development, Krogsgaard-Larsen and H. Bundgaard (eds.), Gordon & Breach, 1991, particularly Chapter 5: “Design and Applications of Prodrugs”; Design of Prodrugs, H.
- pharmaceutically acceptable prodrug means a prodrug of a compound of the invention which is, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible.
- phrases “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, and commensurate with a reasonable benefit/risk ratio.
- pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
- examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
- such salts include salts from ammonia, L-arginine, betaine, benethamine, benzathine, calcium hydroxide, choline, deanol, diethanolamine (2,2′-iminobis(ethanol)), diethylamine, 2-(diethylamino)-ethanol, 2-aminoethanol, ethylenediamine, N-ethyl-glucamine, hydrabamine, 1H-imidazole, lysine, magnesium hydroxide, 4-(2-hydroxyethyl)-morpholine, piperazine, potassium hydroxide, 1-(2-hydroxyethyl)-pyrrolidinyl, sodium hydroxide, triethanolamine (2,2′,2′′-nitrilotris(ethanol)), tromethamine, zinc hydroxide, acetic acid, 2.2-dichloro-acetic acid, adipic acid, alginic acid, ascorbic acid, L-aspartic acid, benzenesulf
- the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a sufficient amount of the appropriate base or acid in water or in an organic diluent like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile, or a mixture thereof.
- Salts of other acids than those mentioned above which for example are useful for purifying or isolating the compounds of the present invention e.g. trifluoro acetate salts, also comprise a part of the invention.
- C 1-n -alkyl wherein n is an integer from 2 to 6, either alone or in combination with another radical denotes an acyclic, saturated, branched or linear hydrocarbon radical with 1 to 6 C atoms.
- C 1-5 -alkyl embraces the radicals H 3 C—, H 3 C—CH 2 —, H 3 C—CH 2 —CH 2 —, H 3 C—CH(CH 3 )—, H 3 C—CH 2 —CH 2 —CH 2 —, H 3 C—CH 2 —CH(CH 3 )—, H 3 C—CH(CH 3 )—CH 2 —, H 3 C—C(CH 3 ) 2 —, H 3 C—CH 2 —CH 2 —CH 2 —CH 2 —, H 3 C—CH 2 —CH 2 —CH(CH 3 )—, H 3 C—CH 2 —CH(CH 3 )—CH 2 —CH 2 —, H 3 C—CH 2 —CH(CH 3 )—, H
- C 1-6 -alkylene wherein n is an integer 2 to 6, either alone or in combination with another radical, denotes an acyclic, straight or branched chain divalent alkyl radical containing from 1 to 6 carbon atoms.
- C 1-4 -alkylene includes —CH 2 —, —CH 2 —CH 2 —, —CH(CH 3 )—, —CH 2 —CH 2 —CH 2 —, —C(CH 3 ) 2 —, —CH(CH 2 CH 3 )—, —CH(CH 3 )—CH 2 —, —CH 2 —CH(CH 3 )—, —CH 2 —CH 2 —CH 2 —CH 2 —, —CH 2 —CH 2 —CH(CH 3 )—, —CH(CH 3 )—CH 2 —CH 2 —, —CH 2 —CH(CH 3 )—, —CH(CH 3 )—CH 2 —CH 2 —, —
- C 2-n -alkylene wherein n is an integer 3 to 5, either alone or in combination with another radical, denotes an acyclic, straight or branched chain divalent alkyl radical containing from 2 to 5 carbon atoms.
- C 2-5 -alkylene includes —CH 2 —CH 2 —, —CH(CH 3 )—, —CH 2 —CH 2 —CH 2 —, —C(CH 3 ) 2 —, —CH(CH 2 CH 3 )—, —CH(CH 3 )—CH 2 —, —CH 2 —CH(CH 3 )—, —CH 2 —CH 2 —CH 2 —CH 2 —, —CH 2 —CH 2 —CH(CH 3 )—, —CH(CH 3 )—CH 2 —CH 2 —, —CH 2 —CH(CH 3 )—CH 2 —CH 2 —, —CH 2 —CH(CH 3 )—CH 2 —CH 2
- halo added to a “alkyl”, “alkylene” or “cycloalkyl” group (saturated or unsaturated) is such a alkyl or cycloalkyl group meant wherein one or more hydrogen atoms are replaced by a halogen atom selected from among fluorine, chlorine or bromine, preferably fluorine and chlorine, particularly preferred is fluorine. Examples include: H 2 FC—, HF 2 C—, F 3 C—.
- C 3-6 -cycloalkyl wherein n is an integer from 4 to 6, either alone or in combination with another radical denotes a cyclic, saturated, unbranched hydrocarbon radical with 3 to 6 C atoms.
- C 3-6 -cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
- aryl as used herein, either alone or in combination with another radical, denotes a carbocyclic aromatic monocyclic group containing 6 carbon atoms which may be further fused to a second five- or six-membered, carbocyclic group which may be aromatic, saturated or unsaturated.
- Aryl includes, but is not limited to, phenyl, indanyl, indenyl, naphthyl, anthracenyl, phenanthrenyl, tetrahydronaphthyl and dihydronaphthyl.
- a phenyl ring contains 6 elements which are all carbon atoms
- a pyrrol ring contains 5 elements, wherein 4 elements are carbon atoms and the remaining element is a nitrogen atom.
- the term is intended to include all possible isomeric forms.
- the term includes (if not otherwise restricted) the following exemplary structures which are not depicted as radicals as each form may be attached through a covalent bond to any atom so long as appropriate valences are maintained:
- the compounds according to the present invention and their intermediates may be obtained using methods of synthesis which are known to the one skilled in the art and described in the literature of organic synthesis.
- the compounds are obtained in analogous fashion to the methods of preparation explained more fully hereinafter, in particular as described in the experimental section.
- the order in carrying out the reaction steps may be varied. Variants of the reaction methods that are known to the one skilled in the art but not described in detail here may also be used.
- the general processes for preparing the compounds according to the invention will become apparent to the one skilled in the art studying the following schemes.
- Starting materials are commercially available or may be prepared by methods that are described in the literature or herein, or may be prepared in an analogous or similar manner Any functional groups in the starting materials or intermediates may be protected using conventional protecting groups. These protecting groups may be cleaved again at a suitable stage within the reaction sequence using methods familiar to the one skilled in the art.
- Starting material I can be prepared as described in US2003/87940.
- Intermediates II can be prepared as described in WO10133973 and US2003/87940 by heating starting material I with amines R—NH 2 in the presence of a strong base, for example sodium tert-butoxide or sodium ethoxide, in an organic solvent, for example ethanol. The reaction usually takes place within 2 to 72 hours. Preferred reaction temperatures are between 50° C. and 150° C.
- the amide coupling (Step B, intermediates II ⁇ intermediates III, intermediates IV ⁇ intermediates V, intermediates VI ⁇ compounds of the invention) can be achieved by reacting carboxylic acid intermediates II, IV or VI with amines R′—NH 2 in the presence of an amide coupling reagent, for example O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU), O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) or propane phosphonic acid anhydride, and in the presence of a base, for example triethylamine, diisopropylethylamine (DIPEA, Hünig's base) or N-methyl-morpholine, in an organic solvent, for example N, N-dimethylformamide (DMF), N-methyl-2-pyrrol
- reaction usually takes place within 1 to 72 hours. Preferred reaction temperatures are between 0° C. and 50° C., most preferred room temperature.
- carboxylic acid intermediates can be activated first as described in US2003/87940, for example with 1,1′-carbonyldiimidazole (CDI) in DMF, followed by reaction with the amine R′—NH 2 .
- CDI 1,1′-carbonyldiimidazole
- bromination agents for example bromine or N-bromosuccinimide
- iodination agents for example iodine, iodinechloride (I—Cl) or N-iodosuccinimide
- organic solvent for example acetic acid, methanol, ethanol, dichloromethane, acetonitrile, N, N-dimethylformamide, tetrahydrofuran or mixtures thereof.
- the halogenation reaction usually takes place within 1 to 72 hours.
- Step D intermediates IV ⁇ intermediates VI, intermediates V ⁇ compounds according to the invention
- aryl or heteroaryl boronic acids R′′—B(OH) 2 or the corresponding boronic esters in the presence of a palladium catalyst, for example tetrakis(triphenylphosphine)palladium(0) or [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II)
- a base for example, potassium carbonate, barium dihydroxide or cesium carbonate
- organic solvent for example toluene, benzene, ethanol, ethylene glycol dimethyl ether, acetonitrile, dioxane or mixtures thereof, optionally in the presence of water.
- Preferred reaction temperatures are between 50° C. and 150° C.
- the alkylation of the pyridone nitrogen can be achieved by reacting intermediate VII with alkylating agents, for example alkyl bromides, alkyl iodides, alkyl tosylates, alkyl mesylates or dialkyl sulfates, in the presence of a base, for example sodium carbonate, potassium carbonate, potassium hydroxide, sodium hydroxide or cesium carbonate, in an organic solvent, N, N-dimethylformamide (DMF), N-methyl-2-pyrrolidone (NMP) or dimethylacetamide (DMA).
- alkylating agents for example alkyl bromides, alkyl iodides, alkyl tosylates, alkyl mesylates or dialkyl sulfates
- a base for example sodium carbonate, potassium carbonate, potassium hydroxide, sodium hydroxide or cesium carbonate
- NMF N-dimethylformamide
- NMP N-methyl-2-pyrrolidone
- Intermediates VIII can be prepared as described in Bolm et al., Org. Lett. 9, 3809-3811 (2007) via direct imination of a thioether (intermediates VII) with cyanamide (Step F, intermediates VII ⁇ intermediates VIII) by reaction with an halogenating agent, for example N-bromo- or N-chlorosuccinimide, tert-butyl hypochlorite or iodine in the presence of cyanamide and a base, for example potassium or sodium tert-butoxide, in an organic solvent, for example methanol, tetrahydrofuran (THF) or acetonitrile.
- an organic solvent for example methanol, tetrahydrofuran (THF) or acetonitrile.
- Preferred reaction temperatures are between 0° C. and 50° C., most preferred is room temperature.
- the imination (Step F, intermediates VII ⁇ intermediates VIII) can be achieved as described in Bolm et al., Org. Lett. 9, 2951-2954 (2007), by using phenyliodo diacetate [PhI(OAc) 2 ] and cyanamide in an organic solvent, for example acetonitrile or tetrahydrofuran (THF).
- the reaction usually takes place within 1 to 72 hours.
- Preferred reaction temperatures are between 0° C. and room temperature.
- the oxidation (Step G, intermediates VIII ⁇ intermediates IX, intermediates XI ⁇ intermediates XII) can be achieved using a peroxycarboxylic acid as oxidizing agent, for example meta-chloroperoxybenzoic acid (mCPBA), optionally in the presence of a base, for example potassium carbonate, in an organic solvent, for example ethanol, methanol, dichloromethane or chloroform.
- mCPBA meta-chloroperoxybenzoic acid
- a base for example potassium carbonate
- organic solvent for example ethanol, methanol, dichloromethane or chloroform.
- Preferred reaction temperatures are between 0° C. and room temperature.
- oxidizing agents for example hydrogen peroxide, tert-butyl hydroperoxide, sodium hypochlorite, sodium iodate, sodium periodate, potassium permanganate, ruthenium tetroxide, potassium peroxymonosulfate (Oxone) or dimethyldioxirane.
- Intermediates X can be obtained by imination of intermediates VII (Step H, intermediates VII ⁇ intermediates X) as described in Bolm. et al., Org. Lett. 6, 1305-1307 (2004), by reacting a thioether (intermediates VII) with trifluoroacetamide, phenyliodo diacetate [PhI(OAc) 2 ], rhodium acetate dimer [Rh 2 (OAc) 4 ] and MgO in an organic solvent, for example dichloromethane. The reaction usually takes place within 1 to 72 hours. Preferred reaction temperatures are between 0° C. and room temperature.
- Step K intermediates X ⁇ intermediates XI
- a base for example potassium carbonate
- organic solvent for example methanol
- intermediates XI can be prepared by the imination of intermediates VII using other electrophilic nitrogen sources, for example tert-butyl 3-(4-cyano-phenyl)-oxaziridine-2-carboxylate (followed by cleavage of the Boc-protecting group), O-mesityl sulfonyl hydroxylamine (MSH), or hydrazoic azid.
- other electrophilic nitrogen sources for example tert-butyl 3-(4-cyano-phenyl)-oxaziridine-2-carboxylate (followed by cleavage of the Boc-protecting group), O-mesityl sulfonyl hydroxylamine (MSH), or hydrazoic azid.
- Step K intermediates XI ⁇ intermediates VIII, intermediates XII ⁇ intermediates IX
- Step K intermediates XI ⁇ intermediates VIII, intermediates XII ⁇ intermediates IX
- cyanogen bromide optionally 4-dimethylaminopyridine (DMAP) and optionally a base, for example triethylamine
- DMAP 4-dimethylaminopyridine
- a base for example triethylamine
- Sulfinamides (starting material XIII) can be prepared as described in Johnson et al., J. Org. Chem. 44, 2055-2061 (1975) by reacting sulfinyl chlorides with a primary or secondary amine, optionally in the presence of an additional base, for example pyridine or a tertiary amine, in an organic solvent, for example dichloromethane, tetrahydrofuran, diethylether, acetonitrile, toluene, N,N-dimethylformamide, ethanol or ethyl acetate.
- the reaction usually takes place within 1-72 hours.
- Preferred reaction temperatures are between 0° C. and room temperature.
- Sulfonimidoyl chlorides can be prepared as described in Johnson et al., J. Org. Chem. 44, 2055-2061 (1975), by reacting sulfinamides (starting material XIII) with a chlorinating agent, for example chlorine, N-chlorosuccinimide (NCS), N-chloro-benzotriazole or tert-butyl hypochlorite in an organic solvent, for example dichloromethane, diethylether, benzene, toluene, carbon tetrachloride, acetonitrile or tetrahydrofuran (Step L).
- a chlorinating agent for example chlorine, N-chlorosuccinimide (NCS), N-chloro-benzotriazole or tert-butyl hypochlorite
- an organic solvent for example dichloromethane, diethylether, benzene, toluene, carbon tetrach
- Sulfonimidoyl fluorides can be prepared as described in Johnson et al., J. Org. Chem. 48, 1-3 (1983) and Gnamm et al., Bioorg. Med. Chem. Lett. 12, 3800-3806 (2012), by reacting sulfonimidoyl chlorides (intermediates XIV) with a fluoride salt, for example potassium fluoride, sodium fluoride or tetrabutylammonium fluoride, optionally in the presence of a crown ether, for example 18-crown-6, in an organic solvent, for example acetonitrile or tetrahydrofuran (Step M). The reaction takes place within 1 to 24 hours. Preferred reaction temperatures are between 0° C. and room temperature, mostly preferred room temperature.
- Sulfonimidamides can be prepared as described in Johnson et al., J. Org. Chem. 44, 2055-2061 (1975), Bolm et al., J. Org. Chem. 75, 3301-3310 (2010), and WO09156336 by reacting sulfonimidoyl chlorides (intermediates XIV) with a primary or secondary, aliphatic or aromatic amine, optionally in the presence of an additional base, for example pyridine or a tertiary amine, in an organic solvent, for example acetonitrile, tetrahydrofuran, N,N-dimethylformamide or benzene (Step N). The reaction takes place within 1 to 72 hours. Preferred reaction temperatures are between 0° C. and room temperature.
- sulfonimidamides can be prepared as described in Gnamm et al., Bioorg. Med. Chem. Lett. 22, 3800-3806 (2012) by reacting sulfonimidoyl fluorides (intermediates XV) with a primary or secondary, aliphatic or aromatic amine, optionally in the presence of an additional base, for example pyridine or a tertiary amine, for example 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), in an organic solvent, for example acetonitrile, tetrahydrofuran, N,N-dimethylformamide or benzene (Step 0).
- the reaction takes place within 1 to 72 hours.
- Preferred reaction temperatures are between 0° C. and the boiling point of the solvent, mostly preferred between room temperature and 110° C.
- Preparation 2b is prepared following the procedure described for preparation 1c, substituting preparation 1b with preparation 2a as starting material.
- ESI mass spectrum: 260 (bromine isotope pattern); r.t. HPLC: 0.89 min (Z002_007).
- Preparation 2c is prepared following the procedure described for preparation 1d, substituting preparation 1c with preparation 2b as starting material and substituting TBTU with HBTU as coupling reagent.
- ESI mass spectrum: [M+H] + 451 (bromine isotope pattern); r.t. HPLC: 0.81 min (Z012_S04).
- Preparation 3b is prepared following the procedure described for preparation 1c, substituting preparation 1b with preparation 3a as starting material.
- ESI mass spectrum: [M+H] + 286 (bromine isotope pattern); r.t. HPLC: 0.82 min (Z002_002).
- Preparation 3c is prepared following the procedure described for preparation 1d, substituting preparation 1c with preparation 3b as starting material and substituting TBTU with HBTU as coupling reagent.
- ESI mass spectrum: [M+H] + 477 (bromine isotope pattern); r.t. HPLC: 0.90 min (Z018_S04).
- Preparation 4a is prepared following the procedure described for preparation 1b, substituting isopropylamine with 1-methyl-1H-pyrazol-5-ylamine.
- ESI mass spectrum: [M+H] + 234; r.t. HPLC: 0.63 min (Z018_S04).
- Preparation 4b is prepared following the procedure described for preparation 1d, substituting preparation 1c with preparation 4a as starting material and substituting TBTU with HBTU as coupling reagent.
- ESI mass spectrum: [M+H] + 425; r.t. HPLC: 0.79 min (Z018_S04).
- Preparation 5a is prepared following the procedure described for preparation 1b, substituting isopropylamine with 4-cyanobenzylamine.
- ESI mass spectrum: [M+H] + 269; r.t. HPLC: 0.86 min (Z002_005).
- Preparation 5b is prepared following the procedure described for preparation 1c, substituting preparation 1b with preparation 5a as starting material.
- ESI mass spectrum: [M+H] + 347 (bromine isotope pattern); r.t. HPLC: 1.07 min (Z002_005).
- racemic example 1 63 mg are separated by chiral HPLC (Daicel IB, 250 mm ⁇ 20 mm, 15% MeOH+0.2% diethylamine in supercritical CO 2 , 40° C.).
- Example 2 is prepared following the procedure described for example 1, substituting 3-(difluoromethyl)phenylboronic acid with 3-(trifluoromethyl)phenylboronic acid.
- ESI mass spectrum: [M+H] + 531; r.t. HPLC: 0.99 min (Z003_001).
- racemic example 2 100 mg are separated by chiral HPLC (Daicel OZ-H, 250 mm ⁇ 20 mm, 40% MeOH+0.2% diethylamine in supercritical CO 2 , 40° C.).
- Example 3 is prepared following the procedure described for example 1, substituting 3-(difluoromethyl)phenylboronic acid with 2-(trifluoromethyl)pyridine-4-boronic acid.
- ESI mass spectrum: [M+H] + 532; r.t. HPLC: 0.86 min (Z003_001).
- racemic example 3 50 mg are separated by chiral HPLC (Daicel IB, 250 mm ⁇ 20 mm, 15% MeOH+0.2% diethylamine in supercritical CO 2 , 40° C.).
- Example 4 is prepared following the procedure described for example 1, substituting 3-(difluoromethyl)phenylboronic acid with 2-(trifluoromethyl)pyridine-4-boronic acid and substituting preparation 1 with preparation 2 as starting material.
- ESI mass spectrum: [M+H] + 517; r.t. HPLC: 0.85 min (Z011_S03).
- racemic example 4 are separated by chiral HPLC (Daicel OZH, 250 mm ⁇ 20 mm, 40% MeOH+0.2% diethylamine in supercritical CO 2 , 40° C.).
- Example 5 is prepared following the procedure described for example 1, substituting preparation 1 with preparation 2 as starting material.
- ESI mass spectrum: [M+H] + 499; r.t. HPLC: 0.79 min (Z011_S03).
- Example 6 is prepared following the procedure described for example 1, substituting preparation 1 with preparation 3 as starting material.
- ESI mass spectrum: [M+H] + 525; r.t. HPLC: 0.84 min (Z011_S03).
- Example 7 is prepared following the procedure described for example 1, substituting preparation 1 with preparation 4 as starting material.
- ESI mass spectrum: [M+H] + 551; r.t. HPLC: 0.96 min (Z018_S04).
- Example 8 is prepared following the procedure described for example 1, substituting 3-(difluoromethyl)phenylboronic acid with 3-(trifluoromethyl)phenylboronic acid and substituting preparation 1 with preparation 4 as starting material.
- ESI mass spectrum: [M+H] + 569; r.t. HPLC: 1.00 min (Z018_S04).
- Example 9 is prepared following the procedure described for preparation 1d, substituting preparation 1c with preparation 5 as starting material.
- ESI mass spectrum: [M+H] + 604; r.t. HPLC: 0.63 min (X012_S01).
- racemic example 9 58 mg are separated by chiral HPLC (Daicel ASH, 250 mm ⁇ 20 mm, 20% MeOH+0.2% diethylamine in supercritical CO 2 , 40° C.).
- bromo intermediates are prepared as described for preparation 1c, employing the appropriate des-bromo intermediates as starting material.
- Racemic preparation 6c (2.0 g) is separated by chiral HPLC (Daicel Chiralcel OZ-H, 250 mm ⁇ 30 mm, 32% MeOH in supercritical CO 2 ).
- racemic preparation 6d The early eluting enantiomer of racemic preparation 6d is prepared following the procedure described for preparation 6d, substituting racemic 2-(4-(N-cyano-S-methyl-sulfonimidoyl)benzyl)isoindoline-1,3-dione with preparation 11A.
- the late eluting enantiomer of racemic preparation 6d is prepared following the procedure described for preparation 6d, substituting racemic 2-(4-(N-cyano-S-methylsulfonimidoyl)-benzyl)isoindoline-1,3-dione with preparation 11B.
- Phthalic anhydride (4.42 g, 30 mmol) is added to a solution of 4-(ethylthio)benzylamine (5.00 g, 30 mmol) in acetic acid. The mixture is heated at reflux for 5 h and cooled at room temperature. Water ist added, and the precipitate is filtered and dried.
- a solution of 5-methylsulfanyl-pyridine-2-carbonitrile (preparation described in WO05026124, 4.28 g, 28.5 mmol) in THF is cooled at ⁇ 78° C. in a dry ice/ethanol bath.
- Lithium aluminium hydride (2.4 M in THF, 12 mL, 28.8 mmol) is added dropwise. After 10 min water (1 mL) and THF (3 mL) are added. After 5 min, aqueous sodium hydroxide solution (4 M, 1 mL) and water (3 mL) is added.
- 60a Thioacetic acid 4-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-phenyl ester
- Example 61 is prepared as described for Example 60, substituting preparation 9.2 with preparation 9.12.
- ESI mass spectrum: [M+H] + 531; r.t. HPLC: 0.86 min (Z011_503).
- Meta-chloroperoxybenzoic acid (77%, 8.0 mg, 36 ⁇ mol) is added to a solution of 5-(3-trifluoromethyl-phenyl)-1-isopropyl-6-methyl-4-oxo-1,4-dihydro-pyridine-3-carboxylic acid (5-(N-cyano-S-methylsulfonimidoyl)pyridin-2-yl)methylamide (example 16, 17.0 mg, 32 ⁇ mol) in dichloromethane (0.5 mL), and the mixture is stirred at room temperature for 2 h. The mixture is heated at reflux and stirred for 2 h. The mixture is cooled at room temperature and stirred over night.
- N-Bromosuccinimide (63 mg, 0.35 mmol) is added to a mixture of 1-isopropyl-6-methyl-4-oxo-5-(3-trifluoromethyl-phenyl)-1,4-dihydro-pyridine-3-carboxylic acid 3-methyl-4-methylsulfanyl-benzylamide (preparation 66c, 115 mg, 0.24 mmol), cyanamide (14 mg, 0.33 mmol) and potassium tert-butoxide (32 mg, 0.29 mmol) in methanol (1.1 mL). After 20 min saturated aqueous sodium thiosulfate solution is added, and the mixture is extracted twice with dichloromethane.
- Human neutrophil elastase was purchased from Calbiochem (Cat.No.: 324681) and the elastase substrate MeOSuc-Ala-Ala-Pro-Val-AMC from Bachem (Cat.No.: I-1270). All other materials were of the highest grade commercially available.
- Test compounds were prediluted in DMSO and subsequently in compound buffer (5% DMSO final). 5 ⁇ L of these compound dilutions were mixed with 10 ⁇ l Neutrophil elastase (9 ng/ml in assay buffer) in a black 384 well OptiPlate (Perkin Elmer, Cat No.: 6007270) and incubated for 15 min at room temperature. Subsequently 10 ⁇ L substrate solution in assay buffer were added (250 ⁇ M final concentration) and the plates were incubated for 60 min at room temperature. After inactivation of the enzyme, fluorescence intensities were measured at 380 nm excitation and 460 nm emission wavelengths.
- the compounds of general formula I may be used on their own or combined with other active substances of formula I according to the invention.
- the compounds of general formula I may optionally also be combined with other pharmacologically active substances. These include, 132-adrenoceptor-agonists (short and long-acting), anti-cholinergics (short and long-acting), anti-inflammatory steroids (oral and topical corticosteroids), cromoglycate, methylxanthine, dissociated-glucocorticoidmimetics, PDE3 inhibitors, PDE4-inhibitors, PDE7-inhibitors, LTD4 antagonists, EGFR-inhibitors, Dopamine agonists, PAF antagonists, Lipoxin A4 derivatives, FPRL1 modulators, LTB4-receptor (BLT1, BLT2) antagonists, Histamine H1 receptor antagonists, Histamine H4 receptor antagonists, dual Histamine H1/H3-receptor antagonists, PI3-kinase inhibitors
- the compounds of the invention and their pharmaceutically acceptable salts have activity as pharmaceuticals, in particular as inhibitors of neutrophil elastase, and thus may be used in the treatment of:
- respiratory tract obstructive diseases of the airways including: asthma, including bronchial, allergic, intrinsic, extrinsic, exercise-induced, drug-induced (including aspirin and NSAID-induced) and dust-induced asthma, both intermittent and persistent and of all severities, and other causes of airway hyper-responsiveness; chronic obstructive pulmonary disease (COPD); bronchitis, including infectious and eosinophilic bronchitis; emphysema; alpha1-antitrypsin deficiency; bronchiectasis; cystic fibrosis; sarcoidosis; farmer's lung and related diseases; hypersensitivity pneumonitis; lung fibrosis, including cryptogenic fibrosing alveolitis, idiopathic interstitial pneumonias, fibrosis complicating anti-neoplastic therapy and chronic infection, including tuberculosis and aspergillosis and other fungal infections; complications of lung transplantation; vasculitic
- skin psoriasis, atopic dermatitis, contact dermatitis or other eczematous dermatoses, and delayed-type hypersensitivity reactions; phyto- and photodermatitis; seborrhoeic dermatitis, dermatitis herpetiformis, lichen planus, lichen sclerosus et atrophica, pyoderma gangrenosum, skin sarcoid, discoid lupus erythematosus, pemphigus, pemphigoid, epidermolysis bullosa, urticaria, angioedema, vasculitides, toxic erythemas, cutaneous eosinophilias, alopecia areata, male-pattern baldness, Sweet's syndrome, Weber-Christian syndrome, erythema multiforme; cellulitis, both infective and non-infective; panniculitis; cutaneous lymphomas, non-melanom
- eyes blepharitis; conjunctivitis, including perennial and vernal allergic conjunctivitis; ulceris; anterior and posterior uveitis; choroiditis; autoimmune, degenerative or inflammatory disorders affecting the retina; ophthalmitis including sympathetic ophthalmitis; sarcoidosis; infections including viral, fungal, and bacterial;
- nephritis including interstitial and glomerulonephritis; nephrotic syndrome; cystitis including acute and chronic (interstitial) cystitis and Hunner's ulcer; acute and chronic urethritis, prostatitis, epididymitis, oophoritis and salpingitis; vulvo-vaginitis; Peyronie's disease; erectile dysfunction (both male and female);
- allograft rejection acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea or following blood transfusion; or chronic graft versus host disease;
- oncology treatment of common cancers including prostate, breast, lung, ovarian, pancreatic, bowel and colon, stomach, skin and brain tumors and malignancies affecting the bone marrow (including the leukaemias) and lymphoproliferative systems, such as Hodgkin's and non-Hodgkin's lymphoma; including the prevention and treatment of metastatic disease and tumour recurrences, and paraneoplastic syndromes; and,
- infectious diseases virus diseases such as genital warts, common warts, plantar warts, hepatitis B, hepatitis C, herpes simplex virus, molluscum contagiosum, variola, human immunodeficiency virus (HIV), human papilloma virus (HPV), cytomegalovirus (CMV), varicella zoster virus (VZV), rhinovirus, adenovirus, coronavirus, influenza, para-influenza; bacterial diseases such as tuberculosis and mycobacterium avium , leprosy; other infectious diseases, such as fungal diseases, chlamydia, Candida, aspergillus , cryptococcal meningitis, Pneumocystis carnii , cryptosporidiosis, histoplasmosis, toxoplasmosis, trypanosome infection and leishmaniasis.
- virus diseases such as genital warts, common warts,
- a therapeutically effective dose will generally be in the range from about 0.01 mg to about 100 mg/kg of body weight per dosage of a compound of the invention; preferably, from about 0.1 mg to about 20 mg/kg of body weight per dosage.
- the dosage range would be from about 0.7 mg to about 7000 mg per dosage of a compound of the invention, preferably from about 7.0 mg to about 1400 mg per dosage.
- Some degree of routine dose optimization may be required to determine an optimal dosing level and pattern.
- the active ingredient may be administered from 1 to 6 times a day.
- the actual pharmaceutically effective amount or therapeutic dosage will of course depend on factors known by those skilled in the art such as age and weight of the patient, route of administration and severity of disease.
- the active ingredient will be administered at dosages and in a manner which allows a pharmaceutically effective amount to be delivered based upon patient's unique condition.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Abstract
This invention relates to substituted 4-pyridones of formula 1
and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.
Description
- This invention relates to substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.
-
-
- The following references describe neutrophil elastase inhibitors with a 2-pyridone central core: WO04043924, WO05026123, WO05026124, WO06098683, WO06098684, WO07129962, WO10094964, WO11039528.
- The following references describe neutrophil elastase inhibitors with a 2-pyrazinone central core: WO07129963, WO09061271, WO09058076, WO11110852.
- For a review on various inhibitors of neutrophil elastase see: P. Sjö (Future Med. Chem. 2012, 4, 651-660).
- Neutrophil elastase is a 29 kDa serine protease. It is expressed in bone marrow precursor cells, stored in the granula of peripheral blood granulocytes at high concentrations and it is released upon cellular activation. To the substrates of NE belong major elements of the extracellular matrix: elastin, fibronectin, laminin, collagen and proteoglycans. Neutrophil elastase activity leads to ECM degradation, increases migration and chemotaxis of monocytes and vascular smooth muscle cells and directly affects components of the coagulation and fibrinolytic pathways (PAI-1 and TFPI). Increased activity of neutrophil elastase is associated with chronic inflammatory and fibrotic diseases of several organs. Inhibitors of neutrophil elastase will therefore have an important role for the treatment of different diseases like COPD, fibrosis, cancer and others.
- The compounds according to the present invention, including the physiologically acceptable salts, are effective as inhibitors of neutrophil elastase and exhibit favourable inhibitory potency, as determined by the half maximal inhibitory concentration (IC50), in an enzymatic inhibition assay.
- Some compounds according to the present invention, including the physiologically acceptable salts, exhibit favourable inhibitory potency, as determined by the half maximal effective concentration (EC50), in a plasma or whole-blood assay, for instance as described in T. Stevens et al., J. Pharm. Exp. Ther. 339, 313-320 (2011).
- Some compounds according to the present invention, including the physiologically acceptable salts, exhibit favourable in vivo potency, as determined, for example, by the half maximal effective dose (ED50), in models of human neutrophil elastase-induced lung injury in mice, rat or hamster, for instance as described in Tremblay et al. (Chest 2002, 121, 582-588) or T. Stevens et al. (J. Pharm. Exp. Ther. 2011, 339, 313-320).
- Some compounds according to the present invention, including the physiologically acceptable salts, exhibit favourable metabolic stability in an in vitro microsomal assay for metabolic stability as described in E. Kerns & L. Di, Drug-like properties: concepts, structure design and methods: from ADME to toxicity optimization, Elsevier, 1st ed, 2008, chapter 29 and references therein.
- Some compounds according to the present invention, including the physiologically acceptable salts, exhibit favourable metabolic stability in an in vitro hepatocytes assay for metabolic stability as described in E. Kerns & L. Di, Drug-like properties: concepts, structure design and methods: from ADME to toxicity optimization, Elsevier, 1st ed, 2008, chapter 29 and references therein.
- An improved metabolic stability in an in vitro test system is expected to translate into a reduced in vivo clearance (CL), because the metabolic conversion in the liver is reduced. Based on the pharmacokinetic equation CL/Foral=Dose/AUC (Foral: oral bioavailability, AUC: area under the curve), a reduced in vivo clearance is expected lead to higher dose-normalized systemic exposure (AUC) of the drug.
- Some compounds according to the present invention, including the physiologically acceptable salts, exhibit favourable permeability in an in vitro Caco-2 cell layer method for permeability as described in E. Kerns & L. Di, Drug-like properties: concepts, structure design and methods: from ADME to toxicity optimization, Elsevier, 1st ed, 2008, chapter 26 and references therein. For an oral drug, improved permeability is expected to translate into a higher fraction of the drug absorbed in the intestinal tract, thus, resulting in higher dose-normalized systemic exposure (AUC).
- Comparatively higher dose-normalized systemic exposure (AUC) can be advantageous in several ways: (1) If a certain systemic exposure (AUC) needs to be achieved for efficacy, the drug can be dosed in a lower amount. Lower dosages have the advantages of lower drug load (parent drug and metabolites thereof) for the patient causing potentially less side effects, and lower production costs for the drug product. (2) Comparatively higher dose-normalized systemic exposure (AUC) can lead to increased efficacy or prolonged duration of action of the drug when the same dose is applied.
- Some compounds according to the present invention, including the physiologically acceptable salts, exhibit favourable metabolic stability and favourable permeability. Accordingly, some compounds of the present invention are expected to exhibit favourable pharmacokinetic (PK) properties, in particular favourable systemic exposure (area under the curve, AUC).
- Some compounds according to the present invention, including the physiologically acceptable salts, exhibit favourable pharmacokinetic (PK) properties. The PK properties can be determined in pre-clinical animal species, for example mouse, rat, dog, guinea pig, mini pig, cynomolgus monkey, rhesus monkey. The PK properties of a compound can be described, for example, by the following parameters: Mean residence time (MRT), elimination half-live (t1/2), volume-of-distribution (VD), area under the curve (AUC), clearance (CL), bioavailability after oral administration (Foral).
- Compounds of formula 1
- wherein
- A is phenyl or a five- or six-membered, aromatic heteroring, wherein one, two or three elements are replaced by an element selected independent from each other from the group consisting of N, (O−)—N+, O and S;
- R1a is
- preferably
-
- R1a.1 is C1-4-alkyl-, C3-6-cycloalkyl-, C1-4-haloalkyl-, H2N—, C1-4-alkyl-NH—, C3-6-cycloalkyl-NH—, (C1-4-alkyl)2N—, (C3-6-cycloalkyl)(C1-4-alkyl)N—, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, piperazinyl-C1-4-alkyl-, C1-4-alkyl-O—NH—, (C1-4-alkyl-O)(C1-4-alkyl)N—;
- R1a.2 is H, NC—, O2N—, C1-4-alkyl-SO2—, aryl-SO2—, (aromatic heteroring)-SO2—, C1-4-alkyl-O—(O)C—, C1-4-alkyl-(O)C—, C3-6-cycloalkyl-(O)C—, H2N—(O)C—, C1-4-alkyl-NH—(O)C—, C3-6-cycloalkyl-NH—(O)C—, (C1-4-alkyl)2N—(O)C—, (C3-6-cycloalkyl)(C1-4-alkyl)N—(O)C—, azetidinyl-(O)C—, pyrrolidinyl-(O)C—, piperidinyl-(O)C—, morpholinyl-(O)C—, piperazinyl-(O)C—, piperazinyl-C1-4-alkyl-(O)C—, C1-4-alkyl-, C3-6-cycloalkyl-, C1-4-haloalkyl-, aryl, heteroaryl;
- R1b is H, C1-4-alkyl-, C3-6-cycloalkyl-, C1-4-haloalkyl- or halogen;
- or R1a and R1b are together C2-4-alkylene forming a carbocyclic heteroring;
- R2 is C1-6-alkyl or a residue selected from the group consisting of C3-6-cycloalkyl-, wherein one element of the ring is optionally replaced by O; phenyl-C1-4-alkyl-, (aromatic heteroring)-C1-4-alkyl- and a five- or six-membered, aromatic heteroring, wherein one, two or three elements are replaced by an element selected independent from each other from the group consisting of N, O and S; each element of one of the rings optionally substituted with one or two groups selected from C1-4-alkyl-, C3-6-cycloalkyl-, halogen, C1-4-haloalkyl-, C1-4-alkyl-O—, C1-4-alkyl-SO2— or NC—;
- R3 is H or C1-4-alkyl-;
- R4 is phenyl, a five- or six-membered, aromatic heteroring containing one, two or three atoms selected from N, O and S; each ring optionally substituted with one or two residues selected independently from each other from the group consisting of C1-4-alkyl-, C3-6-cycloalkyl-, halogen or C1-4-haloalkyl-;
- R5 is H, C1-4-alkyl-, C1-4-haloalkyl-, halogen;
- R6 is H or C1-4-alkyl-;
- R7 is H or C1-4-alkyl-;
- or R6 and R7 are forming together a C2-5-alkylene, wherein one element of the formed ring is optionally replaced by O;
or a pharmaceutically acceptable salt thereof.
- or R6 and R7 are forming together a C2-5-alkylene, wherein one element of the formed ring is optionally replaced by O;
- Preferred are the above compounds of formula 1, wherein
- A is phenyl or pyridinyl; preferably phenyl;
- R1a is
- preferably
-
- R1a.1 is C1-4-alkyl-, C3-6-cycloalkyl-, C1-4-alkyl-NH— or (C1-4-alkyl)2N—, preferably C1-4-alkyl- or C3-6-cycloalkyl-;
- R1a-2 is H, methyl, NC—, Me-SO2—;
- R1b is H, methyl, F, preferably H;
- and R2, R3, R4, R5, R6, R7 have the above given meaning; or a pharmaceutically acceptable salt thereof.
- Preferred are the above compounds of formula 1, wherein
- A is phenyl or pyridinyl; preferably phenyl;
- R1a is
- preferably
-
- R1a.1 is methyl, ethyl, i-propyl, cyclopropyl;
- R1a.2
- R1b is H;
- and R2, R3, R4, R5, R6, R7 have the above given meaning; or a pharmaceutically acceptable salt thereof.
- Preferred are the above compounds of formula 1, wherein
- R3 is methyl;
- and A, R1a, R1b, R2, R4, R5, R6, R7 have the above given meaning; or a pharmaceutically acceptable salt thereof.
- Preferred are the above compounds of formula 1, wherein
- R4 is selected from a group consisting of
- preferably
- preferably
- and A, R1a, R1b, R2, R4, R5, R6, R7 have the above given meaning; or a pharmaceutically acceptable salt thereof.
- Preferred are the above compounds of formula 1, wherein
- R5 is H;
- R6 is H;
- R7 is H;
- and A, R1a, R1b, R2, R3, R4, have the above given meaning; or a pharmaceutically acceptable salt thereof.
- Preferred are the above compounds of formula 1, wherein
- A is phenyl or pyridinyl;
- R1a is
- preferably
-
- R1a.1 is C1-4-alkyl-;
- R1a.2 is NC—;
- R1b is H;
- R2 is C1-6-alkyl or a residue selected from the group consisting of C3-6-cycloalkyl-, phenyl-C1-4-alkyl- and a five- or six-membered, aromatic heteroring containing one or two nitrogen atoms, each of the above rings optionally substituted with C1-4-alkyl-, halogen or NC—;
- R3 is methyl;
- R4 is phenyl, a five- or six-membered, aromatic ring containing one or two nitrogen atom, each ring optionally substituted with one or two residues selected independently from each other from the group consisting of C1-4-alkyl-, halogen or C1-4-haloalkyl-;
- R5 is H;
- R6 is H;
- R7 is H;
or a pharmaceutically acceptable salt thereof. - Preferred are the above compounds of formula 1, wherein
- A is phenyl or pyridinyl;
- R1a is
- preferably
-
- R1a.1 is C1-4-alkyl-;
- R1a.2 is NC—;
- R1b is H;
- R2 is C1-6-alkyl or a residue selected from the group consisting of C3-6-cycloalkyl-, phenyl-C1-4-alkyl- and a five-membered, aromatic ring containing two nitrogen atoms; each optionally substituted with methyl or NC—;
- R3 is methyl;
- R4 is phenyl or a six-membered, aromatic heteroring containing one or two nitrogen atom; each ring optionally substituted with one or two residues selected independently from each other from the group consisting of C1-4-alkyl-, halogen or C1-4-haloalkyl-;
- R5 is H;
- R6 is H;
- R7 is H;
or a pharmaceutically acceptable salt thereof. - Preferred are the above compounds of formula 1, wherein
- A is phenyl or pyridinyl;
- R1a is
- preferably
-
- R1a.1 is methyl, ethyl, i-propyl, n-propyl;
- R1a.2 is NC—;
- R1b is H;
- R2 is ethyl, i-propyl, 2-butyl, cyclobutyl, 1-methylpyrazolyl, or benzyl or 4-NC-benzyl;
- R3 is methyl;
- R4 is phenyl or pyridinyl, each ring optionally substituted with one or two residues selected independently from each other from the group consisting of methyl, ethyl, propyl, F, Br, Cl, F2HC— or F3C—;
- R5 is H;
- R6 is H;
- R7 is H;
or a pharmaceutically acceptable salt thereof. - Preferred are the above compounds of formula 1, wherein
- A is phenyl;
- R1a is
- preferably
-
- R1a.1 is methyl;
- R1a.2 is NC—;
- R1b is H;
- R2 is ethyl, i-propyl, cyclobutyl, 1-methylpyrazolyl, benzyl or 4-NC-benzyl;
- R3 is methyl;
- R4 is phenyl or pyridinyl, each ring optionally substituted with one or two residues selected independently from each other from the group consisting of F, F2HC— or F3C—;
- R5 is H;
- R6 is H;
- R7 is H;
or a pharmaceutically acceptable salt thereof. - Preferred are the above compounds of formula 1, wherein
- A is phenyl;
- R1a is
- preferably
-
- R1a.1 is methyl;
- R1a.2 is NC—;
- R1b is H;
- R2 is selected from a group consisting of
- R3 is methyl;
- R4 is selected from a group consisting of
- preferably
- preferably
- R5 is H;
- R6 is H;
- R7 is H;
or a pharmaceutically acceptable salt thereof. - In a preferred embodiment of the invention R4 is one of the above mentioned ring carrying the above mentioned optional substituted in meta-position to the element connection R4 with the compound of formula 1.
- From the above mentioned compounds those are preferred wherein R4 is
- From the above mentioned compounds those are preferred wherein R4 is
- From the above mentioned compounds those are preferred wherein R4 is
- From the above mentioned compounds those are preferred wherein R4 is
- From the above mentioned compounds those are preferred wherein R4 is
- In another embodiment of the invention preferred are the above compounds of formula 1, wherein
- A is phenyl or pyridinyl; preferably phenyl;
- R1a is
-
- R1a.1 is C1-4-alkyl-, C3-6-cycloalkyl-, C1-4-alkyl-NH— or (C1-4-alkyl)2N—, preferably C1-4-alkyl- or C3-6-cycloalkyl-;
- R1a.2 is H, methyl, NC—, Me-SO2—;
- R1b is H, methyl, F, preferably H;
- R2 is C1-6-alkyl or a residue selected from the group consisting of C3-6-cycloalkyl-, and a five-membered, aromatic heteroring containing one or two nitrogen atoms, each of the above rings optionally substituted with C1-4-alkyl-;
- R3 is H or C1-4-alkyl-;
- R4 is phenyl, a six-membered, aromatic heteroring containing one or two N; each optionally substituted with one or two residues selected independently from each other from the group consisting of halogen or C1-4-haloalkyl-; preferably F, F2HC— or F3C—;
- R5 is H;
- R6 is H;
- R7 is H;
or a pharmaceutically acceptable salt thereof. - In another embodiment of the invention preferred are the above compounds of formula 1, wherein
- A is phenyl;
- R1a is
-
- R1a.1 is C1-4-alkyl-;
- R1a.2 is NC—;
- R2 is ethyl, i-propyl, cyclopropyl, cyclobutyl, 1-methyl-pyrazolyl;
- R3 is methyl;
- R4 is phenyl; substituted with one or two residues selected independently from each other from the group consisting of F, F2HC— or F3C—;
- R1b, R5, R6 and R7 is H;
or a pharmaceutically acceptable salt thereof. - Preferred are
- The residue R1a is chiral, preferred is the Eutomer.
- Terms not specifically defined herein should be given the meanings that would be given to them by one of skill in the art in light of the disclosure and the context. As used in the specification, however, unless specified to the contrary, the following terms have the meaning indicated and the following conventions are adhered to.
- In the groups, radicals, or moieties defined below, the number of carbon atoms is often specified preceding the group, for example, C1-6-alkyl means an alkyl group or radical having 1 to 6 carbon atoms.
- In general in single groups like HO, H2N, OS, O2S, NC (cyano), HOOC, F3C or the like, the skilled artisan can see the radical attachment point(s) to the molecule from the free valences of the group itself. For combined groups comprising two or more subgroups, the last named subgroup is the radical attachment point, for example, the substituent “aryl-C1-3-alkyl-” means an aryl group which is bound to a C1-3-alkyl-group, the latter of which is bound to the core or to the group to which the substituent is attached.
- In case a compound of the present invention is depicted in form of a chemical name and as a formula in case of any discrepancy the formula shall prevail. An asterisk, a dashed or a dotted line may be used in sub-formulas to indicate the bond which is connected to the core molecule as defined.
- For example, the term “3-carboxypropyl-group” represents the following substituent:
- wherein the carboxy group is attached to the third carbon atom of the propyl group. The terms “1-methylpropyl-”, “2,2-dimethylpropyl-” or “cyclopropylmethyl-” group represent the following groups:
- A X with a subscript number or “#”, a dashed or a dotted line may be used in sub-formulas to indicate the bond which is connected to the core molecule as defined.
- Many of the followings terms may be used repeatedly in the definition of a formula or group and in each case have one of the meanings given above, independently of one another.
- The term “substituted” as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valence is not exceeded, and that the substitution results in a stable compound.
- The expressions “prevention”, “prophylaxis”, “prophylactic treatment” or “preventive treatment” used herein should be understood synonymous and in the sense that the risk to develop a condition mentioned hereinbefore is reduced, especially in a patient having elevated risk for said conditions or a corresponding anamnesis, e.g. elevated risk of developing metabolic disorder such as diabetes or obesity or another disorder mentioned herein. Thus the expression “prevention of a disease” as used herein means the management and care of an individual at risk of developing the disease prior to the clinical onset of the disease. The purpose of prevention is to combat the development of the disease, condition or disorder, and includes the administration of the active compounds to prevent or delay the onset of the symptoms or complications and to prevent or delay the development of related diseases, conditions or disorders. Success of said preventive treatment is reflected statistically by reduced incidence of said condition within a patient population at risk for this condition in comparison to an equivalent patient population without preventive treatment.
- The expression “treatment” or “therapy” means therapeutic treatment of patients having already developed one or more of said conditions in manifest, acute or chronic form, including symptomatic treatment in order to relieve symptoms of the specific indication or causal treatment in order to reverse or partially reverse the condition or to delay the progression of the indication as far as this may be possible, depending on the condition and the severity thereof. Thus the expression “treatment of a disease” as used herein means the management and care of a patient having developed the disease, condition or disorder. The purpose of treatment is to combat the disease, condition or disorder. Treatment includes the administration of the active compounds to eliminate or control the disease, condition or disorder as well as to alleviate the symptoms or complications associated with the disease, condition or disorder.
- Unless specifically indicated, throughout the specification and the appended claims, a given chemical formula or name shall encompass tautomers and all stereo, optical and geometrical isomers (e.g. enantiomers, diastereomers, E/Z isomers etc. . . . ) and racemates thereof as well as mixtures in different proportions of the separate enantiomers, mixtures of diastereomers, or mixtures of any of the foregoing forms where such isomers and enantiomers exist, as well as salts, including pharmaceutically acceptable salts thereof and solvates thereof such as for instance hydrates including solvates of the free compounds or solvates of a salt of the compound.
- When in the claimed ring system A (e.g. SA) the two residues R1a and R1b are “together a C2-4-alkylene forming a carbocyclic heteroring; rings similar to example SB are meant in this case R1a and R1b are in ortho position to each other.
- The term halogen generally denotes fluorine, chlorine, bromine and iodine.
- As used herein the term “prodrug” refers to (i) an inactive form of a drug that exerts its effects after metabolic processes within the body converting it to a usable or active form, or (ii) a substance that gives rise to a pharmacologically active metabolite, although not itself active (i.e. an inactive precursor).
- The terms “prodrug” or “prodrug derivative” mean a covalently-bonded derivative, carrier or precursor of the parent compound or active drug substance which undergoes at least some biotransformation prior to exhibiting its pharmacological effect(s). Such prodrugs either have metabolically cleavable or otherwise convertible groups and are rapidly transformed in vivo to yield the parent compound, for example, by hydrolysis in blood or by activation via oxidation as in case of thioether groups. Most common prodrugs include esters and amide analogs of the parent compounds. The prodrug is formulated with the objectives of improved chemical stability, improved patient acceptance and compliance, improved bioavailability, prolonged duration of action, improved organ selectivity, improved formulation (e.g., increased hydrosolubility), and/or decreased side effects (e.g., toxicity). In general, prodrugs themselves have weak or no biological activity and are stable under ordinary conditions. Prodrugs can be readily prepared from the parent compounds using methods known in the art, such as those described in A Textbook of Drug Design and Development, Krogsgaard-Larsen and H. Bundgaard (eds.), Gordon & Breach, 1991, particularly Chapter 5: “Design and Applications of Prodrugs”; Design of Prodrugs, H. Bundgaard (ed.), Elsevier, 1985; Prodrugs: Topical and Ocular Drug Delivery, K. B. Sloan (ed.), Marcel Dekker, 1998; Methods in Enzymology, K. Widder et al. (eds.), Vol. 42, Academic Press, 1985, particularly pp. 309-396; Burger's Medicinal Chemistry and Drug Discovery, 5th Ed., M. Wolff (ed.), John Wiley & Sons, 1995, particularly Vol. 1 and pp. 172-178 and pp. 949-982; Pro-Drugs as Novel Delivery Systems, T. Higuchi and V. Stella (eds.), Am. Chem. Soc., 1975; Bioreversible Carriers in Drug Design, E. B. Roche (ed.), Elsevier, 1987, each of which is incorporated herein by reference in their entireties.
- The term “pharmaceutically acceptable prodrug” as used herein means a prodrug of a compound of the invention which is, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible.
- The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, and commensurate with a reasonable benefit/risk ratio.
- As used herein, “pharmaceutically acceptable salts” refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. For example, such salts include salts from ammonia, L-arginine, betaine, benethamine, benzathine, calcium hydroxide, choline, deanol, diethanolamine (2,2′-iminobis(ethanol)), diethylamine, 2-(diethylamino)-ethanol, 2-aminoethanol, ethylenediamine, N-ethyl-glucamine, hydrabamine, 1H-imidazole, lysine, magnesium hydroxide, 4-(2-hydroxyethyl)-morpholine, piperazine, potassium hydroxide, 1-(2-hydroxyethyl)-pyrrolidinyl, sodium hydroxide, triethanolamine (2,2′,2″-nitrilotris(ethanol)), tromethamine, zinc hydroxide, acetic acid, 2.2-dichloro-acetic acid, adipic acid, alginic acid, ascorbic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, 2,5-dihydroxybenzoic acid, 4-acetamido-benzoic acid, (+)-camphoric acid, (+)-camphor-10-sulfonic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, decanoic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxy-ethanesulfonic acid, ethylenediaminetetraacetic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, D-glucoheptonic acid, D-gluconic acid, D-glucuronic acid, glutamic acid, glutaric acid, 2-oxo-glutaric acid, glycerophosphoric acid, glycine, glycolic acid, hexanoic acid, hippuric acid, hydrobromic acid, hydrochloric acid, isobutyric acid, DL-lactic acid, lactobionic acid, lauric acid, lysine, maleic acid, (−)-L-malic acid, malonic acid, DL-mandelic acid, methanesulfonic acid, galactaric acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, nitric acid, octanoic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid (embonic acid), phosphoric acid, propionic acid, (−)-L-pyroglutamic acid, salicylic acid, 4-amino-salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, (+)-L-tartaric acid, thiocyanic acid, p-toluenesulfonic acid and undecylenic acid. Further pharmaceutically acceptable salts can be formed with cations from metals like aluminium, calcium, lithium, magnesium, potassium, sodium, zinc and the like. (also see Pharmaceutical salts, Berge, S. M. et al., J. Pharm. Sci., (1977), 66, 1-19).
- The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a sufficient amount of the appropriate base or acid in water or in an organic diluent like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile, or a mixture thereof.
- Salts of other acids than those mentioned above which for example are useful for purifying or isolating the compounds of the present invention (e.g. trifluoro acetate salts,) also comprise a part of the invention.
- The term “C1-n-alkyl”, wherein n is an integer from 2 to 6, either alone or in combination with another radical denotes an acyclic, saturated, branched or linear hydrocarbon radical with 1 to 6 C atoms. For example the term C1-5-alkyl embraces the radicals H3C—, H3C—CH2—, H3C—CH2—CH2—, H3C—CH(CH3)—, H3C—CH2—CH2—CH2—, H3C—CH2—CH(CH3)—, H3C—CH(CH3)—CH2—, H3C—C(CH3)2—, H3C—CH2—CH2—CH2—CH2—, H3C—CH2—CH2—CH(CH3)—, H3C—CH2—CH(CH3)—CH2—, H3C—CH(CH3)—CH2—CH2—, H3C—CH2—C(CH3)2—, H3C—C(CH3)2—CH2—, H3C—CH(CH3)—CH(CH3)— and H3C—CH2—CH(CH2CH3)—.
- The term “C1-6-alkylene” wherein n is an integer 2 to 6, either alone or in combination with another radical, denotes an acyclic, straight or branched chain divalent alkyl radical containing from 1 to 6 carbon atoms. For example the term C1-4-alkylene includes —CH2—, —CH2—CH2—, —CH(CH3)—, —CH2—CH2—CH2—, —C(CH3)2—, —CH(CH2CH3)—, —CH(CH3)—CH2—, —CH2—CH(CH3)—, —CH2—CH2—CH2—CH2—, —CH2—CH2—CH(CH3)—, —CH(CH3)—CH2—CH2—, —CH2—CH(CH3)—CH2—, —CH2—C(CH3)2—, —C(CH3)2—CH2—, —CH(CH3)—CH(CH3)—, —CH2—CH(CH2CH3)—, —CH(CH2CH3)—CH2—, —CH(CH2CH2CH3)—, —CH(CH(CH3))2— and —C(CH3)(CH2CH3)—.
- The term “C2-n-alkylene” wherein n is an integer 3 to 5, either alone or in combination with another radical, denotes an acyclic, straight or branched chain divalent alkyl radical containing from 2 to 5 carbon atoms. For example the term C2-5-alkylene includes —CH2—CH2—, —CH(CH3)—, —CH2—CH2—CH2—, —C(CH3)2—, —CH(CH2CH3)—, —CH(CH3)—CH2—, —CH2—CH(CH3)—, —CH2—CH2—CH2—CH2—, —CH2—CH2—CH(CH3)—, —CH(CH3)—CH2—CH2—, —CH2—CH(CH3)—CH2—, —CH2—C(CH3)2—, —C(CH3)2—CH2—, —CH(CH3)—CH(CH3)—, —CH2—CH(CH2CH3)—, —CH(CH2CH3)—CH2—, —CH(CH2CH2CH3)—, —CH(CH(CH3))2— and —C(CH3)(CH2CH3)—.
- By the term “halo” added to a “alkyl”, “alkylene” or “cycloalkyl” group (saturated or unsaturated) is such a alkyl or cycloalkyl group meant wherein one or more hydrogen atoms are replaced by a halogen atom selected from among fluorine, chlorine or bromine, preferably fluorine and chlorine, particularly preferred is fluorine. Examples include: H2FC—, HF2C—, F3C—.
- The term “C3-6-cycloalkyl”, wherein n is an integer from 4 to 6, either alone or in combination with another radical denotes a cyclic, saturated, unbranched hydrocarbon radical with 3 to 6 C atoms. For example the term C3-6-cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
- The term “aryl” as used herein, either alone or in combination with another radical, denotes a carbocyclic aromatic monocyclic group containing 6 carbon atoms which may be further fused to a second five- or six-membered, carbocyclic group which may be aromatic, saturated or unsaturated. Aryl includes, but is not limited to, phenyl, indanyl, indenyl, naphthyl, anthracenyl, phenanthrenyl, tetrahydronaphthyl and dihydronaphthyl.
- With the elements of a ring the atoms forming this ring are meant. So, a phenyl ring contains 6 elements which are all carbon atoms, a pyrrol ring contains 5 elements, wherein 4 elements are carbon atoms and the remaining element is a nitrogen atom.
- The term “aromatic heteroring” means a unsaturated monocyclic-ring system containing one, two, three or four heteroatoms selected from N, (O−)N+, O or (O)rS, wherein r=0, 1 or 2, consisting of four, five or six ring atoms. If the term is connected with a more detailed definition of the amount or kind of heteroatoms and the possible size of the aromatic heteroring, the detailed definition is restricting the above mentioned definition.
- Furthermore the term is intended to include all possible isomeric forms. Thus, the term includes (if not otherwise restricted) the following exemplary structures which are not depicted as radicals as each form may be attached through a covalent bond to any atom so long as appropriate valences are maintained:
- The compounds according to the present invention and their intermediates may be obtained using methods of synthesis which are known to the one skilled in the art and described in the literature of organic synthesis. Preferably, the compounds are obtained in analogous fashion to the methods of preparation explained more fully hereinafter, in particular as described in the experimental section. In some cases, the order in carrying out the reaction steps may be varied. Variants of the reaction methods that are known to the one skilled in the art but not described in detail here may also be used. The general processes for preparing the compounds according to the invention will become apparent to the one skilled in the art studying the following schemes.
- Starting materials are commercially available or may be prepared by methods that are described in the literature or herein, or may be prepared in an analogous or similar manner Any functional groups in the starting materials or intermediates may be protected using conventional protecting groups. These protecting groups may be cleaved again at a suitable stage within the reaction sequence using methods familiar to the one skilled in the art.
- Starting material I can be prepared as described in US2003/87940.
- Intermediates II can be prepared as described in WO10133973 and US2003/87940 by heating starting material I with amines R—NH2 in the presence of a strong base, for example sodium tert-butoxide or sodium ethoxide, in an organic solvent, for example ethanol. The reaction usually takes place within 2 to 72 hours. Preferred reaction temperatures are between 50° C. and 150° C.
- The amide coupling (Step B, intermediates II→intermediates III, intermediates IV→intermediates V, intermediates VI→compounds of the invention) can be achieved by reacting carboxylic acid intermediates II, IV or VI with amines R′—NH2 in the presence of an amide coupling reagent, for example O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU), O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) or propane phosphonic acid anhydride, and in the presence of a base, for example triethylamine, diisopropylethylamine (DIPEA, Hünig's base) or N-methyl-morpholine, in an organic solvent, for example N, N-dimethylformamide (DMF), N-methyl-2-pyrrolidone (NMP) or dimethylacetamide (DMA) or mixtures thereof. The reaction usually takes place within 1 to 72 hours. Preferred reaction temperatures are between 0° C. and 50° C., most preferred room temperature. Alternatively, the carboxylic acid intermediates can be activated first as described in US2003/87940, for example with 1,1′-carbonyldiimidazole (CDI) in DMF, followed by reaction with the amine R′—NH2.
- The bromination (Step C, X=Br, intermediates II→intermediates IV, intermediates III→intermediates V) can be achieved by reacting intermediates II or III with bromination agents, for example bromine or N-bromosuccinimide, in an organic solvent, for example acetic acid, dichloromethane, methanol, acetonitrile, tetrahydrofuran or mixtures thereof. The iodination (Step C, X=I, intermediates II→intermediates IV, intermediates III→intermediates V) can be achieved by reacting intermediates II or III with iodination agents, for example iodine, iodinechloride (I—Cl) or N-iodosuccinimide, in an organic solvent, for example acetic acid, methanol, ethanol, dichloromethane, acetonitrile, N, N-dimethylformamide, tetrahydrofuran or mixtures thereof. The halogenation reaction usually takes place within 1 to 72 hours. Preferred reaction temperatures are between 0° C. and 50° C., most preferred room temperature.
- The Suzuki coupling (Step D, intermediates IV→intermediates VI, intermediates V→compounds according to the invention) can be achieved by reacting intermediates IV or V with aryl or heteroaryl boronic acids R″—B(OH)2 or the corresponding boronic esters in the presence of a palladium catalyst, for example tetrakis(triphenylphosphine)palladium(0) or [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), and in the presence of a base, for example, potassium carbonate, barium dihydroxide or cesium carbonate, in an organic solvent, for example toluene, benzene, ethanol, ethylene glycol dimethyl ether, acetonitrile, dioxane or mixtures thereof, optionally in the presence of water. The reaction usually takes place within 1 to 72 hours. Preferred reaction temperatures are between 50° C. and 150° C.
- Compounds according to the present invention can also be prepared according to the following scheme starting from 4-hydroxy-6-methyl-nicotinic acid. Halogenation (Step C) as described above, followed by Suzuki coupling (Step D) as described above, followed by amide coupling (Step B) as described above, yields intermediates VII. The alkylation of the pyridone nitrogen (Step E) can be achieved by reacting intermediate VII with alkylating agents, for example alkyl bromides, alkyl iodides, alkyl tosylates, alkyl mesylates or dialkyl sulfates, in the presence of a base, for example sodium carbonate, potassium carbonate, potassium hydroxide, sodium hydroxide or cesium carbonate, in an organic solvent, N, N-dimethylformamide (DMF), N-methyl-2-pyrrolidone (NMP) or dimethylacetamide (DMA). The reaction usually takes place within 1 to 72 hours. Preferred reaction temperatures are between 50° C. and 150° C.
- The intermediates for compounds according to the present invention with 2-alkyl substituents can be prepared according to Venkatramani et al., J. Het. Chem. 30, 723-738 (1993).
- The synthesis of sulfinimides (sulfilimines) and sulfonimides (sulfoximines) has been extensively described in Reggelin et al., Synthesis, 1-64 (2000) and Bolm et al., Chem. Lett. 33, 482-487 (2004). The general processes for the preparation of N-cyano-sulfonimides (N-cyano-sulfoximines) are illustrated in the following scheme. As indicated, the order of imination and oxidation can usually be interchanged, and the syntheses can likewise start from sulfoxides instead of sulfides.
- Intermediates VIII can be prepared as described in Bolm et al., Org. Lett. 9, 3809-3811 (2007) via direct imination of a thioether (intermediates VII) with cyanamide (Step F, intermediates VII→intermediates VIII) by reaction with an halogenating agent, for example N-bromo- or N-chlorosuccinimide, tert-butyl hypochlorite or iodine in the presence of cyanamide and a base, for example potassium or sodium tert-butoxide, in an organic solvent, for example methanol, tetrahydrofuran (THF) or acetonitrile. The reaction usually takes place within 1 to 72 hours. Preferred reaction temperatures are between 0° C. and 50° C., most preferred is room temperature. Alternatively, the imination (Step F, intermediates VII→intermediates VIII) can be achieved as described in Bolm et al., Org. Lett. 9, 2951-2954 (2007), by using phenyliodo diacetate [PhI(OAc)2] and cyanamide in an organic solvent, for example acetonitrile or tetrahydrofuran (THF). The reaction usually takes place within 1 to 72 hours. Preferred reaction temperatures are between 0° C. and room temperature.
- The oxidation (Step G, intermediates VIII→intermediates IX, intermediates XI→intermediates XII) can be achieved using a peroxycarboxylic acid as oxidizing agent, for example meta-chloroperoxybenzoic acid (mCPBA), optionally in the presence of a base, for example potassium carbonate, in an organic solvent, for example ethanol, methanol, dichloromethane or chloroform. The reaction usually takes place within 1 to 72 hours. Preferred reaction temperatures are between 0° C. and room temperature. Alternatively, other common oxidizing agents may be used to achieve this transformation, for example hydrogen peroxide, tert-butyl hydroperoxide, sodium hypochlorite, sodium iodate, sodium periodate, potassium permanganate, ruthenium tetroxide, potassium peroxymonosulfate (Oxone) or dimethyldioxirane.
- Intermediates X can be obtained by imination of intermediates VII (Step H, intermediates VII→intermediates X) as described in Bolm. et al., Org. Lett. 6, 1305-1307 (2004), by reacting a thioether (intermediates VII) with trifluoroacetamide, phenyliodo diacetate [PhI(OAc)2], rhodium acetate dimer [Rh2(OAc)4] and MgO in an organic solvent, for example dichloromethane. The reaction usually takes place within 1 to 72 hours. Preferred reaction temperatures are between 0° C. and room temperature.
- The cleavage of the trifluoroacetamide (Step K, intermediates X→intermediates XI) can be achieved as described in Bolm. et al., Org. Lett. 6, 1305-1307 (2004), using a base, for example potassium carbonate, in an organic solvent, for example methanol. The reaction usually takes place within 1 to 72 hours. Preferred reaction temperatures are between 0° C. and 50° C., most preferred room temperature.
- Alternatively, intermediates XI can be prepared by the imination of intermediates VII using other electrophilic nitrogen sources, for example tert-butyl 3-(4-cyano-phenyl)-oxaziridine-2-carboxylate (followed by cleavage of the Boc-protecting group), O-mesityl sulfonyl hydroxylamine (MSH), or hydrazoic azid.
- The cyanation of sulfinimides or sulfonimides (Step K, intermediates XI→intermediates VIII, intermediates XII→intermediates IX) can be achieved as described in Bolm et al., Org. Lett. 9, 2951-2954 (2007), by reacting the starting material with cyanogen bromide, optionally 4-dimethylaminopyridine (DMAP) and optionally a base, for example triethylamine, in an organic solvent, for example dichloromethane. The reaction usually takes place within 1 to 72 hours. Preferred reaction temperatures are between 0° C. and 50° C., most preferred room temperature.
- The synthesis of sulfonimidamides has been described in Johnson et al., J. Org. Chem. 44, 2055-2061 (1975), Bolm et al., J. Org. Chem. 75, 3301-3310 (2010) and in WO09156336. The general synthetic scheme for the preparation of sulfonimidamides from sulfinamides is depicted in the following scheme.
- Sulfinamides (starting material XIII) can be prepared as described in Johnson et al., J. Org. Chem. 44, 2055-2061 (1975) by reacting sulfinyl chlorides with a primary or secondary amine, optionally in the presence of an additional base, for example pyridine or a tertiary amine, in an organic solvent, for example dichloromethane, tetrahydrofuran, diethylether, acetonitrile, toluene, N,N-dimethylformamide, ethanol or ethyl acetate. The reaction usually takes place within 1-72 hours. Preferred reaction temperatures are between 0° C. and room temperature.
- Sulfonimidoyl chlorides (intermediates XIV) can be prepared as described in Johnson et al., J. Org. Chem. 44, 2055-2061 (1975), by reacting sulfinamides (starting material XIII) with a chlorinating agent, for example chlorine, N-chlorosuccinimide (NCS), N-chloro-benzotriazole or tert-butyl hypochlorite in an organic solvent, for example dichloromethane, diethylether, benzene, toluene, carbon tetrachloride, acetonitrile or tetrahydrofuran (Step L). The reaction usually takes place within less than 1 hour. Preferred reaction temperatures are between −78° C. and room temperature, mostly preferred between 0° C. and room temperature.
- Sulfonimidoyl fluorides (intermediates XV) can be prepared as described in Johnson et al., J. Org. Chem. 48, 1-3 (1983) and Gnamm et al., Bioorg. Med. Chem. Lett. 12, 3800-3806 (2012), by reacting sulfonimidoyl chlorides (intermediates XIV) with a fluoride salt, for example potassium fluoride, sodium fluoride or tetrabutylammonium fluoride, optionally in the presence of a crown ether, for example 18-crown-6, in an organic solvent, for example acetonitrile or tetrahydrofuran (Step M). The reaction takes place within 1 to 24 hours. Preferred reaction temperatures are between 0° C. and room temperature, mostly preferred room temperature.
- Sulfonimidamides (intermediates XVI) can be prepared as described in Johnson et al., J. Org. Chem. 44, 2055-2061 (1975), Bolm et al., J. Org. Chem. 75, 3301-3310 (2010), and WO09156336 by reacting sulfonimidoyl chlorides (intermediates XIV) with a primary or secondary, aliphatic or aromatic amine, optionally in the presence of an additional base, for example pyridine or a tertiary amine, in an organic solvent, for example acetonitrile, tetrahydrofuran, N,N-dimethylformamide or benzene (Step N). The reaction takes place within 1 to 72 hours. Preferred reaction temperatures are between 0° C. and room temperature.
- Alternatively, sulfonimidamides (intermediates XVI) can be prepared as described in Gnamm et al., Bioorg. Med. Chem. Lett. 22, 3800-3806 (2012) by reacting sulfonimidoyl fluorides (intermediates XV) with a primary or secondary, aliphatic or aromatic amine, optionally in the presence of an additional base, for example pyridine or a tertiary amine, for example 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), in an organic solvent, for example acetonitrile, tetrahydrofuran, N,N-dimethylformamide or benzene (Step 0). The reaction takes place within 1 to 72 hours. Preferred reaction temperatures are between 0° C. and the boiling point of the solvent, mostly preferred between room temperature and 110° C.
- Preliminary Remarks:
- 1H-NMR have been obtained for the examples of the invention. The HPLC data given are measured under the following conditions (r.t.=retention time):
-
Method Name: V001_007 Column: XBridge C18, 4.6 × 30 mm, 3.5 μm Column Supplier: Waters Gradient/Solvent % Sol % Sol Flow Temp Time [min] [H2O, 0.1% TFA] [Methanol] [ml/min] [° C.] 0.0 95 5 4 60 1.6 0 100 4 60 1.85 0 100 4 60 1.9 95 5 4 60 Method Name: V003_003 Column: XBridge C18, 4.6 × 30 mm, 3.5 μm Column Supplier: Waters Gradient/Solvent % Sol % Sol Flow Temp Time [min] [H2O, 0.1% NH3] [Methanol] [ml/min] [° C.] 0.0 95 5 4 60 0.2 95 5 4 60 1.5 0 100.0 4 60 1.75 0 100 4 60 Method Name: X001_004 Column: XBridge C18, 2.1 × 20 mm, 2.5 μm Column Supplier: Waters Gradient/Solvent % Sol % Sol Flow Temp Time [min] [H2O, 0.10% TFA] [Methanol] [ml/min] [° C.] 0.0 95 5 1.4 60 0.05 95 5 1.4 60 1.00 0 100 1.4 60 1.1 0 100 1.4 60 Method Name: X012_S01 Column: Xbridge BEH C18, 2.1 × 30 mm, 1.7 μm Column Supplier: Waters % Sol Gradient/Solvent % Sol [Aceto- Flow Temp Time [min] [H2O, 0.1% TFA] nitrile] [ml/min] [° C.] 0.0 99 1 1.6 60 0.02 99 1 1.6 60 1.00 0 100 1.6 60 Method Name: X012_S01 1.10 0 100 1.6 60 Method Name: Z002_005 Column: Sunfire C18, 3 × 30 mm, 2.5 μm Column Supplier: Waters Gradient/Solvent % Sol % Sol Flow Temp Time [min] [H2O, 0.1% TFA] [Methanol] [ml/min] [° C.] 0.0 95 5 1.8 60 0.25 95 5 1.8 60 1.70 0 100 1.8 60 1.75 0 100 2.5 60 1.90 0 100 2.5 60 Method Name: Z002_007 Column: Sunfire C18, 3 × 30 mm, 2.5 μm Column Supplier: Waters Gradient/Solvent % Sol % Sol Flow Temp Time [min] [H2O, 0.1% TFA] [Methanol] [ml/min] [° C.] 0.0 95 5 1.9 60 0.20 95 5 1.9 60 1.55 0 100 1.9 60 1.60 0 100 2.4 60 1.80 0 100 2.4 60 Method Name: Z002_006 Column: Sunfire C18, 3 × 30 mm, 2.5 μm Column Supplier: Waters Gradient/Solvent % Sol % Sol Flow Temp Time [min] [H2O, 0.1% TFA] [Methanol] [ml/min] [° C.] 0.0 95 5 1.9 60 0.20 95 5 1.9 60 1.55 0 100 1.9 60 1.60 0 100 2.4 60 1.80 0 100 2.4 60 Method Name: Z002_002 Column: Sunfire C18, 3 × 30 mm, 2.5 μm Column Supplier: Waters Gradient/Solvent % Sol % Sol Flow Temp Time [min] [H2O, 0.1% TFA] [Methanol] [ml/min] [° C.] 0.0 95 5 2.2 60 0.05 95 5 2.2 60 1.40 0 100 2.2 60 1.80 0 100 2.2 60 Method Name: Z003_001 Column: XBridge C18, 3 × 30 mm, 2.5 μm Column Supplier Waters Gradient/Solvent % Sol % Sol Flow Temp Time [min] [H2O, 0.1% NH3] [Methanol] [ml/min] [° C.] 0.0 95 5 2.2 60 0.05 95 5 2.2 60 1.40 0 100 2.2 60 1.80 0 100 2.2 60 Method Name: Z011_S03 Column: XBridge C18, 3 × 30 mm, 2.5 μm Column Supplier Waters % Sol Gradient/Solvent % Sol [Aceto- Flow Temp Time [min] [H2O, 0.1% NH3] nitrile] [ml/min] [° C.] 0.00 97 3 2.2 60 0.20 97 3 2.2 60 1.20 0 100 2.2 60 1.25 0 100 3 60 1.40 0 100 3 60 Method Name: Z012_S04 Column: XBridge C18, 3 × 30 mm, 2.5 μm Column Supplier Waters % Sol Gradient/Solvent % Sol [Aceto- Flow Temp Time [min] [H2O, 0.1% TFA] nitrile] [ml/min] [° C.] 0.00 97 3 2.2 60 0.20 97 3 2.2 60 1.20 0 100 2.2 60 1.25 0 100 3 60 1.40 0 100 3 60 Method Name: Z017_S04 Column: Stable Bond, 3 × 30 mm, 1.8 μm Column Supplier: Agilent % Sol Gradient/Solvent % Sol [Aceto- Flow Temp Time [min] [H2O, 0.1% TFA] nitrile] [ml/min] [° C.] 0.00 97 3 2.2 60 0.20 97 3 2.2 60 1.20 0 100 2.2 60 1.25 0 100 3 60 1.40 0 100 3 60 Method Name: Z018_S04 Column: Sunfire, 3 × 30 mm, 2.5 μm Column Supplier: Waters % Sol Gradient/Solvent % Sol [Aceto- Flow Temp Time [min] [H2O, 0.1% TFA] nitrile] [ml/min] [° C.] 0.00 97 3 2.2 60 0.20 97 3 2.2 60 1.20 0 100 2.2 60 1.25 0 100 3 60 1.40 0 100 3 60 Method Name: 004_CC_CA01 Column: SunFire C18_4.6 × 30 mm, 3.5 μm Column Supplier: Waters % Sol Gradient/Solvent % Sol [Aceto- Flow Temp Time [min] [H2O 0.1% TFA] nitrile] [ml/min] [° C.] 0.0 98.0 2.0 2.5 60.0 1.5 0.0 100.0 2.5 60.0 1.8 0.0 100.0 2.5 60.0 Method Name: 001_CA03 Column: SunFire C18_4.6 × 30 mm, 3.5 μm Column Supplier: Waters % Sol Gradient/Solvent [Acetonitrile Flow Temp Time [min] 0.1% TFA] [ml/min] [° C.] 0.0 2.0 2.5 60.0 1.5 100.0 2.5 60.0 1.8 100.0 2.5 60.0 Method Name: X011_S03 Method Name: X011_S03 Column: Xbridge BEH C18, 2.1 × 30 mm, 1.7 μm Column Supplier: Waters % Sol Gradient/Solvent % Sol [Aceto- Flow Temp Time [min] [H2O, 0.1% NH3] nitrile] [ml/mm] [° C.] 0.00 95 5 1.3 60 0.02 95 5 1.3 60 1.00 0 100 1.3 60 1.10 0 100 1.3 60 Method Name: X012_S02 Column: Xbridge BEH C18, 2.1 × 30 mm, 1.7 μm Column Supplier: Waters % Sol Gradient/Solvent % Sol [Aceto- Flow Temp Time [min] [H2O, 0.1% TFA] nitrile] [ml/min] [° C.] 0.0 99 1 1.3 60 0.02 99 1 1.3 60 1.00 0 100 1.3 60 1.10 0 100 1.3 60 Method Name: V011_S01 Column: XBridge C18, 4.6 × 30 mm, 3.5 μm Column Supplier: Waters % Sol Gradient/Solvent % Sol [Aceto- Flow Temp Time [min] [H2O, 0.1% NH3] nitrile] [ml/min] [° C.] 0.0 97 3 5 60 0.2 97 3 5 60 1.6 0 100 5 60 1.7 0 100 5 60 Method Name: LCMS-FA-2 Column: Aquity UPLC BEH C18, 2.1 × 100 mm, 1.7 μm Column Supplier: Waters % Sol % Sol Gradient/Solvent [H2O, [MeCN, Flow Temp Time [min] 0.1% HCO2H] 0.1% HCO2H] [ml/min] [° C.] 0.00 90 10 0.4 40 1.00 90 10 0.4 40 4.50 25 75 0.4 40 5.50 25 75 0.4 40 6.00 5 95 0.4 40 7.00 5 95 0.4 40 7.01 90 10 0.4 40 Method Name: LCMS-FA-8 Method Name: LCMS-FA-8 Column: Aquity UPLC BEH C18, 2.1 × 50 mm, 1.7 μm Column Supplier: Waters % Sol % Sol Gradient/Solvent [H2O, [MeCN, Flow Temp Time [min] 0.1% HCO2H] 0.1% HCO2H] [ml/mm] [° C.] 0.00 98 2 0.4 40 0.80 98 2 0.4 40 2.00 55 45 0.4 40 3.00 25 75 0.4 40 3.50 5 95 0.4 40 4.00 0 100 0.4 40 5.00 0 100 0.4 40 5.01 98 2 0.4 40 Method Name: 5-95AB Column: Chromolith Flash RP-18e, 25 × 2 mm, 1.5 μm Column Supplier: Merck Milipore % Sol % Sol Gradient/Solvent [H2O, [MeCN, Flow Temp Time [min] 0.0375% TFA] 0.18% TFA] [ml/min] [° C.] 0.00 95 5 1.5 40 0.70 5 95 1.5 40 1.15 5 95 1.5 40 1.16 95 5 1.5 40 1.60 5 95 1.5 40 Method Name: 0-30AB Column: Venusil XBP-C18, 50 × 2.1 mm, 5 μm Column Supplier: Bonna Agela % Sol % Sol Gradient/Solvent [H2O, [MeCN, Flow Temp Time [min] 0.0375% TFA] 0.18% TFA] [ml/min] [° C.] 0.00 100 0 1.0 50 2.60 70 30 1.0 50 2.70 70 30 1.0 50 2.71 100 0 1.0 50 3.00 100 0 1.0 50 -
-
- To a solution of 4-hydroxy-6-methyl-2-pyrone (11.50 g, 91.2 mmol) in toluene (30 mL) is added N,N-dimethylformamide dimethyl acetal (13.00 mL, 97.9 mmol). After stirring for 2 h at room temperature, the reaction mixture is evaporated under reduced pressure and co-evaporated with toluene several times. Yield: 18.5 g; ESI mass spectrum: [M+H]+=182; r.t. HPLC: 0.72 min (Z002_007).
-
- A solution of 3-dimethylaminomethylene-6-methyl-pyran-2,4-dione (preparation 1a, 10.00 g, 38.6 mmol based on 70% purity), isopropylamine (5.00 mL, 58.4 mmol) and sodium tert-butoxide (5.50 g, 57.2 mmol) in ethanol (20 mL) is heated for 18 h at 90° C. The reaction mixture is evaporated under reduced pressure, treated with water and extracted with dichloromethane. The aqueous layer is acidified with 4 N aqueous HCl and extracted with dichloromethane. The combined organic layer is washed with water, dried over Na2SO4 and evaporated under reduced pressure. Yield: 7.16 g; ESI mass spectrum: [M+H]+=196; r.t. HPLC: 0.71 min (Z002_006).
-
- To a solution of 1-isopropyl-6-methyl-4-oxo-1,4-dihydro-pyridine-3-carboxylic acid (preparation 1b, 1.50 g, 6.92 mmol based on 90% purity) in glacial acetic acid (10 ml) is added at room temperature bromine (0.60 mL, 11.7 mmol). After stirring for 3 d at room temperature, additional bromine (1.00 mL, 19.5 mmol) is added to the reaction mixture and stirring is continued for 2 h at room temperature. The reaction mixture is diluted with water. Upon addition of dichloromethane a precipitate forms which is filtered off and dried. Yield: 2.55 g; ESI mass spectrum: [M+H]+=274 (bromine isotope pattern); r.t. HPLC: 0.76 min (Z002_002).
-
- A solution of 5-bromo-1-isopropyl-6-methyl-4-oxo-1,4-dihydro-pyridine-3-carboxylic acid (preparation 1c, 270 mg, 0.99 mmol), TBTU (316 mg, 0.99 mmol) and DIPEA (513 μL, 2.97 mmol) in DMF (3.00 mL) is stirred for 10 min at room temperature. Then, a solution of (4-(N-cyano-S-methylsulfonimidoyl)phenyl)methanamine (preparation 6, 247 mg, 1.18 mmol) in DMF (1.00 mL) is added and the reaction mixture is stirred for 18 h at room temperature. The reaction mixture is purified by preparative reversed phase HPLC (Sunfire, gradient of acetonitrile in water, 0.1% TFA, 60° C.). Yield: 70 mg (15% of theory); ESI mass spectrum: [M+H]+=465 (bromine isotope pattern); r.t. HPLC: 0.86 min (Z017_S04).
-
-
- Preparation 2a is prepared following the procedure described for preparation 1b, substituting isopropylamine with ethylamine ESI mass spectrum: [M+H]+=182; r.t. HPLC: 0.62 min (Z002_006).
-
- Preparation 2b is prepared following the procedure described for preparation 1c, substituting preparation 1b with preparation 2a as starting material. ESI mass spectrum: =260 (bromine isotope pattern); r.t. HPLC: 0.89 min (Z002_007).
-
- Preparation 2c is prepared following the procedure described for preparation 1d, substituting preparation 1c with preparation 2b as starting material and substituting TBTU with HBTU as coupling reagent. ESI mass spectrum: [M+H]+=451 (bromine isotope pattern); r.t. HPLC: 0.81 min (Z012_S04).
-
-
- Preparation 3a is prepared following the procedure described for preparation 1b, substituting isopropylamine with cyclopropylamine ESI mass spectrum: [H+H]+=208; r.t. HPLC: 0.62 min (Z002_002).
-
- Preparation 3b is prepared following the procedure described for preparation 1c, substituting preparation 1b with preparation 3a as starting material. ESI mass spectrum: [M+H]+=286 (bromine isotope pattern); r.t. HPLC: 0.82 min (Z002_002).
-
- Preparation 3c is prepared following the procedure described for preparation 1d, substituting preparation 1c with preparation 3b as starting material and substituting TBTU with HBTU as coupling reagent. ESI mass spectrum: [M+H]+=477 (bromine isotope pattern); r.t. HPLC: 0.90 min (Z018_S04).
-
-
- Preparation 4a is prepared following the procedure described for preparation 1b, substituting isopropylamine with 1-methyl-1H-pyrazol-5-ylamine. ESI mass spectrum: [M+H]+=234; r.t. HPLC: 0.63 min (Z018_S04).
-
- Preparation 4b is prepared following the procedure described for preparation 1d, substituting preparation 1c with preparation 4a as starting material and substituting TBTU with HBTU as coupling reagent. ESI mass spectrum: [M+H]+=425; r.t. HPLC: 0.79 min (Z018_S04).
-
- To a solution of 6-methyl-1-(2-methyl-2H-pyrazol-3-yl)-4-oxo-1,4-dihydro-pyridine-3-carboxylic acid 4-(N-cyano-S-methylsulfonimidoyl)-benzylamide (preparation 4b, 150 mg, 0.118 mmol) in dichloromethane (2 mL) is added N-bromosuccinimide (21 mg, 0.35 mmol) and five drops of glacial acetic acid. After stirring for 18 h at room temperature the reaction mixture is concentrated under reduced pressure and purified by preparative reversed phase HPLC (Xbridge, gradient of acetonitrile in water, 0.1% TFA, 60° C.). Yield: 40 mg (23% of theory); ESI mass spectrum: [M+H]+=503 (bromine isotope pattern); r.t. HPLC: 0.82 min (Z012_S04).
-
-
- Preparation 5a is prepared following the procedure described for preparation 1b, substituting isopropylamine with 4-cyanobenzylamine. ESI mass spectrum: [M+H]+=269; r.t. HPLC: 0.86 min (Z002_005).
-
- Preparation 5b is prepared following the procedure described for preparation 1c, substituting preparation 1b with preparation 5a as starting material. ESI mass spectrum: [M+H]+=347 (bromine isotope pattern); r.t. HPLC: 1.07 min (Z002_005).
-
- A mixture of 5-bromo-1-(4-cyano-benzyl)-6-methyl-4-oxo-1,4-dihydro-pyridine-3-carboxylic acid (preparation 5b, 2.55 g, 7.34 mmol), 3-(trifluoromethyl)phenylboronic acid (1.65 g, 8.69 mmol), 1,1′-[bis(diphenylphosphino)ferrocene]dichloropalladium(II) (340 mg, 0.47 mmol) and Cs2CO3 (4.20 g, 12.9 mmol) in dioxane (20.0 mL) is heated for 72 h at 80° C. The reaction mixture is filtered over silica and the filtrate is concentrated under reduced pressure and purified by preparative reversed phase HPLC (first purification: Sunfire, gradient of methanol in water, 0.1% TFA; second purification: Xbridge, gradient of methanol in water, 0.1% NH4OH, 60° C.). Yield: 514 mg (17% of theory); ESI mass spectrum: [M+H]+=413; r.t. HPLC: 1.37 min (Z002_005).
-
-
- A mixture of 4-(methylthio)benzylamine (2.00 mL, 2.20 g, 14.38 mmol) and phthalic anhydride (2.39 g, 15.79 mmol) in acetic acid (40 mL, 42 g, 700 mmol) is heated at reflux for 3 h. The mixture is concentrated under reduced pressure, and the residue is partitioned between water and dichloromethane. The phases are separated, and the aqueous phase is extracted twice with dichloromethane. The combined organic layers are concentrated under reduced pressure and the residue is purified by flash chromatography on silica (gradient cyclohexane/ethyl acetate 9:1 to 7:3). Yield: 3.60 g (88% of theory); ESI mass spectrum: =284; r.t. HPLC: 0.75 min (X001_004).
-
- A solution of 2-(4-(methylthio)benzyl)isoindoline-1,3-dione (preparation 6a, 3.60 g, 12.71 mmol), cyanamide (694 mg, 16.5 mmol) and potassium tert-butoxide (1.71 g, 15.25 mmol) in methanol (30 mL) is treated with N-bromosuccinimide (3.39 g, 19.06 mmol). The mixture is stirred for 1 h and concentrated under reduced pressure. Saturated aqueous Na2S2O3 solution is added and the mixture is extracted twice with dichloromethane. The combined organic layers are dried over Na2SO4 and concentrated under reduced pressure. The residue is purified by flash chromatography on silica (gradient cyclohexane/ethyl acetate 1:1 to ethyl acetate to ethyl acetate/methanol 4:1). Yield: 2.43 g (59% of theory); ESI mass spectrum: [M+H]+=324; r.t. HPLC: 0.52 min (X001_004).
-
- A solution of 2-(4-(N-cyano-S-methylsulfinimidoyl)benzyl)isoindoline-1,3-dione (preparation 6b, 5.75 g, 17.78 mmol) and potassium carbonate (7.37 g, 53.34 mmol) in ethanol (130 mL) is cooled at 0° C. and treated with meta-chloroperoxybenzoic acid (mCPBA, 5.98 g, 26.67 mmol). The reaction mixture is warmed to room temperature and stirred overnight before more mCPBA (2.39 g, 10.66 mmol) is added and the mixture is stirred for 4 h. Saturated aqueous Na2S2O3 solution is added, and the mixture is extracted twice with dichloromethane. The combined organic layers are dried over Na2SO4 and concentrated under reduced pressure. The residue is purified by flash chromatography on silica (gradient cyclohexane/ethyl acetate 1:1 to ethyl acetate). Yield: 2.47 g (41% of theory); ESI mass spectrum: [M+H]+=334; r.t. HPLC: 1.02 min (V003_003).
-
- A solution of 2-(4-(N-cyano-S-methylsulfonimidoyebenzyl)isoindoline-1,3-dione (preparation 6c, 684 mg, 2.02 mmol) and 1,2-diaminoethane (243 μL, 219 mg, 3.64 mmol) in a mixture of acetonitrile (8 mL), tetrahydrofuran (4 mL) and ethanol (4 mL) is heated at 60° C. for 5 h. All volatiles are removed under reduced pressure and the residue is suspended in dichloromethane. The mixture is filtered and the filtrate is concentrated under reduced pressure. Yield: 326 mg (77% of theory); ESI mass spectrum: [M+H]+=210; r.t. HPLC: 0.223 min (V001_007).
-
- To a solution of preparation 1 (70 mg, 0.15 mmol), 3-(difluoromethyl)phenylboronic acid (36 mg, 0.21 mmol) and 1,1′-[bis(diphenylphosphino)ferrocene]dichloropalladium(II) (11 mg, 0.015 mmol) in acetonitrile (2.00 mL) is added aqueous K2CO3 solution (2 M, 0.155 mL, 0.31 mmol). After stirring for 18 h at 75° C., the reaction mixture is filtered and the filtrate is purified by preparative reversed phase HPLC (XBridge, gradient of methanol in water, 0.1% NH4OH, 60° C.). Yield: 32 mg (42% of theory); ESI mass spectrum: [M+H]+=513; r.t. HPLC: 0.90 min (Z003_001).
- 63 mg of racemic example 1 are separated by chiral HPLC (Daicel IB, 250 mm×20 mm, 15% MeOH+0.2% diethylamine in supercritical CO2, 40° C.).
- Early eluting enantiomer (Example 1A): r.t. chiral HPLC=5.10 min (Daicel Chiralcel® OZ-H 4.6 mm×250 mm, 5 μm, 4 ml/min, 10 min, 40% MeOH+0.2% diethylamine in supercritical CO2, 40° C., 100 bar back pressure); ESI mass spectrum: [M+H]+=513; Yield: 23 mg
- Late eluting enantiomer (Example 1B): r.t. chiral HPLC=7.80 min (Daicel Chiralcel®OZ-H 4.6 mm×250 mm, 5 μm, 4 ml/min, 10 min, 40% MeOH+0.2% diethylamine in supercritical CO2, 40° C., 100 bar back pressure); ESI mass spectrum: [M+H]+=513; Yield: 20 mg
-
- Example 2 is prepared following the procedure described for example 1, substituting 3-(difluoromethyl)phenylboronic acid with 3-(trifluoromethyl)phenylboronic acid. ESI mass spectrum: [M+H]+=531; r.t. HPLC: 0.99 min (Z003_001).
- 100 mg of racemic example 2 are separated by chiral HPLC (Daicel OZ-H, 250 mm×20 mm, 40% MeOH+0.2% diethylamine in supercritical CO2, 40° C.).
- Early eluting enantiomer (Example 2A): r.t. chiral HPLC=3.62 min (Daicel Chiralcel®OZ-H 4.6 mm×250 mm, 5 μm, 4 ml/min, 10 min, 40% MeOH+0.2% diethylamine in supercritical CO2, 40° C., 100 bar back pressure); ESI mass spectrum: [M+H]+=531; Yield: 41 mg
- Late eluting enantiomer (Example 2B): r.t. chiral HPLC=5.23 min (Daicel Chiralcel®OZ-H 4.6 mm×250 mm, 5 μm, 4 ml/min, 10 min, 40% MeOH+0.2% diethylamine in supercritical CO2, 40° C., 100 bar back pressure); ESI mass spectrum: [M+H]+=531; Yield: 43 mg.
-
- Example 3 is prepared following the procedure described for example 1, substituting 3-(difluoromethyl)phenylboronic acid with 2-(trifluoromethyl)pyridine-4-boronic acid. ESI mass spectrum: [M+H]+=532; r.t. HPLC: 0.86 min (Z003_001).
- 50 mg of racemic example 3 are separated by chiral HPLC (Daicel IB, 250 mm×20 mm, 15% MeOH+0.2% diethylamine in supercritical CO2, 40° C.).
- Early eluting enantiomer (Example 3A): r.t. chiral HPLC=2.81 min (Daicel Chiralcel®OZ-H 4.6 mm×250 mm, 5 μm, 4 ml/min, 10 min, 40% MeOH+0.2% diethylamine in supercritical CO2, 40° C., 100 bar back pressure); ESI mass spectrum: [M+H]+=532; Yield: 23 mg.
- Late eluting enantiomer (Example 3B): r.t. chiral HPLC=4.25 min (Daicel Chiralcel®OZ-H 4.6 mm×250 mm, 5 μm, 4 ml/min, 10 min, 40% MeOH+0.2% diethylamine in supercritical CO2, 40° C., 100 bar back pressure); ESI mass spectrum: [M+H]+=532; Yield: 20 mg.
-
- Example 4 is prepared following the procedure described for example 1, substituting 3-(difluoromethyl)phenylboronic acid with 2-(trifluoromethyl)pyridine-4-boronic acid and substituting preparation 1 with preparation 2 as starting material. ESI mass spectrum: [M+H]+=517; r.t. HPLC: 0.85 min (Z011_S03).
- 30 mg of racemic example 4 are separated by chiral HPLC (Daicel OZH, 250 mm×20 mm, 40% MeOH+0.2% diethylamine in supercritical CO2, 40° C.).
- Early eluting enantiomer (Example 4A): r.t. chiral HPLC=5.08 min (Daicel Chiralpak®IB, 4.6 mm×250 mm, 5 μm, 4 ml/min, 10 min, 20% MeOH+0.2% diethylamine in supercritical CO2, 40° C., 150 bar back pressure); ESI mass spectrum: [M+H]+=517; Yield: 11 mg.
- Late eluting enantiomer (Example 4B): r.t. chiral HPLC=5.47 min (Daicel Chiralpak®IB, 4.6 mm×250 mm, 5 μm, 4 ml/min, 10 min, 20% MeOH+0.2% diethylamine in supercritical CO2, 40° C., 150 bar back pressure); ESI mass spectrum: [M+H]+=517; Yield: 9 mg.
-
- Example 5 is prepared following the procedure described for example 1, substituting preparation 1 with preparation 2 as starting material. ESI mass spectrum: [M+H]+=499; r.t. HPLC: 0.79 min (Z011_S03).
-
- Example 6 is prepared following the procedure described for example 1, substituting preparation 1 with preparation 3 as starting material. ESI mass spectrum: [M+H]+=525; r.t. HPLC: 0.84 min (Z011_S03).
-
- Example 7 is prepared following the procedure described for example 1, substituting preparation 1 with preparation 4 as starting material. ESI mass spectrum: [M+H]+=551; r.t. HPLC: 0.96 min (Z018_S04).
-
- Example 8 is prepared following the procedure described for example 1, substituting 3-(difluoromethyl)phenylboronic acid with 3-(trifluoromethyl)phenylboronic acid and substituting preparation 1 with preparation 4 as starting material. ESI mass spectrum: [M+H]+=569; r.t. HPLC: 1.00 min (Z018_S04).
-
- Example 9 is prepared following the procedure described for preparation 1d, substituting preparation 1c with preparation 5 as starting material. ESI mass spectrum: [M+H]+=604; r.t. HPLC: 0.63 min (X012_S01).
- 58 mg of racemic example 9 are separated by chiral HPLC (Daicel ASH, 250 mm×20 mm, 20% MeOH+0.2% diethylamine in supercritical CO2, 40° C.).
- Early eluting enantiomer (Example 9A): r.t. chiral HPLC=5.76 min (Daicel Chiralpak® ASH, 250 mm×4.6 mm, 5 μm, 4 ml/min, 10 min, 20% MeOH+0.2% diethylamine in supercritical CO2, 40° C., 150 bar back pressure); ESI mass spectrum: [M+H]+=604; Yield: 8 mg
- Late eluting enantiomer (Example 9B): r.t. chiral HPLC=6.86 min (Daicel Chiralpak® ASH, 250 mm×4.6 mm, 5 μm, 4 ml/min, 10 min, 20% MeOH+0.2% diethylamine in supercritical CO2, 40° C., 150 bar back pressure); ESI mass spectrum: [M+H]+=604; Yield: 7 mg
- The following intermediates are prepared as described for preparation 1b, substituting isopropylamine with the appropriate amine.
-
MS r.t. HPLC/ Preparation Structure [M + H]+ Method 7.1 194 0.52 min Z002_002 7.2 249 0.68 min Z018_S04 7.3 235 0.70 min Z018_S04 7.4 249 0.76 min Z018_S04 7.5 235 0.74 min Z018_S04 7.6 234 0.60 min Z018_S04 7.7 248 0.71 min Z018_S04 7.8 238 0.58 min Z018_S04 7.9 224 0.54 min Z018_S04 7.10 238 0.64 min Z018_S04 7.11 237 0.65 min Z018_S04 7.12 230 0.75 min Z018_S04 7.13 231 0.65 min Z018_S04 7.14 231 0.54 min Z018_S04 7.15 245 0.59 min Z018_S04 7.16 245 0.60 min Z018_S04 7.17 245 0.63 min Z018_S04 7.18 231 0.48 min Z018_S04 7.19 232 0.35 min Z018_S04 - The following bromo intermediates are prepared as described for preparation 1c, employing the appropriate des-bromo intermediates as starting material.
-
MS r.t. HPLC/ Preparation Starting material Structure [M + H]+ Method 8.1 Preparation 7.1 272 (Br pattern) 0.76 min Z018_S04 8.2 Preparation 7.2 327 (Br pattern) 0.84 min Z018_S04 8.3 Preparation 7.3 313 (Br pattern) 0.83 min Z018_S04 8.4 Preparation 7.4 327 (Br pattern) 0.87 min Z018_S04 8.5 Preparation 7.5 313 (Br pattern) 0.85 min Z018_S04 8.6 Preparation 7.6 312 (Br pattern) 0.81 min Z018_S04 8.7 Preparation 7.7 326 (Br pattern) 0.83 min Z018_S04 8.8 Preparation 7.8 316 (Br pattern) 0.72 min Z017_S04 8.9 Preparation 7.9 302 (Br pattern) 0.68 min Z017_S04 8.10 Preparation 7.10 316 (Br pattern) 0.78 min Z018_S04 8.11 Preparation 7.11 315 (Br pattern) 0.80 min Z018_S04 8.12 Preparation 7.12 308 (Br pattern) 0.87 min Z018_S04 8.13 Preparation 7.13 309 (Br pattern) 0.80 min Z018_S04 8.14 Preparation 7.14 309 (Br pattern) 0.71 min Z018_S04 8.15 Preparation 7.15 323 (Br pattern) 0.75 min Z018_S04 8.16 Preparation 7.16 323 (Br pattern) 0.74 min Z018_S04 8.17 Preparation 7.17 323 (Br pattern) 0.78 min Z018_S04 8.18 Preparation 7.18 309 (Br pattern) 0.68 min Z018_S04 8.19 Preparation 7.19 310 (Br pattern) 0.65 min Z018_S04 -
-
- To a solution of preparation 4a (1.8 g, 90% purity, 6.95 mmol) in methanol (5 mL) is added slowly thionyl chloride (1.64 g, 13.8 mmol) at 0° C. The reaction mixture is stirred at 70° C. for 1.5 h, concentrated under reduced pressure and purified by reversed-phase HPLC (Gilson: Sunfire, 30° C., gradient of acetonitrile in water+0.1% formic acid). Yield: 199 mg (12% of theory). ESI mass spectrum: [M+H]+=248; r.t. HPLC: 0.56 min (Z018_S04).
-
- The title compound is prepared as described for preparation 4c, substituting preparation 4b with preparation 8.20a as starting material. ESI mass spectrum: [M+H]+=326 (bromine pattern); r.t. HPLC: 0.69 min (Z012_S04).
- The following intermediates are prepared as described for Example 2, substituting preparation 1 with the appropriate bromo intermediate as starting material.
-
Starting MS r.t. Preparation Material Structure [M + H]+ HPLC Method 9.1 Prep. 2b 326 0.93 min Z017_S04 9.2 Prep. 1c 340 0.99 min Z017_S04 9.3 Prep. 8.20 378 0.98 min Z018_S04 9.4 Prep. 8.1 338 0.98 min Z018_S04 9.5 Prep. 8.2 393 1.05 min Z018_S04 9.6 Prep. 8.12 374 1.06 min Z018_S04 9.7 Prep. 8.13 375 1.00 min Z018_S04 9.8 Prep. 8.14 375 0.96 min Z018_S04 9.9 Prep. 8.18 375 0.93 min Z018_S04 9.10 Prep. 8.19 375 0.93 min Z018_S04 - The following intermediates are prepared as described for Example 1, substituting preparation 1 with the appropriate bromo intermediate as starting material.
- The following intermediates are prepared as described for Example 1, substituting preparation 1 with preparation 1c and employing the appropriate boronic acid or ester in the Suzuki reaction.
- The following intermediates are prepared as described for Example 3, substituting preparation 1 with the appropriate bromo intermediate as starting material.
- The following intermediates are prepared as described for preparation 1d, substituting preparation 1c with the appropriate starting material acid and substituting racemic preparation 6 with enantiomerically pure preparation 12B. The asterisk in the structures indicates that the compound is prepared from the enantiomer preparation 12B.
-
Starting r.t. Material MS HPLC Preparation Acid Structure [M + H]+ Method 10.1 Prep. 8.3 504 (Br pattern) 0.75 min Z011_S03 10.2 Prep. 8.4 518 (Br pattern) 0.77 min Z011_S03 10.3 Prep. 8.5 504 (Br pattern) 0.76 min Z011_S03 10.4 Prep. 8.6 503 (Br pattern) 0.75 min Z011_S03 10.5 Prep. 8.7 517 (Br pattern) 0.74 min Z011_S03 10.6 Prep. 8.8 507 (Br pattern) 0.68 min Z011_S03 10.7 Prep. 8.9 493 (Br pattern) 0.67 min Z011_S03 10.8 Prep. 8.10 507 (Br pattern) 0.70 min Z011_S03 10.9 Prep. 8.11 506 (Br pattern) 0.73 min Z011_S03 10.10 Prep. 8.15 514 (Br pattern) 0.70 min Z011_S03 10.11 Prep. 8.16 514 (Br pattern) 0.71 min Z011_S03 10.12 Prep. 8.17 514 (Br pattern) 0.72 min Z011_S03 - Racemic preparation 6c (2.0 g) is separated by chiral HPLC (Daicel Chiralcel OZ-H, 250 mm×30 mm, 32% MeOH in supercritical CO2).
- Early eluting enantiomer (preparation 11A): r.t. chiral HPLC=10.19 min (Daicel Chiralpak® IA 4.6 mm×250 mm×5 μm, 1 mL/min, 20 min, 70% hexane+15% isopropanol+15% dichloromethane+0.1% TFA, 20° C.); ESI mass spectrum: [M+H]+=334; Yield: 600 mg.
- Late eluting enantiomer (preparation 11B): r.t. chiral HPLC=10.70 min (Daicel Chiralpak® IA 4.6 mm×250 mm×5 μm, 1 mL/min, 20 min, 70% hexane+15% isopropanol+15% dichloromethane+0.1% TFA, 20° C.); ESI mass spectrum: [M+H]+=334; Yield: 700 mg.
- The early eluting enantiomer of racemic preparation 6d is prepared following the procedure described for preparation 6d, substituting racemic 2-(4-(N-cyano-S-methyl-sulfonimidoyl)benzyl)isoindoline-1,3-dione with preparation 11A. r.t. chiral HPLC=2.92 min (Daicel Chiralpak® IC 4.6 mm×250 mm 5 μm, 4 ml/min, 10 min, 30% MeOH+0.2% diethylamine in supercritical CO2, 40° C., 100 bar back pressure); ESI mass spectrum: [M+H]+=210.
- The late eluting enantiomer of racemic preparation 6d is prepared following the procedure described for preparation 6d, substituting racemic 2-(4-(N-cyano-S-methylsulfonimidoyl)-benzyl)isoindoline-1,3-dione with preparation 11B.
- r.t. chiral HPLC=3.59 min (Daicel Chiralpak® IC 4.6 mm×250 mm 5 μm, 4 ml/min, 10 min, 30% MeOH+0.2% diethylamine in supercritical CO2, 40° C., 100 bar back pressure); ESI mass spectrum: [M+H]+=210.
-
-
- Phthalic anhydride (4.42 g, 30 mmol) is added to a solution of 4-(ethylthio)benzylamine (5.00 g, 30 mmol) in acetic acid. The mixture is heated at reflux for 5 h and cooled at room temperature. Water ist added, and the precipitate is filtered and dried.
- The residue is dissolved in methanol (50 mL), and the mixture is treated with potassium tert-butoxide (2.26 g, 20 mmol) and cyanamide (920 mg, 22 mmol). N-Bromosuccinimide (4.49 g, 25 mmol) is added, and the mixture is stirred at room temperature for 2 h. The mixture is concentrated under reduced pressure and treated with saturated aqueous Na2S2O3 solution. The mixture is extracted four times with dichloromethane, and the combined organic layers are dried over Na2SO4 and concentrated under reduced pressure. The residue is purified by flash chromatography on silica (dichloromethane/methanol 95:5). Yield: 3.0 g (30% of theory); ESI mass spectrum: [M+H]+=338; r.t. HPLC: 3.14 min (LCMS-FA-8).
-
- The title compound is prepared in analogy to preparation 6c, substituting 2-(4-(N-cyano-S-methylsulfinimidoyl)benzyl)isoindoline-1,3-dione with 2-(4-(N-cyano-S-ethylsulfinimidoyl)benzyl)isoindoline-1,3-dione (preparation 13a). ESI mass spectrum: [M+H]+=354; r.t. HPLC: 3.33 min (LCMS-FA-8).
-
- The title compound is prepared in analogy to preparation 6d, substituting 2-(4-(N-cyano-S-methylsulfonimidoyl)benzyl)isoindoline-1,3-dione with 2-(4-(N-cyano-S-ethylsulfonimidoyl)benzyl)isoindoline-1,3-dione (preparation 13b). ESI mass spectrum: [M+H]+=224; r.t. HPLC: 0.52 min (Z011_S03).
-
-
- The title compound is prepared in analogy to preparation 13a, substituting 4-(ethylthio)-benzylamine with 4-(isopropylthio)benzylamine ESI mass spectrum: [M+H]+=352; r.t. HPLC: 0.50 min (X012_S01).
-
- The title compound is prepared in analogy to preparation 6c, substituting 2-(4-(N-cyano-S-methylsulfinimidoyl)benzyl)isoindoline-1,3-dione with 2-(4-(N-cyano-S-isopropylsulfinimidoyl)benzyl)isoindoline-1,3-dione (preparation 14a). ESI mass spectrum: [M+H]+=368; r.t. HPLC: 3.42 min (LCMS-FA-8).
-
- The title compound is prepared in analogy to preparation 6d, substituting 2-(4-(N-cyano-S-methylsulfonimidoyl)benzyl)isoindoline-1,3-dione with 2-(4-(N-cyano-S-isopropylsulfonimidoyl)benzyl)isoindoline-1,3-dione (preparation 14b). ESI mass spectrum: [M+H]+=238; r.t. HPLC: 0.59 min (Z011_S03).
-
-
- A mixture of 3-fluoro-4-methylsulfanyl-benzonitrile (6.00 g, 34.1 mmol), Raney-Nickel (100 mg) and concentrated aqueous ammonia (30 mL) in methanol (300 mL) is treated with hydrogen (3.4 bar) at room temperature for 3 h. The mixture is filtered through a pad of silica gel, and the filtrate is concentrated under reduced pressure.
- The residue is dissolved in toluene (250 mL), treated with phthalic anhydride (4.0 g, 26.3 mmol) and triethylamine (0.98 g, 9.50 mmol), and the mixture is heated at reflux over night. All volatiles are removed, and the residue is recrystallized from ethanol. Yield: 4.8 g (46% of theory). ESI mass spectrum: [M+H]+=302; r.t. HPLC: 0.67 min (X012_S01).
-
- Cyanamide (350 mg, 8.20 mmol) and potassium tert-butoxide (860 mg, 7.60 mmol) are added to a solution of 2-(3-fluoro-4-methylsulfanyl-benzyl)-isoindole-1,3-dione (preparation 15a, 2.00 g, 6.31 mmol) in methanol (50 mL). N-Bromosuccinimide (1.70 g, 9.50 mmol) is added and the mixture is stirred at room temperature over night. All volatiles are removed under reduced pressure, and the residue is treated with dichloromethane (20 mL). The mixture is washed with saturated aqueous sodium chloride solution, dried over Na2SO4 and concentrated under reduced pressure. The residue is directly used in the next step without further purification. Yield: 1.61 g (60% of theory); ESI mass spectrum: [M+H]+=342; r.t. HPLC: 0.76 min (5-95AB).
-
- 2-(3-Fluoro-4-(N-cyano-S-methylsulfinimidoyl)-benzyl)-isoindole-1,3-dione (preparation 15b, 1.60 g, 4.22 mmol) and acetic acid (0.25 g, 4.22 mmol) are added to a solution of potassium permanganate (670 mg, 4.22 mmol) in a mixture of water (8 mL) and acetonitrile (9.6 ml). The mixture is stirred over night, and saturated aqueous Na2S2O3 solution is added. The mixture is extracted with ethyl acetate and the organic layer is dried over Na2SO4. The residue is directly used in the next step without further purification. Yield: 1.34 g (80% of theory); ESI mass spectrum: [M+H]+=358; r.t. HPLC: 0.73 min (5-95AB).
-
- Hydrazine (85% in water, 2.0 g, 53 mmol) is added to a solution of 2-(3-fluoro-4-(N-cyano-S-methylsulfonimidoyl)-benzyl)-isoindole-1,3-dione (preparation 15c, 3.5 g, 8.8 mmol) in a 1:1 mixture of dichloromethane and methanol (140 mL). The mixture is stirred over night and concentrated under reduced pressure. The residue is purified by preparative reversed phase HPLC (Luna C18(2), gradient of acetonitrile in water, 0.01 M NH3). Yield: 1.2 g (58% of theory); ESI mass spectrum: [M+H]+=228; r.t. HPLC: 0.26 min (X011_S03).
-
-
- A solution of 5-methylsulfanyl-pyridine-2-carbonitrile (preparation described in WO05026124, 4.28 g, 28.5 mmol) in THF is cooled at −78° C. in a dry ice/ethanol bath. Lithium aluminium hydride (2.4 M in THF, 12 mL, 28.8 mmol) is added dropwise. After 10 min water (1 mL) and THF (3 mL) are added. After 5 min, aqueous sodium hydroxide solution (4 M, 1 mL) and water (3 mL) is added. After 10 min the mixture is concentrated under reduced pressure, and the residue is dissolved in a mixture of water, methanol and acetic acid and purified by preparative reversed phase HPLC (Sunfire, gradient of acetonitrile in water, 0.1% formic acid). Yield: 1.36 g (31% of theory); ESI mass spectrum: [M+H]+=155; r.t. HPLC: 0.44 min (Z018_S04).
-
- The title compound is prepared in analogy to preparation 6a, substituting 4-(methylthio)-benzylamine with (5-methylsulfanyl-pyridin-2-yl)-methylamine (preparation 16a). ESI mass spectrum: [M+H]+=285; r.t. HPLC: 0.51 min (X012_S01).
-
- The title compound is prepared in analogy to preparation 6b, substituting 2-(4-(methylthio)benzyl)isoindoline-1,3-dione with 2-(5-methylsulfanyl-pyridin-2-ylmethyl)-isoindole-1,3-dione (preparation 16b). ESI mass spectrum: [M+H]+=325; r.t. HPLC: 0.63 min (Z018_S04).
-
- The title compound is prepared in analogy to preparation 6c, substituting 2-(4-(N-cyano-S-methylsulfinimidoyl)benzyl)isoindoline-1,3-dione with 2-(5-(N-cyano-S-methylsulfinimidoyl)pyridin-2-yl)-isoindole-1,3-dione (preparation 16c). ESI mass spectrum: [M+H]+=341; r.t. HPLC: 0.88 min (Z018_S04).
-
- The title compound is prepared in analogy to preparation 6d, substituting 2-(4-(N-cyano-S-methylsulfonimidoyl)benzyl)isoindoline-1,3-dione with 2-(5-(N-cyano-S-methylsulfonimidoyl)pyridin-2-yl)-isoindole-1,3-dione (preparation 16d). ESI mass spectrum: [M+H]+=211; r.t. HPLC: 0.23 min (Z011_S03).
-
-
- A solution of 2-(4-(N-cyano-S-methylsulfonimidoyl)benzyl)isoindoline-1,3-dione (preparation 6c, 2.00 g, 6.00 mmol) in dichloromethane (20 mL) is cooled at 0° C., and trifluoroacetic anhydride (2.48 mL, 3.72 g, 17.7 mmol) is added. The mixture is allowed to warm to room temperature, stirred for 2 h and poured into water. The aqueous layer is extracted three times with dichloromethane, and the combined organic layers are dried over Na2SO4 and concentrated under reduced pressure. The residue is purified by flash chromatography on silica (ethyl acetate/dichloromethane 9:1). Yield: 2.10 g (86% of theory); ESI mass spectrum: [M+H]+=411, r.t. HPLC: 4.50 min (LCMS-FA-2).
-
- Potassium carbonate (3.37 g, 24.4 mmol) is added to a solution of 2-(4-(N-trifluoracetyl-S-methylsulfonimidoyl)benzyl)isoindoline-1,3-dione (preparation 17a, 2.00 g, 4.88 mmol) in methanol (20 mL). The mixture is stirred at room temperature for 16 h and filtered. The filtrate is concentrated under reduced pressure, and the residue is purified by flash chromatography on silica (methanol/dichloromethane 7:3). Yield: 0.90 g (58% of theory); ESI mass spectrum: [M+H]+=315, r.t. HPLC: 1.08 min (V003_003).
-
- A solution of 2-(4-(S-methylsulfonimidoyl)benzyl)isoindoline-1,3-dione (preparation 17b, 2.50 g, 7.95 mmol) and triethylamine (2.2 mL, 16 mmol) in dichloromethane (20 mL) is cooled at 0° C. and treated with methanesulfonyl chloride (620 μL, 8.0 mmol). The mixture is stirred at this temperature for 1.5 h and then washed with water. The organic layer is concentrated under reduced pressure, and the residue is suspended in a mixture of methanol and water. The precipitate is filtered, washed with water, and dried. Yield: 273 mg (8% of theory); ESI mass spectrum: [M+H]+=393, r.t. HPLC: 0.44 min (X012_S01).
-
- A solution of 2-(4-(S-methyl-N-(methylsulfonyl)sulfonimidoyl)benzyl)isoindoline-1,3-dione (preparation 17c, 270 mg, 0.69 mmol) and 1,2-diaminoethane (83 μL, 74 mg, 1.24 mmol) in a 2:1:1 mixture of acetonitrile, tetrahydrofuran and ethanol (3 mL) is heated at 60° C. for 4 h. The mixture is concentrated under reduced pressure, and the residue is suspended in dichloromethane. The mixture is filtered and the filtrate is concentrated under reduced pressure. Yield: 178 mg (99% of theory); ESI mass spectrum: [M+H]+=263, r.t. HPLC: 0.17 min (X012_S01).
-
-
- A mixture of 2-fluoro-4-methylsulfanyl-benzonitrile (8.0 g, 45.5 mmol), Raney-Nickel (20.0 g) and concentrated aqueous ammonia (300 mL) in methanol (3.0 L) is treated with hydrogen (3.4 bar) at room temperature and stirred over night. The mixture is filtered through a pad of silica gel, and the filtrate is concentrated under reduced pressure. Yield: 6.3 g (81% of theory); ESI mass spectrum: [M+H]+=155; r.t. HPLC: 1.38 min (0-30AB).
-
- Triethylamine (3.40 g, 33.3 mmol) and di-tert-butyl dicarbonate (7.4 g, 33.3 mmol) are added to a solution of 2-fluoro-4-methylsulfanyl-benzylamine (preparation 18a, 4.0 g, 22.2 mmol) in dichloromethane (100 mL). After 30 min water is added and the mixture is extracted with dichloromethane. The organic layer is washed with brine, dried over Na2SO4 and concentrated under reduced pressure. Yield: 5.0 g (79% of theory); ESI mass spectrum: [M+H]+=294; r.t. HPLC: 0.86 min (5-95AB).
-
- The title compound is prepared following the procedure described for preparation 15b, using (2-fluoro-4-methylsulfanyl-benzyl)-carbamic acid tert-butyl ester (preparation 18b) as starting material. ESI mass spectrum: [M+H]+=312; r.t. HPLC: 0.68 min (5-95AB).
-
- The title compound is prepared following the procedure described for preparation 15c, using (2-fluoro-4-(N-cyano-S-methylsulfinimidoyl)-benzyl)-carbamic acid tert-butyl ester (preparation 18c) as starting material. ESI mass spectrum: [M+H]+=312; r.t. HPLC: 0.68 min (5-95AB).
-
- A solution of (2-fluoro-4-(N-cyano-S-methylsulfonimidoyl)-benzyl)-carbamic acid tert-butyl ester (preparation 18c, 2.20 g, 6.38 mmol) in dichloromethane (20 mL) is cooled at 0° C. and treated with a solution of hydrogen chloride in ethyl acetate (4 M, 16 mL, 64 mmol). After 2 h all volatiles are removed under reduced pressure and the residue is purified by preparative reversed phase HPLC (Gemini, gradient of acetonitrile in water, 0.04% NH3). ESI mass spectrum: [M+H]+=228; r.t. HPLC: 2.16 min (0-30AB).
-
- The title compound is prepared following the procedure described for preparation 15, substituting 3-fluoro-4-methylsulfanyl-benzonitrile with 2-methyl-4-methylsulfanyl-benzonitrile as starting material. ESI mass spectrum: [M+H]+=224; r.t. HPLC: 2.18 min (0-30AB).
- The following examples are prepared as described for preparation 1d, substituting preparation 1c with the appropriate starting material acid and substituting preparation 6 with the appropriate starting material amine. The asterisk in the structures indicates that the compound is prepared from the enantiomer preparation 12B (prep.=preparation).
-
Starting Starting r.t. Material Material MS HPLC Example Acid Amine Structure [M + H]+ Method 10 Prep. 9.1 Prep.13 531 1.11 min 044_CC_C A01 11 Prep. 9.1 Prep.14 545 1.14 min 044_CC_C A01 12 Prep. 9.2 Prep.13 545 1.04 min Z018_S04 13 Prep. 9.2 Prep. 15 549 0.63 min X011_S03 14 Prep. 9.2 Prep. 18 549 0.62 min X011_S03 15 Prep. 9.2 Prep. 19 545 0.62 min X011_S03 16 Prep. 9.2 Prep. 16 532 0.77 min 003_CA04 17 Prep. 9.2 Prep. 17 584 1.06 min V011_S01 18 Prep. 9.3 Prep.13 583 1.01 min Z017_S04 19 Prep. 9.3 Prep.14 597 1.93 min 001_CA03 20 Prep. 9.4 Prep. 12B 529 0.61 min X011_S03 21 Prep. 9.4 Prep.13 543 0.63 min X011_S03 22 Prep. 9.4 Prep.14 557 0.65 min X011_S03 23 Prep. 9.5 Prep. 12B 584 0.91 min Z018_S04 24 Prep. 9.6 Prep. 12B 565 0.94 min Z011_S03 25 Prep. 9.7 Prep. 12B 566 0.94 min Z011_S03 26 Prep. 9.8 Prep. 12B 566 0.84 min Z011_S03 27 Prep. 9.9 Prep. 12B 566 0.83 min Z011_S03 28 Prep. 9.10 Prep. 12B 567 0.81 min Z011_S03 29 Prep. 9.11 Prep.13 513 1.03 min 004_CC_C A01 30 Prep. 9.11 Prep.14 527 1.07 min 004_CC_C A01 31 Prep. 9.12 Prep.13 527 1.00 min Z018_S04 32 Prep. 9.12 Prep. 15 531 0.57 min X011_S03 33 Prep. 9.12 Prep. 18 531 0.56 min X011_S03 34 Prep. 9.12 Prep. 19 527 0.57 min X011_S03 35 Prep. 9.12 Prep. 17 566 0.99 min V011_S01 36 Prep. 9.13 Prep.13 565 1.28 min 001_CA03 37 Prep. 9.13 Prep.14 579 1.31 min 0010_CA03 38 Prep. 9.14 Prep. 12B 547 0.88 min Z011_S03 39 Prep. 9.15 Prep. 12B 548 0.78 min Z011_S03 40 Prep. 9.16 Prep. 12B 548 0.75 min Z011_S03 41 Prep. 9.17 Prep. 12B 549 0.88 min Z011_S03 42 Prep. 9.18 Prep. 12B 531 0.83 min Z011_S03 43 Prep. 9.19 Prep. 12B 566 0.85 min Z011_S03 44 Prep. 9.20 Prep. 12B 567 0.79 min Z011_S03 45 Prep. 9.21 Prep. 12B 567 0.75 min Z011_S03 46 Prep. 9.22 Prep. 12B 567 0.75 min Z011_S03 47 Prep. 9.2 Prep. 12B 569 0.86 min Z011_S03 - The following examples are prepared as described for Example 2, substituting preparation 1 with the appropriate bromo starting material (prep.=preparation).
-
Bromo r.t. Starting MS HPLC Example Material Structure [M + H]+ Method 48 Prep. 10.1 570 1.03 min Z017_S04 49 Prep. 10.2 584 1.07 min Z017_S03 50 Prep. 10.3 570 1.06 min Z018_S04 51 Prep. 10.4 569 0.90 min Z011_S03 52 Prep. 10.5 583 1.00 min Z018_S04 53 Prep. 10.6 573 0.99 min Z018_S04 54 Prep. 10.7 559 0.98 min Z018_S04 55 Prep. 10.8 573 0.99 min Z018_S04 56 Prep. 10.9 572 1.10 min Z018_S04 57 Prep. 10.10 580 0.97 min Z018_S04 58 Prep. 10.11 580 0.98 min Z018_S04 59 Prep. 10.12 580 1.00 min Z018_S04 - Several racemic examples are separated into the respective enantiomers by preparative chiral HPLC as described for the separation of racemic Example 1 into the enantiomers Example 1A and Example 1B, employing HPLC conditions as indicated in the following table.
-
Preparative Racemic Chiral HPLC Enantiomeric Analytical Chiral HPLC MS Example Conditions Example Method r.t. [M + H]+ 10 Daicel OJ-H 10A Daicel Chiralpak ®OJ-H, 2.33 min 531 10% MeOH + 10B 250 mm × 4.6 mm, 4 ml/min, 2.53 min 531 0.2% DEA 10 min, 15% MeOH + 0.2% diethylamine in supercritical CO2, 40° C. 21 Daicel OJ-H 21A Daicel Chiralpak ®OJ-H, 2.24 min 543 10% MeOH + 21B 250 mm × 4.6 mm, 4 ml/min, 2.41 min 543 0.2% DEA 10 min, 15% MeOH + 0.2% diethylamine in supercritical CO2, 40° C. 22 Daicel AS-H 22A Daicel Chiralpak ®AS-H, 2.05 min 557 20% MeOH + 22B 250 mm × 4.6 mm, 4 ml/min, 2.35 min 557 0.2% DEA 10 min, 15% MeOH + 0.2% diethylamine in supercritical CO2, 40° C. 29 Daicel OJ-H 29A Daicel Chiralpak ®OJ-H, 3.48 min 513 10% MeOH + 29B 250 mm × 4.6 mm, 4 ml/min, 3.91 min 513 0.2% DEA 10 min, 15% MeOH + 0.2% diethylamine in supercritical CO2, 40° C. 30 Daicel OZ-H 30A Daicel Chiralpak ®OZ-H, 6.50 min 527 35% MeOH + 30B 250 mm × 4.6 mm, 4 ml/min, 7.55 min 527 0.2% DEA 10 min, 40% MeOH + 0.2% diethylamine in supercritical CO2, 40° C. 31 Daicel OJ-H 31A Daicel Chiralpak ®OJ-H, 2.44 min 527 10% MeOH + 31B 250 mm × 4.6 mm, 4 ml/min, 2.71 min 527 0.2% DEA 10 min, 15% MeOH + 0.2% diethylamine in supercritical CO2, 40° C. 5.5 Daicel OJ-H 5.5A Daicel Chiralpak ®OJ-H, 2.36 min 499 10% MeOH + 5.5B 250 mm × 4.6 mm, 4 ml/min, 2.65 min 499 0.2% DEA 10 min, 20% MeOH + 0.2% diethylamine in supercritical CO2, 40° C. -
-
- A solution of 2-benzyl-isoindole-1,3-dione (prepared as described in WO07093452, 22.0 g, 92.7 mmol) in dichloromethane (150 mL) is cooled in an ice bath at 0° C. Chlorosulfonic acid (12.3 mL, 185 mmol) is added dropwise and the mixture is allowed to warm to room temperature. After 1.5 h the mixture is cooled at 0° C., and thionyl chloride (10.1 mL, 139 mmol) is added. The mixture is heated at reflux for 3.5 h, and chlorosulfonic acid (3.1 mL, 46 mmol) and thionyl chloride (2.0 mL, 28 mmol) is added. The mixture is stirred at room temperature over night and poured into ice water. The aqueous phase is extracted twice with dichloromethane, and the combined organic phases are concentrated under reduced pressure.
- The residue is dissolved in toluene (250 mL), and the mixture is cooled at 0° C. A solution of triphenylphosphine (70.9 g, 270 mmol) in toluene (250 mL) is added dropwise, and the mixture is warmed at room temperature. After 2.5 h water is added and the phases are separated.
- The organic layer is concentrated under reduced pressure and the residue is dissolved in DMF (200 mL). Acetic anhydride (29 mL) is added and the mixture is stirred at room temperature for 2 h. The mixture is concentrated under reduced pressure and purified by flash chromatography on silica (gradient cyclohexane to cyclohexane/ethyl acetate 8:2). Yield: 14 g (15% of theory). ESI mass spectrum: [M+H]+=312; r.t. HPLC: 1.36 min (V001_007).
-
- A solution of acetic anhydride (4.34 mL, 45.9 mmol) in dichloromethane (50 mL) is added dropwise to a precooled solution of thioacetic acid 4-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-phenyl ester (preparation 60a, 13.0 g, 41.8 mmol) in dichloromethane (500 mL) at −20° C. A solution of sulfuryl chloride (7.4 mL, 91.9 mmol) in dichloromethane (50 mL) is added at this temperature, and the mixture is stirred for 1 h. The mixture is warmed to room temperature, and all volatiles are removed under reduced pressure.
- The residue is dissolved in dichloromethane (400 mL), and the solution is cooled in an ice bath at 0° C. Methylamine (2 M in tetrahydrofuran, 84 mL, 168 mmol) is added dropwise at 0° C., and the mixture is stirred for 2 and then warmed to room temperature. Saturated sodium chloride solution is added, and the mixture is extracted with dichloromethane. The combined organic layers are dried over Na2SO4 and concentrated under reduced pressure. Yield: 3.44 g (23% of theory). ESI mass spectrum: [M+H]+=315; r.t. HPLC: 0.89 min (X012_S01).
-
- A mixture of 4-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-benzenesulfinic acid methylamide (preparation 60b, 250 mg, 0.795 mmol) in acetonitrile is cooled at 0° C. in an ice bath and treated with tert-butyl hypochlorite (100 μL, 0.88 mmol). After 15 min dimethylamine (2 M in tetrahydrofuran, 600 μL, 1.2 mmol) is added and the mixture is warmed to room temperature. Water is added, and the mixture is extracted twice with dichloromethane. The combined organic layers are dried over Na2SO4 and concentrated under reduced pressure. The residue is purified by flash chromatography on silica (gradient cyclohexane/ethyl acetate 7:3 to ethyl acetate). Yield: 284 mg (99% of theory). ESI mass spectrum: [M+H]+=358; r.t. HPLC: 0.43 min (X012_S01).
-
- A solution of 4-((1,3-dioxoisoindolin-2-yl)methyl)-N,N,N-trimethyl-benzene-sulfonimidamide (preparation 60c, 280 mg, 0.78 mmol) in a 2:1:1 mixture of acetonitrile, tetrahydrofuran and ethanol (8 mL) is treated with 1,2-diaminoethane (116 μL, 1.74 mmol). The mixture is heated at 60° C. for 5 h, and another portion of 1,2-diaminoethane (26 μL, 0.39 mmol) is added. After 1.5 h all volatiles are removed under reduced pressure. The residue is treated with dichloromethane, and the mixture is filtered. The filtrate is concentrated under reduced pressure. Yield: 172 mg (97% of theory). ESI mass spectrum: [M+H]+=228; r.t. HPLC: 0.66 min (V011_S01).
-
- A solution of 1-isopropyl-6-methyl-4-oxo-5-(3-trifluoromethyl-phenyl)-1,4-dihydro-pyridine-3-carboxylic acid (preparation 9.2, 186 mg, 0.55 mmol) in DMF (5 mL) is treated with DIPEA (300 μL, 1.72 mmol) and stirred at room temperature for 10 min HBTU at (312 mg, 0.82 mmol) is added, and the mixture is stirred for 20 min. A solution of 4-(aminomethyl)-N,N,N-trimethylbenzenesulfonimidamide (preparation 60d, 156 mg, 0.69 mmol) in DMF (0.5 mL) is added and the mixture is stirred for 2 h. Water is added and the mixture is extracted with dichloromethane. The organic layer is dried over Na2SO4 and concentrated under reduced pressure. The residue is purified by preparative reversed phase HPLC (Xbridge, gradient of acetonitrile in water, 0.1% TFA). Yield: 41 mg (11% of theory); ESI mass spectrum: [M+H]+=549; r.t. HPLC: 1.17 min (Z001_005).
-
- Example 61 is prepared as described for Example 60, substituting preparation 9.2 with preparation 9.12. ESI mass spectrum: [M+H]+=531; r.t. HPLC: 0.86 min (Z011_503).
-
- Meta-chloroperoxybenzoic acid (77%, 8.0 mg, 36 μmol) is added to a solution of 5-(3-trifluoromethyl-phenyl)-1-isopropyl-6-methyl-4-oxo-1,4-dihydro-pyridine-3-carboxylic acid (5-(N-cyano-S-methylsulfonimidoyl)pyridin-2-yl)methylamide (example 16, 17.0 mg, 32 μmol) in dichloromethane (0.5 mL), and the mixture is stirred at room temperature for 2 h. The mixture is heated at reflux and stirred for 2 h. The mixture is cooled at room temperature and stirred over night. A second portion of m-CPBA (77%, 4.3 mg, 19 μmol) is added and the mixture is heated at reflux for 2.5 h. A third portion of m-CPBA (77%, 4.3 mg, 19 μmol) is added and the mixture is stirred at room temperature over night. Saturated aqueous sodium thiosulfate solution is added and the mixture is extracted twice with dichloromethane. The organic layer is dried and concentrated under reduced pressure. The residue is purified by preparative reversed phase HPLC (Xbridge, gradient of acetonitrile in water, 0.1% NH3). Yield: 3.3 mg (19% of theory); ESI mass spectrum: [M+H]+=548; r.t. HPLC: 0.54 min (X011_503).
-
-
- Thionyl chloride (340 μL, 4.7 mmol) is added to a solution of 4-cyclopropylsulfanylbenzoic acid (prepared as described in WO07003960, 190 mg, 0.98 mmol) in dichloromethane (1.9 mL), and the mixture is heated at reflux for 30 min. All volatiles are removed under reduced pressure, and the residue is dissolved in chloroform (1.9 mL). Concentrated aqueous ammonia (28%, 770 μL, 9.8 mmol) is added and the mixture is stirred at room temperature for 1 h. Water is added and the phases are separated. The organic layer is concentrated under reduced pressure. Yield: 137 mg (72% of theory); ESI mass spectrum: [M+H]+=194; r.t. HPLC: 0.45 min (X011_S03).
-
- A solution of 4-cyclopropylsulfanyl-benzamide (preparation 63a, 137 mg, 0.71 mmol) in THF is added to lithium aluminium hydride (1 M in THF, 2.1 mL, 2.1 mmol) precooled at 0° C. The mixture is stirred at 0° C. for 1 h and then heated at reflux for 1 h. The mixture is cooled to room temperature and stirred for 1.5 h. Water is added, and the mixture is extracted twice with dichloromethane. The combined organic layers are dried over Na2SO4 and concentrated under reduced pressure. Yield: 75 mg (60% of theory); ESI mass spectrum: [M+H]+=180; r.t. HPLC: 0.51 min (X011_S03).
-
- The title compound is prepared following the procedure described for example 60, substituting 4-(aminomethyl)-N,N,N-trimethylbenzenesulfonimidamide with 4-cyclopropylsulfanyl-benzylamine (preparation 63b), and replacing HBTU with TBTU. ESI mass spectrum: [M+H]+=501; r.t. HPLC: 0.77 min (X012_501).
-
- A mixture of 1-isopropyl-6-methyl-4-oxo-5-(3-trifluoromethyl-phenyl)-1,4-dihydro-pyridine-3-carboxylic acid 4-cyclopropylsulfanyl-benzylamide (preparation 63c, 75 mg, 0.15 mmol), cyanamide (8 mg, 0.19 mmol), N-bromosuccinimide (40 mg, 0.22 mmol) and potassium tert-butoxide (20 mg, 0.18 mmol) in methanol (1 mL) is stirred at room temperature for 1 h. Saturated aqueous sodium thiosulfate solution is added, and the mixture is extracted twice with dichloromethane. The organic layer is dried over Na2SO4 and concentrated under reduced pressure. The residue is purified by preparative reversed phase HPLC (Xbridge, gradient of acetonitrile in water, 0.1% NH3). Yield: 7 mg (8% of theory); ESI mass spectrum: [M+H]+=541; r.t. HPLC: 0.64 min (X012_502).
-
- A mixture of 1-isopropyl-6-methyl-4-oxo-5-(3-trifluoromethyl-phenyl)-1,4-dihydro-pyridine-3-carboxylic acid 4-(S-cyclopropyl-N-cyanosulfinimidoyl)-benzylamide (preparation 63d, 40 mg, 74 μmol), meta-chloroperoxybenzoic acid (77%, 25 mg, 0.11 mmol) and potassium carbonate (31 mg, 0.22 mmol) in ethanol is stirred at room temperature for 1 h. Another portion of meta-chloroperoxybenzoic acid (77%, 5 mg, 0.02 mmol) is added and stirring is continued for 1.5 h. Saturated aqueous sodium thiosulfate solution is added, and the mixture is extracted with dichloromethane. The organic layer is dried over Na2SO4 and concentrated under reduced pressure. The residue is purified by preparative reversed phase HPLC (Xbridge, gradient of acetonitrile in water, 0.1% TFA). Yield: 13 mg (31% of theory); ESI mass spectrum: [M+H]E=557; r.t. HPLC: 0.65 min (X011_503).
-
-
- A mixture of 2-(4-(S-methylsulfonimidoyl)benzyl)isoindoline-1,3-dione (preparation 17b, 500 mg, 1.59 mmol) and 1,2-dimethoxyethane (2 mL) is added to a mixture of potassium hydride (30%, 260 mg, 1.95 mmol) in 1,2-dimethoxyethane (3 mL). The mixture is stirred for 15 min at room temperature and treated with tetraethylammonium bromide (10 mg, 0.05 mmol) and bromoacetonitrile (220 μL, 3.16 mmol). The mixture is heated at 110° C. over night and cooled to room temperature. Water is added, and the mixture is extracted twice with dichloromethane. The organic layer is concentrated under reduced pressure, and the residue is purified by flash chromatography on silica (gradient cyclohexane/ethyl acetate 1:0 to 0:1). Yield: 155 mg (27% of theory). ESI mass spectrum: [M+H]+=354; r.t. HPLC: 0.47 min (X011_S03).
-
- The title compounds is prepared in analogy to preparation 60d, using 2-(4-(N-cyano-methyl-S-methylsulfonimidoyl)benzyl)isoindoline-1,3-dione (preparation 64a) as starting material. ESI mass spectrum: [M+H]+=224; r.t. HPLC: 0.22 min (X011_S03).
-
- The title compound is prepared following the procedure described for example 60, substituting 4-(aminomethyl)-N,N,N′-trimethylbenzenesulfonimidamide with 4-(N-cyano-methyl-S-methylsulfonimidoyl)benzylamine (preparation 64b), and replacing HBTU with TBTU. ESI mass spectrum: [M+H]+=545; r.t. HPLC: 0.59 min (X012_S01).
-
-
- The title compound is prepared following the procedure described for example 60, substituting 4-(aminomethyl)-N,N,N-trimethylbenzenesulfonimidamide with 1-(4-methylsulfanyl-phenyl)-ethylamine, and replacing HBTU with TBTU. ESI mass spectrum: [M+H]+=489; r.t. HPLC: 0.76 min (X011_S03).
-
- A mixture of 1-isopropyl-6-methyl-4-oxo-5-(3-trifluoromethyl-phenyl)-1,4-dihydro-pyridine-3-carboxylic acid [1-(4-methylsulfanyl-phenyl)-ethyl]-amide (preparation 65a, 50 mg, 0.10 mmol), cyanamide (6 mg, 0.14 mmol) and potassium tert-butoxide (14 mg, 0.13 mmol) in methanol (0.5 mL) is treated with N-bromosuccinimide (27 mg, 0.15 mmol) and stirred at room temperature for 15 min Saturated aqueous Na2S2O3 solution is added, and the mixture is extracted with dichloromethane. The organic layer is concentrated under reduced pressure, and the residue is dissolved in ethanol (0.5 mL).
- Potassium carbonate (16 mg, 120 μmol) and meta-chloroperoxybenzoic acid (77%, 13 mg, 60 μmol) is added, and the mixture is stirred at room temperature for 1.5 h. Another portion of potassium carbonate (10 mg, 70 μmol) and meta-chloroperoxybenzoic acid (77%, 13 mg, 60 μmol) is added and stirring is continued for 1 h. Saturated aqueous Na2S2O3 solution is added, and the mixture is extracted twice with dichloromethane. The residue is purified by flash chromatography on silica (gradient cyclohexane/ethyl acetate 8:2 to ethyl acetate). Yield: 5 mg (25% of theory); ESI mass spectrum: [M+H]+=545; r.t. HPLC: 0.72 min (Y001_U01).
-
-
- Sodium methanethiolate (1.60 g, 22.8 mmol) is added to a solution of 4-fluoro-3-methyl-benzonitrile (2.50 g, 18.5 mmol) in DMF, and the mixture is heated at 80° C. for 15 min. All volatiles are evaporated, and the residue is treated with water. The mixture is extracted with ethyl acetate twice, and the organic layer is dried over Na2SO4 and concentrated. Yield: 3.0 g (99% of theory); ESI mass spectrum: [M+H]+=164; r.t. HPLC: 0.61 min (X011_503).
-
- A solution of lithium aluminium hydride (1.0 M in THF, 18.4 mL, 18.4 mmol) is cooled in an ice bath and treated slowly with a solution of 3-methyl-4-methylsulfanyl-benzonitrile (preparation 66a, 1.0 g, 6.1 mmol) in THF (10 mL) while the temperature is kept below 5° C. The mixture is allowed to warm to room temperature and stirred over night. The mixture is cooled again at 0° C., and water (2 mL) and aqueous sodium hydroxide (4 M, 2 mL) is added. The mixture is filtered and the filtrate is extracted twice with dichloromethane. The combined organic layers are concentrated under reduced pressure. Yield: 923 mg (90% of theory); ESI mass spectrum: [M+H-NH3]+=151; r.t. HPLC: 0.61 min (X011_503).
-
- The title compound is prepared following the procedure described for example 60, using 3-methyl-4-methylsulfanyl-benzylamine (preparation 66b) as starting material, and replacing HBTU with TBTU. ESI mass spectrum: [M+H]+=489; r.t. HPLC: 0.77 min (X011_S03).
-
- N-Bromosuccinimide (63 mg, 0.35 mmol) is added to a mixture of 1-isopropyl-6-methyl-4-oxo-5-(3-trifluoromethyl-phenyl)-1,4-dihydro-pyridine-3-carboxylic acid 3-methyl-4-methylsulfanyl-benzylamide (preparation 66c, 115 mg, 0.24 mmol), cyanamide (14 mg, 0.33 mmol) and potassium tert-butoxide (32 mg, 0.29 mmol) in methanol (1.1 mL). After 20 min saturated aqueous sodium thiosulfate solution is added, and the mixture is extracted twice with dichloromethane. The combined organic layers is dried over Na2SO4 and concentrated under reduced pressure. The residue is directly used in the next step without further purification. Yield: 99 mg (80% of theory); ESI mass spectrum: [M+H]+=529; r.t. HPLC: 0.58 min (X012_S01).
-
- A solution of 1-isopropyl-6-methyl-4-oxo-5-(3-trifluoromethyl-phenyl)-1,4-dihydro-pyridine-3-carboxylic acid 3-methyl-4-(N-cyano-S-methylsulfinimidoyl)-benzylamide (preparation 66d, 25 mg, 47 μmol) and acetic acid (3 μL, 50 μmol) in acetonitrile (0.2 mL) is added to a solution of potassium permanganate (8 mg, 50 μmol) in acetonitrile (0.15 mL) and water (0.15 mL). After 3 h another portion of potassium permanganate at (8 mg, 50 μmol) is added and the mixture is heated at reflux. After 2 h saturated aqueous sodium thiosulfate solution is added, and the mixture is extracted twice with dichloromethane. The organic layer is dried over Na2SO4 and concentrated under reduced pressure. The residue is purified by preparative reversed phase HPLC (Xbridge, gradient of acetonitrile in water, 0.1% TFA). Yield: 2 mg (8% of theory); ESI mass spectrum: [M+H]+=545; r.t. HPLC: 0.61 min (X012_S01).
-
-
- A mixture of 2-(4-(S-methylsulfonimidoyl)benzyl)isoindoline-1,3-dione (preparation 17b, 200 mg, 63.6 mmol) and paraformaldehyde (115 mg, 1.27 mmol) in acetic acid (2 mL) is heated in a microwave at 100° C. for 4 h. The mixture is concentrated under reduced pressure, and the residue is purified by flash chromatography on silica (gradient dichloromethane to dichloromethane/methanol 95:5). Yield: 189 mg (90% of theory); ESI mass spectrum: [M+H]+=329; r.t. HPLC: 0.45 min (X011_S03).
-
- A mixture of 2-(4-(N,S-dimethylsulfonimidoyl)benzyl)isoindoline-1,3-dione (189 mg, 0.58 mmol) and 1,2-diaminoethane (132 μL, 3.44 mmol) in a 2:1:1 mixture of acetonitrile, tetrahydrofuran and ethanol (2 mL) is heated at reflux for 1 h. All volatiles are removed under reduced pressure, and the residue is treated with dichloromethane. The mixture is filtered, and the filtrate is concentrated under reduced pressure. Yield: 114 mg (85% of theory); ESI mass spectrum: [M+H]+=199; r.t. HPLC: 0.22 min (X011_S03).
-
- The title compound is prepared following the procedure described for example 60, substituting 4-(aminomethyl)-N,N,N-trimethylbenzenesulfonimidamide with 4-(N,S-Dimethylsulfonimidoyl)benzylamine (preparation 67b), and replacing HBTU with TBTU. ESI mass spectrum: [M+H]+=520; r.t. HPLC: 0.58 min (X011_S03).
- Other features and advantages of the present invention will become apparent from the following more detailed examples which illustrate, by way of example, the principles of the invention.
- Materials: Human neutrophil elastase was purchased from Calbiochem (Cat.No.: 324681) and the elastase substrate MeOSuc-Ala-Ala-Pro-Val-AMC from Bachem (Cat.No.: I-1270). All other materials were of the highest grade commercially available.
- The following buffers were used: Compound buffer: 100 mM Tris, 500 mM NaCl, adjusted to pH 7.5; Assay buffer: 100 mM Tris, 500 mM NaCl, adjusted to pH 7.5, containing 0.01% BSA.
- Assay conditions: Test compounds were prediluted in DMSO and subsequently in compound buffer (5% DMSO final). 5 μL of these compound dilutions were mixed with 10 μl Neutrophil elastase (9 ng/ml in assay buffer) in a black 384 well OptiPlate (Perkin Elmer, Cat No.: 6007270) and incubated for 15 min at room temperature. Subsequently 10 μL substrate solution in assay buffer were added (250 μM final concentration) and the plates were incubated for 60 min at room temperature. After inactivation of the enzyme, fluorescence intensities were measured at 380 nm excitation and 460 nm emission wavelengths.
- Each plate contains wells with a high value control (DMSO+enzyme+substrate) and wells with a low value control (DMSO+inactivated enzyme+substrate). IC50 values were estimated using a sigmoidal concentration response curve with variable slope. Means of low values were taken as 0%, means of high values as 100%. IC50 values of selected compound in the Neutrophil Elastase assay:
-
Example IC50 [nM] 1 1.3 1A 3.1 1B 1.3 2 1.7 2A 2.3 2B 1.1 3 4.7 3A 12.0 3B 5.1 4 3.0 4A 4.1 4B 1.6 5 2.5 6 2.4 7 2.1 8 2.4 9 <1 9A <1 9B <1 10 1.2 10A 2.7 10B 1.2 5.5A 5.0 5.5B 2.7 11 <1 12 <1 13 2.4 14 1.5 15 2.2 16 1.9 17 7.3 18 1.5 19 1.0 20 5.6 21A 5.2 21B 2.1 22A 4.5 22B 1.2 23 2.6 24 5.5 25 4.3 26 3.3 27 2.5 28 3.3 29 1.5 29A 2.2 29B <1 30 <1 30A 1.8 30B <1 31 <1 31A <1 31B <1 32 1.1 33 2.5 34 2.4 35 8.0 36 1.0 37 <1 38 3.7 39 3.7 40 4.0 41 1.8 42 4.7 43 13.4 44 14.9 45 14.4 46 11.7 47 1.2 48 9.4 49 7.3 50 8.6 53 2.3 54 2.3 55 1.8 56 3.1 57 1.7 58 4.7 59 7.9 60 22.0 61 10.2 62 2.7 63 1.4 64 24.5 65 57.1 66 3.4 67 49.3 - The compounds of general formula I may be used on their own or combined with other active substances of formula I according to the invention. The compounds of general formula I may optionally also be combined with other pharmacologically active substances. These include, 132-adrenoceptor-agonists (short and long-acting), anti-cholinergics (short and long-acting), anti-inflammatory steroids (oral and topical corticosteroids), cromoglycate, methylxanthine, dissociated-glucocorticoidmimetics, PDE3 inhibitors, PDE4-inhibitors, PDE7-inhibitors, LTD4 antagonists, EGFR-inhibitors, Dopamine agonists, PAF antagonists, Lipoxin A4 derivatives, FPRL1 modulators, LTB4-receptor (BLT1, BLT2) antagonists, Histamine H1 receptor antagonists, Histamine H4 receptor antagonists, dual Histamine H1/H3-receptor antagonists, PI3-kinase inhibitors, inhibitors of non-receptor tyrosine kinases as for example LYN, LCK, SYK, ZAP-70, FYN, BTK or ITK, inhibitors of MAP kinases as for example p38, ERK1, ERK2, JNK1, JNK2, JNK3 or SAP, inhibitors of the NF-κB signalling pathway as for example IKK2 kinase inhibitors, iNOS inhibitors, MRP4 inhibitors, leukotriene biosynthese inhibitors as for example 5-Lipoxygenase (5-LO) inhibitors, cPLA2 inhibitors, Leukotriene A4 Hydrolase inhibitors or FLAP inhibitors, MMP9-inhibitors, MMP12-inhibitors Non-steroidale anti-inflammatory agents (NSAIDs), Cathepsin C (or DPPI/Dipeptidyl-aminopeptidase I) inhibitors, CRTH2 antagonists, DP1-receptor modulators, Thromboxane receptor antagonists, CCR3 antagonists, CCR4 antagonists, CCR1 antagonists, CCR5 antagonists, CCR6 antagonists, CCR7 antagonists, CCR8 antagonists, CCR9 antagonists, CCR30 antagonists, CXCR3 antagonists, CXCR4 antagonists, CXCR2 antagonists, CXCR1 antagonists, CXCR5 antagonists, CXCR6 antagonists, CX3CR3 antagonists, Neurokinin (NK1, NK2) antagonists, Sphingosine 1-Phosphate receptor modulators, Sphingosine 1 phosphate lyase inhibitors, Adenosine receptor modulators as for example A2a-agonists, modulators of purinergic receptors as for example P2X7 inhibitors, Histone Deacetylase (HDAC) activators, Bradykinin (BK1, BK2) antagonists, TACE inhibitors, PPAR gamma modulators, Rho-kinase inhibitors, interleukin 1-beta converting enzyme (ICE) inhibitors, Toll-Like receptor (TLR) modulators, HMG-CoA reductase inhibitors, VLA-4 antagonists, ICAM-1 inhibitors, SHIP agonists, GABAa receptor antagonist, ENaC-inhibitors, Prostasin-inhibitors, Melanocortin receptor (MC1R, MC2R, MC3R, MC4R, MC5R) modulators, CGRP antagonists, Endothelin antagonists, TNFα antagonists, anti-TNF antibodies, anti-GM-CSF antibodies, anti-CD46 antibodies, anti-IL-1 antibodies, anti-IL-2 antibodies, anti-IL-4 antibodies, anti-IL-5 antibodies, anti-IL-13 antibodies, anti-IL-4/IL-13 antibodies, anti-TSLP antibodies, anti-OX40 antibodies, mucoregulators, immunotherapeutic agents, compounds against swelling of the airways, compounds against cough, VEGF inhibitors, but also combinations of two or three active substances.
- Preferred are betamimetics, anticholinergics, corticosteroids, PDE4-inhibitors, LTD4-antagonists, EGFR-inhibitors, Cathepsin C inhibitors, CRTH2 inhibitors, 5-LO-inhibitors, Histamine receptor antagonists and SYK-inhibitors, especially Cathepsin C inhibitors, but also combinations of two or three active substances, i.e.:
-
- Betamimetics with corticosteroids, PDE4-inhibitors, CRTH2-inhibitors or LTD4-antagonists,
- Anticholinergics with betamimetics, corticosteroids, PDE4-inhibitors, CRTH2-inhibitors or LTD4-antagonists,
- Corticosteroids with PDE4-inhibitors, CRTH2-inhibitors or LTD4-antagonists
- PDE4-inhibitors with CRTH2-inhibitors or LTD4-antagonists
- CRTH2-inhibitors with LTD4-antagonists.
- The compounds of the invention and their pharmaceutically acceptable salts have activity as pharmaceuticals, in particular as inhibitors of neutrophil elastase, and thus may be used in the treatment of:
- 1. respiratory tract: obstructive diseases of the airways including: asthma, including bronchial, allergic, intrinsic, extrinsic, exercise-induced, drug-induced (including aspirin and NSAID-induced) and dust-induced asthma, both intermittent and persistent and of all severities, and other causes of airway hyper-responsiveness; chronic obstructive pulmonary disease (COPD); bronchitis, including infectious and eosinophilic bronchitis; emphysema; alpha1-antitrypsin deficiency; bronchiectasis; cystic fibrosis; sarcoidosis; farmer's lung and related diseases; hypersensitivity pneumonitis; lung fibrosis, including cryptogenic fibrosing alveolitis, idiopathic interstitial pneumonias, fibrosis complicating anti-neoplastic therapy and chronic infection, including tuberculosis and aspergillosis and other fungal infections; complications of lung transplantation; vasculitic and thrombotic disorders of the lung vasculature, and pulmonary hypertension; antitussive activity including treatment of chronic cough associated with inflammatory and secretory conditions of the airways, and iatrogenic cough; acute and chronic rhinitis including rhinitis medicamentosa, and vasomotor rhinitis; perennial and seasonal allergic rhinitis including rhinitis nervosa (hay fever); nasal polyposis; acute viral infection including the common cold, and infection due to respiratory syncytial virus, influenza, coronavirus (including SARS) and adenovirus; acute lung injury (ALI) and adult respiratory diseases syndrome (ARDS).
- 2. skin: psoriasis, atopic dermatitis, contact dermatitis or other eczematous dermatoses, and delayed-type hypersensitivity reactions; phyto- and photodermatitis; seborrhoeic dermatitis, dermatitis herpetiformis, lichen planus, lichen sclerosus et atrophica, pyoderma gangrenosum, skin sarcoid, discoid lupus erythematosus, pemphigus, pemphigoid, epidermolysis bullosa, urticaria, angioedema, vasculitides, toxic erythemas, cutaneous eosinophilias, alopecia areata, male-pattern baldness, Sweet's syndrome, Weber-Christian syndrome, erythema multiforme; cellulitis, both infective and non-infective; panniculitis; cutaneous lymphomas, non-melanoma skin cancer and other dysplastic lesions; drug-induced disorders including fixed drug eruptions;
- 3. eyes: blepharitis; conjunctivitis, including perennial and vernal allergic conjunctivitis; iritis; anterior and posterior uveitis; choroiditis; autoimmune, degenerative or inflammatory disorders affecting the retina; ophthalmitis including sympathetic ophthalmitis; sarcoidosis; infections including viral, fungal, and bacterial;
- 4. genitourinary: nephritis including interstitial and glomerulonephritis; nephrotic syndrome; cystitis including acute and chronic (interstitial) cystitis and Hunner's ulcer; acute and chronic urethritis, prostatitis, epididymitis, oophoritis and salpingitis; vulvo-vaginitis; Peyronie's disease; erectile dysfunction (both male and female);
- 5. allograft rejection: acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea or following blood transfusion; or chronic graft versus host disease;
- 6. other auto-immune and allergic disorders including rheumatoid arthritis, irritable bowel syndrome, systemic lupus erythematosus, multiple sclerosis, Hashimoto's thyroiditis, Graves' disease, Addison's disease, diabetes mellitus, idiopathic thrombocytopaenic purpura, eosinophilic fasciitis, hyper-IgE syndrome, antiphospholipid syndrome and Sazary syndrome;
- 7. oncology: treatment of common cancers including prostate, breast, lung, ovarian, pancreatic, bowel and colon, stomach, skin and brain tumors and malignancies affecting the bone marrow (including the leukaemias) and lymphoproliferative systems, such as Hodgkin's and non-Hodgkin's lymphoma; including the prevention and treatment of metastatic disease and tumour recurrences, and paraneoplastic syndromes; and,
- 8. infectious diseases: virus diseases such as genital warts, common warts, plantar warts, hepatitis B, hepatitis C, herpes simplex virus, molluscum contagiosum, variola, human immunodeficiency virus (HIV), human papilloma virus (HPV), cytomegalovirus (CMV), varicella zoster virus (VZV), rhinovirus, adenovirus, coronavirus, influenza, para-influenza; bacterial diseases such as tuberculosis and mycobacterium avium, leprosy; other infectious diseases, such as fungal diseases, chlamydia, Candida, aspergillus, cryptococcal meningitis, Pneumocystis carnii, cryptosporidiosis, histoplasmosis, toxoplasmosis, trypanosome infection and leishmaniasis.
- For treatment of the above-described diseases and conditions, a therapeutically effective dose will generally be in the range from about 0.01 mg to about 100 mg/kg of body weight per dosage of a compound of the invention; preferably, from about 0.1 mg to about 20 mg/kg of body weight per dosage. For Example, for administration to a 70 kg person, the dosage range would be from about 0.7 mg to about 7000 mg per dosage of a compound of the invention, preferably from about 7.0 mg to about 1400 mg per dosage. Some degree of routine dose optimization may be required to determine an optimal dosing level and pattern. The active ingredient may be administered from 1 to 6 times a day.
- The actual pharmaceutically effective amount or therapeutic dosage will of course depend on factors known by those skilled in the art such as age and weight of the patient, route of administration and severity of disease. In any case the active ingredient will be administered at dosages and in a manner which allows a pharmaceutically effective amount to be delivered based upon patient's unique condition.
Claims (6)
1. A compound of formula 1
R1a.1 is C1-4-alkyl-;
R1a.2 is NC—;
R1b is H;
R2 is C1-6-alkyl or a residue selected from the group consisting of C3-6-cycloalkyl-, phenyl-C1-4-alkyl- and a five- or six-membered, aromatic heteroring containing one or two nitrogen atoms, each of the above rings optionally substituted with C1-4-alkyl-, halogen or NC—;
R3 is methyl;
R4 is phenyl, a five- or six-membered, aromatic ring containing one or two nitrogen atom, each ring optionally substituted with one or two residues selected independently from each other from the group consisting of C1-4-alkyl-, halogen or C1-4-haloalkyl-;
R5 is H;
R6 is H;
R7 is H;
or a pharmaceutically acceptable salt thereof.
2. A compound of formula 1, according to claim 1 , wherein
A is phenyl or pyridinyl;
R1a is
R1a.1 is C1-4-alkyl-;
R1a.2 is NC—;
R1b is H;
R2 is C1-6-alkyl or a residue selected from the group consisting of C3-6-cycloalkyl-, phenyl-C1-4-alkyl- and a five-membered, aromatic ring containing two nitrogen atoms; each optionally substituted with methyl or NC—;
R3 is methyl;
R4 is phenyl or a six-membered, aromatic heteroring containing one or two nitrogen atom, each ring substituted with one or two residues selected independently from each other from the group consisting of C1-4-alkyl-, halogen or C1-4-haloalkyl-;
R5 is H;
R6 is H;
R7 is H;
or a pharmaceutically acceptable salt thereof.
3. A compound of formula 1, according to claim 1 , wherein
A is phenyl or pyridinyl;
R1a is
R1a.1 is methyl, ethyl, i-propyl, n-propyl;
R1a.2 is NC—;
R1b is H;
R2 is ethyl, i-propyl, 2-butyl, cyclobutyl, 1-methylpyrazolyl, or benzyl or 4-NC-benzyl;
R3 is methyl;
R4 is phenyl or pyridinyl, each ring substituted with one or two residues selected independently from each other from the group consisting of methyl, ethyl, propyl, F, Br, Cl, F2HC— or F3C—;
R5 is H;
R6 is H;
R7 is H;
or a pharmaceutically acceptable salt thereof.
4. A compound of formula 1, according to claim 1 , wherein
A is phenyl;
R1a is
R1a.1 is methyl;
R1a.2 is NC—;
R1b is H;
R2 is ethyl, i-propyl, cyclobutyl, 1-methylpyrazolyl, benzyl or 4-NC-benzyl;
R3 is methyl;
R4 is phenyl or pyridinyl, each ring substituted with one or two residues selected independently from each other from the group consisting of F, F2HC— or F3C—;
R5 is H;
R6 is H;
R7 is H;
or a pharmaceutically acceptable salt thereof.
6. A pharmaceutical composition comprising a compound of formula 1 according to claim 1 or a pharmaceutically active salt thereof and a pharmaceutically acceptable carrier.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/981,999 US9346794B1 (en) | 2012-08-23 | 2015-12-29 | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12181542 | 2012-08-23 | ||
EP12181542 | 2012-08-23 | ||
EP12181542.7 | 2012-08-23 | ||
US13/971,378 US20140057926A1 (en) | 2012-08-23 | 2013-08-20 | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity |
US14/981,999 US9346794B1 (en) | 2012-08-23 | 2015-12-29 | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/971,378 Continuation US20140057926A1 (en) | 2012-08-23 | 2013-08-20 | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity |
Publications (2)
Publication Number | Publication Date |
---|---|
US20160130265A1 true US20160130265A1 (en) | 2016-05-12 |
US9346794B1 US9346794B1 (en) | 2016-05-24 |
Family
ID=46963420
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/971,378 Abandoned US20140057926A1 (en) | 2012-08-23 | 2013-08-20 | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity |
US14/981,999 Active US9346794B1 (en) | 2012-08-23 | 2015-12-29 | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/971,378 Abandoned US20140057926A1 (en) | 2012-08-23 | 2013-08-20 | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity |
Country Status (7)
Country | Link |
---|---|
US (2) | US20140057926A1 (en) |
EP (1) | EP2888242B1 (en) |
JP (1) | JP6319747B2 (en) |
AR (1) | AR092205A1 (en) |
TW (1) | TW201422586A (en) |
UY (1) | UY34989A (en) |
WO (1) | WO2014029830A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9475779B2 (en) | 2014-07-31 | 2016-10-25 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9657015B2 (en) | 2014-07-31 | 2017-05-23 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9440930B2 (en) | 2014-07-31 | 2016-09-13 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9290457B2 (en) | 2014-07-31 | 2016-03-22 | Boehringer Ingelheim International Gmbh | Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9458113B2 (en) | 2014-07-31 | 2016-10-04 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
UY36547A (en) | 2015-02-05 | 2016-06-01 | Bayer Cropscience Ag | BICYCLIC CONDENSED HETEROCYCLIC DERIVATIVES REPLACED BY 2- (HET) ARILO AS PESTICIDES |
PE20180783A1 (en) | 2015-08-07 | 2018-05-07 | Bayer Cropscience Ag | CONDENSED HETEROCYCLIC DERIVATIVES REPLACED BY 2- (HET) ARILO AS PESTICIDES |
US20200148635A1 (en) | 2017-05-18 | 2020-05-14 | Pi Industries Ltd. | Formimidamidine compounds useful against phytopathogenic microorganisms |
CA3154761A1 (en) | 2019-09-17 | 2021-03-25 | Mereo Biopharma 4 Limited | Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease |
US20230190723A1 (en) | 2020-04-16 | 2023-06-22 | Mereo Biopharma 4 Limited | Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency |
CA3234399A1 (en) | 2021-10-20 | 2023-04-27 | Mereo Biopharma 4 Limited | Neutrophil elastase inhibitors for use in the treatment of fibrosis |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4844732A (en) * | 1985-10-24 | 1989-07-04 | Daicel Chemical Industries Ltd. | Pyridine-3-carboxamide derivatives |
US7211595B2 (en) | 2000-11-30 | 2007-05-01 | Abbott Laboratories | Farnesyltransferase inhibitors |
TW200500341A (en) | 2002-11-12 | 2005-01-01 | Astrazeneca Ab | Novel compounds |
SE0302486D0 (en) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
SE0302487D0 (en) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
TW200700392A (en) | 2005-03-16 | 2007-01-01 | Astrazeneca Ab | Novel compounds |
EP1907383A1 (en) | 2005-06-30 | 2008-04-09 | Prosidion Limited | Gpcr agonists |
ITMI20060285A1 (en) | 2006-02-16 | 2007-08-17 | Polimeri Europa Spa | PERFECTED PROCD FOR THE PREPARATION OF STABLE NITROSILIC RADICALS |
TW200808771A (en) | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds II |
TW200808763A (en) | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds I |
WO2009058076A1 (en) | 2007-11-02 | 2009-05-07 | Astrazeneca Ab | 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase |
CL2008003301A1 (en) | 2007-11-06 | 2009-10-16 | Astrazeneca Ab | Compounds derived from 3,4-dihydropyrazine-2-carboxamide, inhibitors of elastase of human neutrophils; pharmaceutical compositions; compounding and pharmaceutical composition processes; and use in the treatment of respiratory distress syndrome in adults, cystic fibrosis, cancer, among others. |
JP5314050B2 (en) * | 2008-01-23 | 2013-10-16 | ブリストル−マイヤーズ スクイブ カンパニー | 4-pyridinone compounds and their use for cancer |
EA201100003A1 (en) | 2008-06-23 | 2011-08-30 | Басф Се | SULPHOXIMINAMIDE COMPOUNDS FOR ANIMAL ANIMAL CONTROL |
TW201036957A (en) | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
EP2261211A1 (en) * | 2009-05-20 | 2010-12-15 | Université de Lille 2 Droit et Santé | 1,4-dihydropyridine derivatives and their uses |
RU2012116877A (en) | 2009-10-02 | 2013-11-10 | Астразенека Аб | COMPOUNDS OF 2-PYRIDONE USED AS NEUTROPHIL ELASTASE INHIBITORS |
US20110224229A1 (en) | 2010-03-10 | 2011-09-15 | Astrazeneca Ab | Novel Crystalline Form |
-
2013
- 2013-08-20 US US13/971,378 patent/US20140057926A1/en not_active Abandoned
- 2013-08-22 AR ARP130102982A patent/AR092205A1/en unknown
- 2013-08-22 TW TW102130097A patent/TW201422586A/en unknown
- 2013-08-22 WO PCT/EP2013/067425 patent/WO2014029830A1/en active Application Filing
- 2013-08-22 JP JP2015527913A patent/JP6319747B2/en active Active
- 2013-08-22 EP EP13756358.1A patent/EP2888242B1/en active Active
- 2013-08-23 UY UY0001034989A patent/UY34989A/en unknown
-
2015
- 2015-12-29 US US14/981,999 patent/US9346794B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2014029830A1 (en) | 2014-02-27 |
AR092205A1 (en) | 2015-04-08 |
JP6319747B2 (en) | 2018-05-09 |
UY34989A (en) | 2014-02-28 |
EP2888242B1 (en) | 2016-07-13 |
US9346794B1 (en) | 2016-05-24 |
EP2888242A1 (en) | 2015-07-01 |
JP2015526453A (en) | 2015-09-10 |
US20140057926A1 (en) | 2014-02-27 |
TW201422586A (en) | 2014-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9346794B1 (en) | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity | |
US9340507B2 (en) | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity | |
US9670166B2 (en) | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | |
USRE46630E1 (en) | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity | |
US9115093B2 (en) | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | |
US9290457B2 (en) | Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | |
US9221807B2 (en) | Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity | |
CA2956745C (en) | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | |
US9458113B2 (en) | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | |
US9657015B2 (en) | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | |
USRE47493E1 (en) | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | |
OA17445A (en) | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |